<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">65952</article-id><article-id pub-id-type="doi">10.7554/eLife.65952</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title><italic>Naa12</italic> compensates for <italic>Naa10</italic> in mice in the amino-terminal acetylation pathway</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-219536"><name><surname>Kweon</surname><given-names>Hyae Yon</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1534-0767</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-219537"><name><surname>Lee</surname><given-names>Mi-Ni</given-names></name><email>minilee@kribb.re.kr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">‡</xref></contrib><contrib contrib-type="author" id="author-219538"><name><surname>Dorfel</surname><given-names>Max</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219539"><name><surname>Seo</surname><given-names>Seungwoon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-187075"><name><surname>Gottlieb</surname><given-names>Leah</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219540"><name><surname>PaPazyan</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219541"><name><surname>McTiernan</surname><given-names>Nina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1749-6933</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219542"><name><surname>Ree</surname><given-names>Rasmus</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241384"><name><surname>Bolton</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219543"><name><surname>Garcia</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219544"><name><surname>Flory</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219545"><name><surname>Crain</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219546"><name><surname>Sebold</surname><given-names>Alison</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219547"><name><surname>Lyons</surname><given-names>Scott</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219548"><name><surname>Ismail</surname><given-names>Ahmed</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219549"><name><surname>Marchi</surname><given-names>Elaine</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219550"><name><surname>Sonn</surname><given-names>Seong-keun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219551"><name><surname>Jeong</surname><given-names>Se-Jin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6375-5334</contrib-id><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219552"><name><surname>Jeon</surname><given-names>Sejin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3819-3421</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219553"><name><surname>Ju</surname><given-names>Shinyeong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5483-4690</contrib-id><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219554"><name><surname>Conway</surname><given-names>Simon J</given-names></name><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-78952"><name><surname>Kim</surname><given-names>Taesoo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3902-1058</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219555"><name><surname>Kim</surname><given-names>Hyun-Seok</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219556"><name><surname>Lee</surname><given-names>Cheolju</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8482-4696</contrib-id><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219557"><name><surname>Roh</surname><given-names>Tae-Young</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5833-0844</contrib-id><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="fn" rid="con25"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219561"><name><surname>Arnesen</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con26"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-148494"><name><surname>Marmorstein</surname><given-names>Ronen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4373-4752</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con27"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-219559"><name><surname>Oh</surname><given-names>Goo Taeg</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1104-1698</contrib-id><email>gootaeg@ewha.ac.kr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con28"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-219558"><name><surname>Lyon</surname><given-names>Gholson J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5869-0716</contrib-id><email>gholsonjlyon@gmail.com</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="aff" rid="aff19">19</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con29"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Life Science and College of Natural Sciences, Ewha Womans University</institution><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff2"><label>2</label><institution>Laboratory Animal Resource Center Korea ResearchInstitute of Bioscience and Biotechnology</institution><addr-line><named-content content-type="city">Chungbuk</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff3"><label>3</label><institution>Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory</institution><addr-line><named-content content-type="city">Woodbury</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Chemistry, University of Pennsylvania</institution><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania</institution><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Biomedicine, University of Bergen</institution><addr-line><named-content content-type="city">Bergen</named-content></addr-line><country>Norway</country></aff><aff id="aff7"><label>7</label><institution>Department of Molecular Biology, New York State Institute for Basic Research in Developmental Disabilities</institution><addr-line><named-content content-type="city">Staten Island</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Department of Human Genetics, New York State Institute for Basic Research in Developmental Disabilities</institution><addr-line><named-content content-type="city">Staten Island</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>Research Design and Analysis Service, New York State Institute for Basic Research in Developmental Disabilities</institution><addr-line><named-content content-type="city">Staten Island</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution>Center for Cardiovascular Research, Washington University School of Medicine</institution><addr-line><named-content content-type="city">Saint Louis</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution>Center for Theragnosis, Korea Institute of Science and Technology</institution><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff12"><label>12</label><institution>Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine</institution><addr-line><named-content content-type="city">Indianapolis</named-content></addr-line><country>United States</country></aff><aff id="aff13"><label>13</label><institution>Department of Converging Science and Technology, KHU-KIST, Kyung Hee University</institution><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff14"><label>14</label><institution>Department of Life Sciences, Pohang University of Science and Technology</institution><addr-line><named-content content-type="city">Pohang</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff15"><label>15</label><institution>Department of Biological Sciences, University of Bergen</institution><addr-line><named-content content-type="city">Bergen</named-content></addr-line><country>Norway</country></aff><aff id="aff16"><label>16</label><institution>Department of Surgery, Haukeland University Hospital</institution><addr-line><named-content content-type="city">Bergen</named-content></addr-line><country>Norway</country></aff><aff id="aff17"><label>17</label><institution>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania</institution><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff18"><label>18</label><institution>Biology PhD Program, The Graduate Center, The City University of New York</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff19"><label>19</label><institution>George A. Jervis Clinic, New York State Institute for Basic Research in Developmental Disabilities</institution><addr-line><named-content content-type="city">Staten Island</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Lin</surname><given-names>Hening</given-names></name><role>Reviewing Editor</role><aff><institution>Cornell University</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cole</surname><given-names>Philip A</given-names></name><role>Senior Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>‡</label><p>Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Chungbuk, Republic of Korea</p></fn><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>06</day><month>08</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e65952</elocation-id><history><date date-type="received" iso-8601-date="2020-12-20"><day>20</day><month>12</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-08-05"><day>05</day><month>08</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2020-12-20"><day>20</day><month>12</month><year>2020</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2020.12.19.422860"/></event></pub-history><permissions><copyright-statement>© 2021, Kweon et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Kweon et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-65952-v3.pdf"/><abstract><p>Amino-terminal acetylation is catalyzed by a set of N-terminal acetyltransferases (NATs). The NatA complex (including X-linked Naa10 and Naa15) is the major acetyltransferase, with 40–50% of all mammalian proteins being potential substrates. However, the overall role of amino-terminal acetylation on a whole-organism level is poorly understood, particularly in mammals. Male mice lacking <italic>Naa10</italic> show no globally apparent in vivo amino-terminal acetylation impairment and do not exhibit complete embryonic lethality. Rather <italic>Naa10</italic> nulls display increased neonatal lethality, and the majority of surviving undersized mutants exhibit a combination of hydrocephaly, cardiac defects, homeotic anterior transformation, piebaldism, and urogenital anomalies. <italic>Naa12</italic> is a previously unannotated <italic>Naa10</italic>-like paralog with NAT activity that genetically compensates for <italic>Naa10</italic>. Mice deficient for <italic>Naa12</italic> have no apparent phenotype, whereas mice deficient for <italic>Naa10</italic> and <italic>Naa12</italic> display embryonic lethality. The discovery of <italic>Naa12</italic> adds to the currently known machinery involved in amino-terminal acetylation in mice.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>N-terminal acetylation</kwd><kwd>NAA10</kwd><kwd>protein modification</kwd><kwd>NAA12</kwd><kwd>embryonic lethality</kwd><kwd>hydrocephaly</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source><award-id>2020R1A3B2079811</award-id><principal-award-recipient><name><surname>Oh</surname><given-names>Goo Taeg</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source><award-id>2017RIDIAB03032286</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Mi-Ni</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source><award-id>2020RICIC1007686</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Mi-Ni</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R35GM133408</award-id><principal-award-recipient><name><surname>Lyon</surname><given-names>Gholson J</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R35GM118090</award-id><principal-award-recipient><name><surname>Marmorstein</surname><given-names>Ronen</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005416</institution-id><institution>Research Council of Norway</institution></institution-wrap></funding-source><award-id>Project 249843</award-id><principal-award-recipient><name><surname>Arnesen</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>Project 249843</award-id><principal-award-recipient><name><surname>Conway</surname><given-names>Simon J</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Norwegian Health Authorities of Western Norway</institution></institution-wrap></funding-source><award-id>912176</award-id><principal-award-recipient><name><surname>Arnesen</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Norwegian Health Authorities of Western Norway</institution></institution-wrap></funding-source><award-id>F-12540-D11382</award-id><principal-award-recipient><name><surname>Arnesen</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008730</institution-id><institution>Norwegian Cancer Society</institution></institution-wrap></funding-source><award-id>PR-2009-0222</award-id><principal-award-recipient><name><surname>Arnesen</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Mice doubly deficient for <italic>Naa10</italic> and <italic>Naa12</italic> display embryonic lethality, with both enzymes compensating for each other with amino-terminal acetylation of proteins in mouse development.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Amino-terminal acetylation is one of the most common protein modifications, occurring co- and post-translationally. Approximately 80% of cytosolic proteins are amino-terminally acetylated in humans and ~50% in yeast (<xref ref-type="bibr" rid="bib5">Arnesen et al., 2009</xref>), while amino-terminal acetylation is less common in prokaryotes and archaea (<xref ref-type="bibr" rid="bib26">Dörfel and Lyon, 2015</xref>). Amino-terminal acetylation is catalyzed by a set of enzymes, the N-terminal acetyltransferases (NATs), which transfer an acetyl group from acetyl-coenzyme A (Ac-CoA) to the free α-amino group of a protein’s N-terminus. To date, eight distinct NATs (NatA–NatH) have been identified in eukaryotes that are classified based on different subunit compositions and substrate specificities (<xref ref-type="bibr" rid="bib61">Polevoda et al., 2009</xref>; <xref ref-type="bibr" rid="bib1">Aksnes et al., 2019</xref>; <xref ref-type="bibr" rid="bib75">Starheim et al., 2012</xref>). Amino-terminal acetylation has been implicated in steering protein folding, stability or degradation, subcellular targeting, and complex formation (<xref ref-type="bibr" rid="bib68">Ree et al., 2018</xref>; <xref ref-type="bibr" rid="bib73">Shemorry et al., 2013</xref>; <xref ref-type="bibr" rid="bib24">Dikiy and Eliezer, 2014</xref>; <xref ref-type="bibr" rid="bib35">Holmes et al., 2014</xref>; <xref ref-type="bibr" rid="bib72">Scott et al., 2011</xref>). The vital role of NATs and amino-terminal acetylation in development has also emerged (<xref ref-type="bibr" rid="bib47">Lee et al., 2018</xref>).</p><p>NatA, the major NAT complex, targets ~40% of the human proteome, acetylating <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Serine">Ser</ext-link>-, <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Alanine">Ala</ext-link>-, <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Glycine">Gly</ext-link>-, Thr-, <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Valine">Val</ext-link>-, and <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Cysteine">Cys N-termini</ext-link> after removal of the initiator <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Methionine">methionine</ext-link> (<xref ref-type="bibr" rid="bib5">Arnesen et al., 2009</xref>; <xref ref-type="bibr" rid="bib75">Starheim et al., 2012</xref>). Human NatA consists of two main subunits, the catalytic subunit N-α-acetyltransferase 10 (NAA10) (Ard1) and the auxiliary subunit NAA15 (Nat1), and a regulatory subunit HYPK (<xref ref-type="bibr" rid="bib2">Arnesen et al., 2005</xref>; <xref ref-type="bibr" rid="bib6">Arnesen et al., 2010</xref>; <xref ref-type="bibr" rid="bib33">Gottlieb and Marmorstein, 2018</xref>). NAA15 function has been linked to cell survival, tumor progression, and retinal development (<xref ref-type="bibr" rid="bib3">Arnesen et al., 2006a</xref>; <xref ref-type="bibr" rid="bib32">Gendron et al., 2010</xref>). In addition, Naa10-catalyzed N-terminal acetylation has been reported to be essential for development in many species (<xref ref-type="bibr" rid="bib47">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib86">Wang et al., 2010</xref>; <xref ref-type="bibr" rid="bib10">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="bib49">Linster et al., 2015</xref>; <xref ref-type="bibr" rid="bib67">Ree et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Feng et al., 2016</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2018</xref>), and although NatA is not essential in <italic>Saccharomyces cerevisiae</italic>, depletion of <italic>Naa10</italic> or <italic>Naa15</italic> has strong effects, including slow growth and decreased survival when exposed to various stresses (<xref ref-type="bibr" rid="bib55">Mullen et al., 1989</xref>; <xref ref-type="bibr" rid="bib62">Polevoda and Sherman, 2003</xref>).</p><p><italic>NAA10</italic> mutations were found to be associated with several human diseases characterized by severe phenotypes, including global developmental defects (<xref ref-type="bibr" rid="bib47">Lee et al., 2018</xref>). Among these, the X-linked Ogden syndrome (OS) (<xref ref-type="bibr" rid="bib56">Myklebust et al., 2015</xref>; <xref ref-type="bibr" rid="bib70">Rope et al., 2011</xref>) shows the most severe pathological features such as infant lethality and has reduced NatA catalytic activity. In a <italic>S. cerevisiae</italic> model for the Naa10 Ser37Pro mutant, the mutation impairs NatA complex formation and leads to a reduction in NatA catalytic activity and functionality (<xref ref-type="bibr" rid="bib80">Van Damme et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Dörfel et al., 2017</xref>). Further, OS patient-derived cells have impaired amino-terminal acetylation in vivo of some NatA substrates (<xref ref-type="bibr" rid="bib56">Myklebust et al., 2015</xref>). Over the years, many additional pathogenic <italic>NAA10</italic> variants have been identified in <italic>NAA10</italic> or NAA15 (<xref ref-type="bibr" rid="bib27">Esmailpour et al., 2014</xref>; <xref ref-type="bibr" rid="bib63">Popp et al., 2015</xref>; <xref ref-type="bibr" rid="bib9">Casey et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">McTiernan et al., 2018</xref>; <xref ref-type="bibr" rid="bib69">Ree et al., 2019</xref>; <xref ref-type="bibr" rid="bib76">Støve et al., 2018</xref>; <xref ref-type="bibr" rid="bib14">Cheng et al., 2019</xref>; <xref ref-type="bibr" rid="bib13">Cheng et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Johnston et al., 2019</xref>) and the collection of presenting symptoms for families with <italic>NAA10</italic> mutations is currently referred to as Ogden syndrome or <italic>NAA10</italic>-related syndrome (<xref ref-type="bibr" rid="bib90">Wu and Lyon, 2018</xref>).</p><p>The autosomal <italic>NAA10</italic> homolog, <italic>NAA11</italic> (ARD2), has been reported to be present in mice and humans, and is co-expressed with <italic>NAA10</italic> in human cell lines (<xref ref-type="bibr" rid="bib4">Arnesen et al., 2006b</xref>). Therefore, <italic>NAA11</italic> could conceivably compensate when <italic>NAA10</italic> is reduced or lacking (<xref ref-type="bibr" rid="bib47">Lee et al., 2018</xref>). However, <italic>NAA11</italic> was only found in testis and placenta in human and gonadal tissues in mouse, while <italic>NAA10</italic> showed widespread expression in various tissues in embryos and adults (<xref ref-type="bibr" rid="bib58">Pang et al., 2011</xref>). Thus, any functional redundancy or compensation might be limited to certain tissues only.</p><p>To elucidate the functional role of <italic>Naa10</italic> during development in mice, we used two different <italic>Naa10</italic>-deficient mouse lines: one, referred to as <italic>Naa10</italic> knockout (KO), which was previously reported specifically related to bone density in postnatal day 3 (P3) mice (<xref ref-type="bibr" rid="bib91">Yoon et al., 2014</xref>), and another denoted as <italic>Naa10<sup>tm1a(EUCOMM)Hmgu</sup></italic> (<italic>Naa10<sup>tm1a</sup></italic>), generated in this study. These <italic>Naa10</italic>-deficient mice exhibit pleiotropic developmental abnormalities at a range of different ages, overlapping with some of the phenotypes seen in human disease involving NAA10 impairment. Because we did not discover major changes in the overall Nt-acetylome in <italic>Naa10</italic> KO mice, we hypothesized that there might be a compensating gene in mice, which led us to the identification of a new paralog of <italic>Naa10,</italic> which we name <italic>Naa12. Naa12</italic> is expressed in several organs (liver, kidney, heart, and testis) and, like Naa10, binds to Naa15 to mediate NatA activity. Furthermore, lethality was observed in <italic>Naa10 Naa12</italic> double-KO mice, which supports the compensatory role of <italic>Naa12</italic> in vivo. Thus, we demonstrate that <italic>Naa10</italic> is essential for proper development and <italic>Naa12</italic>, a newly identified paralog of <italic>Naa10</italic>, can play a compensatory role in mice.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>Naa10</italic> KO mice can be born, but display pleiotropic developmental defects</title><p>To explore the role of <italic>Naa10</italic> in development, most analyses were carried out using our <italic>Naa10</italic> KO model mice that had been generated previously (<xref ref-type="bibr" rid="bib91">Yoon et al., 2014</xref>) using a targeting vector deleting Exon1, including the start codon, and Exon2 to Exon4 containing the GNAT domain including the acetyl-CoA binding motif, which is crucial for <italic>Naa10</italic> function. We also generated another <italic>Naa10</italic>-deficient mouse, which we called <italic>Naa10<sup>tm1a</sup></italic>, expressing β-galactosidase rather than the <italic>Naa10</italic> gene (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). <italic>Naa10</italic> expression was deficient in <italic>Naa10<sup>tm1a</sup></italic> mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B, C</xref>). Especially strong β-gal staining was observed during embryonic stages in the brain, heart, and spinal cord (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Male <italic>Naa10</italic> KO (<italic>Naa10<sup>-/Y</sup></italic>) embryos displayed mild to severe developmental defects compared to wildtype (WT) (<italic>Naa10<sup>+/Y</sup></italic>) embryos. Some <italic>Naa10<sup>-/Y</sup></italic> mice had lower levels of somites and developmental delay. Additionally, some <italic>Naa10<sup>-/Y</sup></italic> embryos had a normal number of somites but were retarded in growth (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Some of the embryos underwent lysis or remained arrested at an earlier stage than embryonic day 10.5 (E10.5), with no turning, an abnormal trunk, and underdeveloped facial features. These phenotypes also reproduced in <italic>Naa10<sup>tm1a/Y</sup></italic> embryos. Next, we assessed whether <italic>Naa10</italic> is essential for viability and counted the Mendelian ratios. Both <italic>Naa10<sup>-/Y</sup></italic> and <italic>Naa10<sup>tm1a/Y</sup></italic> mice were under-represented after birth, while there was no significant reduction in the embryonic stage in both mouse lines (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a, b</xref>). We monitored the pups daily at postnatal day 0 (P0) to postnatal day 3 (P3) and beyond, and the survival rate of <italic>Naa10<sup>-/Y</sup></italic> mice dramatically decreased relative to either WT (<italic>Naa10<sup>+/Y</sup></italic> and <italic>Naa10<sup>+/+</sup></italic>) or heterozygous female (<italic>Naa10<sup>+/-</sup></italic>) mice after the first few days of life (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), and a few <italic>Naa10<sup>-/Y</sup></italic> mice with postnatal lethality exhibited severe developmental defects such as craniofacial anomaly, an undeveloped lower body, whole-body edema, and ocular malformations (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Deficiency of <italic>Naa10</italic> leads to abnormal development and postnatal lethality.</title><p>(<bold>A</bold>) <italic>Naa10<sup>+/Y</sup></italic>, <italic>Naa10<sup>-/Y</sup></italic>, and <italic>Naa10<sup>tm1a/Y</sup></italic> embryos at E10.5. Growth retardation (5/33, more than five somites lower or undersized compared to littermate controls), kinky trunk, and developmental arrest are shown in <italic>Naa10<sup>-/Y</sup></italic> (4/33) and <italic>Naa10<sup>tm1a/Y</sup></italic> (1/5). Scale bars: 500 μm. (<bold>B</bold>) The percentage lethality in newborns, comparing <italic>Naa10</italic> wildtype (WT) (<italic>Naa10<sup>+/Y</sup></italic> and <italic>Naa10<sup>+/+</sup></italic>), <italic>Naa10<sup>-/+</sup></italic> and <italic>Naa10<sup>-/Y</sup></italic> pups until P3, derived from matings between heterozygous females and WT males. Approximately 11.6% (10/86) of WT, 24% (13/54) of <italic>Naa10<sup>+/-</sup></italic>, and 76.3% (29/38) of <italic>Naa10<sup>-/Y</sup></italic> mice were found dead before P3. (<bold>C</bold>) Representative images of <italic>Naa10<sup>-/Y</sup></italic> pups during early postnatal days compared with <italic>Naa10<sup>+/Y</sup></italic>. Severe developmental defects such as malformations of head and lower body (one leg; black arrowheads), whole-body edema, and anophthalmia (black arrows) are shown (N = 1 each). (<bold>D</bold>) Hematoxylin and eosin (H&amp;E)-stained heart transverse section at E14.5 and vertical section at E18.5, comparing <italic>Naa10<sup>+/Y</sup></italic> and <italic>Naa10<sup>-/Y</sup></italic> embryos. <italic>Naa10<sup>-/Y</sup></italic> embryo shows a ventricular septal defect (VSD) at E14.5 and E18.5. Also, at E18.5, <italic>Naa10<sup>-/Y</sup></italic> embryo shows atrial septal defect (ASD). Arrow indicates VSD, ASD, and double outlet right ventricle (DORV). Scale bars: 20 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Generation and confirmation of Naa10tm1a mice.</title><p>(<bold>A</bold>) Schematic illustration of the Naa10tm1a mice. (<bold>B</bold>) PCR confirmation of Naa10 deficiency. (<bold>C</bold>) Confirmation of Naa10 protein in kidney tissue by western blot. Naa10 protein is not detected in <italic>Naa10<sup>-/Y</sup></italic> mouse. (<bold>D</bold>) Expression pattern of Naa10 in the embryo. β-Gal staining represents Naa10 localization.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Generation and confirmation of Naa10tm1a mice.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-65952-fig1-figsupp1-data1-v3.pdf"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Generation and confirmation of Naa10tm1a mice.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-65952-fig1-figsupp1-data2-v3.pdf"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata3"><label>Figure 1—figure supplement 1—source data 3.</label><caption><title>Generation and confirmation of Naa10tm1a mice.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-65952-fig1-figsupp1-data3-v3.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig1-figsupp1-v3.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Gross anatomy and histology of neonatal mouse hearts.</title><p>(<bold>A</bold>) Wildtype male heart outflow tract region indicating separate aorta and pulmonary trunks nestled between left and right atria. (<bold>B</bold>) Naa10<sup>-/-</sup> female heart from dying P0 pup only has a single outflow tract emerging from the right ventricle, resulting in persistent truncus arteriosus. (<bold>C</bold>) Naa10<sup>-/y</sup> male heart from dying P0 pup has separate outflow tracts but both emerge from the right ventricle, resulting in double outlet right ventricle. (<bold>D</bold>) Normal histology from wildtype male heart of pulmonary artery exiting the right ventricle. (<bold>E</bold>) Histology from Naa10<sup>-/-</sup> heart of single outflow tract exiting the right ventricle with tricuspid valve leaflets. (<bold>F</bold>) Histology from Naa10<sup>-/y</sup> heart of both pulmonary and aortic arteries emerging from right ventricle within the same plane. (<bold>G</bold>) Naa10<sup>-/-</sup> histology showing membranous ventricular septal defect (VSD). (<bold>H</bold>) Naa10<sup>-/y</sup> histology showing muscular VSD. (<bold>I</bold>) Normal heart revealing closed ductus arterious. (<bold>J</bold>) Naa10<sup>-/-</sup> histology showing open ductus arterious leading to pulmonary overload and likely lethality.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig1-figsupp2-v3.tif"/></fig></fig-group><p>Congenital heart defects are one of the main causes of infant lethality, and cardiac diseases are a common developmental anomaly in OS patients (<xref ref-type="bibr" rid="bib9">Casey et al., 2015</xref>), with some OS males dying in infancy with cardiac arrhythmias (<xref ref-type="bibr" rid="bib70">Rope et al., 2011</xref>). Therefore, we investigated whether <italic>Naa10</italic> KO affects cardiac development. Development of a four-chambered septated heart is normally complete at E14.5; therefore, we examined the cardiovascular system at E14.5. We identified ventricular septal defects (VSDs) in several <italic>Naa10<sup>-/Y</sup></italic> embryos, as well as concomitant double outlet right ventricle (DORV) at E14.5 (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, upper). VSDs and atrial septal defects (ASDs) were also observed at E18.5 (<xref ref-type="fig" rid="fig1">Figure 1d</xref>, bottom), and persistent truncus arteriosus (PTA) or DORV, along with concomitant membranous and muscular VSDs, were found in several of the mice that died in the first day of life (n = 6/28 examined). Given the presence of outflow tract defects and VSDs, we examined whether the ductus arteriosus had closed appropriately or not at birth. Significantly, both <italic>Naa10<sup>-/Y</sup></italic> and <italic>Naa10<sup>-/-</sup></italic> females (n = 3/28 examined) exhibited a patent ductus arteriosus, meaning that there is a failure of the mutant in utero cardiovascular system to adapt to adult life (birth) and close the interatrial and aorta-pulmonary trunk shunts that are required for normal fetal life (<xref ref-type="bibr" rid="bib19">Conway et al., 2003</xref>). As murine outflow tract and VSDs are not compatible with postnatal survival (<xref ref-type="bibr" rid="bib19">Conway et al., 2003</xref>), these data suggest that congenital heart defects in <italic>Naa10<sup>-/Y</sup></italic> mice may explain some of their neonatal lethality (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). We also examined surviving adult mice for any possible situs inversus, but we did not observe this in any adult (&gt;4 weeks) <italic>Naa10<sup>-/Y</sup></italic> mice examined (n = 19). Combined, these data suggest that <italic>Naa10</italic> mutant CHDs are mainly confined to aberrant remodeling of the great vessels of the heart, leading to pulmonary overload at birth resulting in lethality.</p><p>Some of the surviving homozygous mice (<italic>Naa10<sup>-/Y</sup></italic> and <italic>Naa10<sup>-/-</sup></italic>) had reduced body weight (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). This reduced body weight continued through weaning, and some mice lost more weight as they developed progressive hydrocephaly. We observed that the smallest weight animal between the <italic>Naa10<sup>+/Y</sup></italic> and one <italic>Naa10<sup>-/Y</sup></italic> genotypes was almost always the <italic>Naa10<sup>-/Y</sup></italic> genotype when the analysis was restricted to only include litters in which there was at least one of each of those genotypes living beyond 4 days of life. For example, 13 litters met this criteria from the mating (<italic>Naa10<sup>+/-</sup></italic> × <italic>Naa10<sup>+/Y</sup></italic>), and 12/13 of the litters had the <italic>Naa10<sup>-/Y</sup></italic> as the lower weight (Fisher's exact test, two-tailed, p-value&lt;0.0001). Five litters met this criteria from the mating (<italic>Naa10<sup>+/-</sup></italic> × <italic>Naa10<sup>-/Y</sup></italic>), and of these, all of them had the <italic>Naa10<sup>-/Y</sup></italic> as the lower weight (Fisher's exact test, two-tailed, p-value=0.0079). Therefore, despite the known variability in weight data as a function of genetic background, environment, and stochastic variation (<xref ref-type="bibr" rid="bib64">Pun et al., 2013</xref>), it does appear at least for ‘within-litter’ analysis that <italic>Naa10<sup>-/Y</sup></italic> males are born at a smaller weight than <italic>Naa10<sup>+/Y</sup></italic> males and on average remained the smallest male in the litter throughout their life.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Pleiotropic phenotypes of <italic>Naa10</italic> knockout (KO) mice.</title><p>(<bold>A–C</bold>) Representative images of abnormalities in <italic>Naa10<sup>-/Y</sup></italic> compared with <italic>Naa10<sup>+/Y</sup></italic>. (<bold>A</bold>) Body weight of male (left) and female (right) versus ages was monitored from 2 weeks. The weight of <italic>Naa10<sup>-/Y</sup></italic> and <italic>Naa10<sup>-/-</sup></italic> mice is markedly reduced compared with that of the wildtype (WT) mice. Asterisks indicate a statistical difference calculated by Student’s <italic>t</italic>-test: *p&lt;0.05. (<bold>B</bold>) Representative images of completely penetrant phenotypes. Hypopigmentation (<italic>Naa10<sup>+/Y</sup></italic>, n = 243; <italic>Naa10<sup>-/Y</sup></italic>, n = 121; <italic>Naa10<sup>tm1a/Y</sup></italic>, n = 17) and supernumerary ribs (<italic>Naa10<sup>+/Y</sup></italic>, n = 3; <italic>Naa10<sup>-/Y</sup></italic>, n = 6; <italic>Naa10<sup>tm1a/Y</sup></italic>, n = 2; E18.5) were found 100% in <italic>Naa10</italic>-deficient mice. (<bold>C</bold>) <italic>Naa10<sup>-/Y</sup></italic> is smaller in size and has round-shaped head (<italic>Naa10<sup>+/Y</sup></italic> 0/59, <italic>Naa10<sup>-/Y</sup></italic> 7/33). Over time, hydrocephaly became apparent (N = 14/29 [~48%] for &gt;P7 male <italic>Naa10<sup>-Y</sup></italic>; N = 7/19 [~36%] for &gt;P7 female <italic>Naa10<sup>-/-</sup></italic>). Hydronephrosis (red arrow, <italic>Naa10<sup>+/Y</sup></italic> 0/23, <italic>Naa10<sup>-/Y</sup></italic> 14/29, <italic>Naa10<sup>+/+</sup></italic> 0/5, <italic>Naa10<sup>-/-</sup></italic> 7/19) and abnormal genitalia (black arrow) of male (middle, <italic>Naa10<sup>+/Y</sup></italic> 0/23, <italic>Naa10<sup>-/Y</sup></italic> 16/29) and female (bottom, hydrometrocolpos, <italic>Naa10<sup>+/+</sup></italic> 0/5, <italic>Naa10<sup>-/-</sup></italic> 7/19) are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Skeletal phenotype by CT scanning.</title><p>(<bold>A</bold>) In wildtype (WT) mice, 13 thoracic vertebrae and ribs are numbered, whereas 14 thoracic vertebrae and ribs are counted in mutants (<italic>Naa10<sup>-/Y</sup></italic>) (WT on the left, mutant on the right). n = 11 CT scans for <italic>Naa10<sup>-/Y</sup></italic> compared to n = 18 <italic>Naa10<sup>+/Y</sup></italic>. (<bold>B–D</bold>) Different number of ribs are linking the sternum between in <italic>Naa10<sup>-/Y</sup></italic>, <italic>Naa10<sup>-/-</sup></italic>, and WT. (<bold>B</bold>) Seven ribs linking the sternum in WT. (<bold>C</bold>) Eight ribs linking the sternum (the white arrow shows the eighth rib) in Naa10<sup>-/Y</sup>. (<bold>D</bold>) Seven on one side plus seven and one almost linking on the other side. In two mice, an asymmetrical link was observed. White arrow shows the eighth asymmetrical rib. (<bold>E, F</bold>) Abnormalities in the cervical phenotype. (<bold>E</bold>) Cervical WT/morphology. (<bold>F</bold>) Partial fusion of C1 and C2 dorsal arch in one mutant mouse.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig2-figsupp1-v3.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Hydronephrosis and hydrocephaly in Naa10 KO mice.</title><p>(<bold>A</bold>) Representative images and histology of renal defects at E18.5 (n = 6 out of 39 examined) and P3 (n = 4 out of 11 examined). (<bold>B</bold>) Hydrocephaly (n = 3 CT scans for <italic>Naa10<sup>-/Y</sup></italic> mice with hydrocephaly compared to n = 3 <italic>Naa10<sup>-/Y</sup></italic> mice without hydrocephaly). (<bold>C</bold>) Kaplan–Meier survival curve of the <italic>Naa10<sup>+/Y</sup></italic> and <italic>Naa10<sup>-/Y</sup></italic> male mice starting at 4 days of life, thus not including any mice that died in the first three days of life.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig2-figsupp2-v3.tif"/></fig></fig-group><p>Although piebaldism has never been reported in humans with OS, all (100%) of the <italic>Naa10<sup>-/Y</sup></italic> and <italic>Naa10<sup>tm1a/Y</sup></italic> mice exhibited hypopigmentation on their belly (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, upper), with this piebaldism quite varied in its extent but not appearing to correlate in any way with other phenotypes, such as hydrocephaly. Another phenotype with complete penetrance was bilateral supernumerary ribs (14 pairs of ribs instead of 13) in all <italic>Naa10<sup>-/Y</sup></italic> and <italic>Naa10<sup>tm1a/Y</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, middle and bottom, <xref ref-type="table" rid="table1">Table 1</xref>). This extra pair of ribs linking to the sternum transforms the T8 vertebrae into an anterior T7-like phenotype (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Skeletal analyses for ribs, sternebrae, and vertebrae.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th colspan="2" valign="top"><italic>Naa10<sup>+/Y</sup></italic> <break/>(n = 50)</th><th colspan="2" valign="top"><italic>Naa10<sup>+/+</sup></italic> <break/>(n = 10)</th><th colspan="2" valign="top"><italic>Naa10<sup>+/-</sup></italic> <break/>(n = 17)</th><th colspan="2" valign="top"><italic>Naa10<sup>-/Y</sup></italic> <break/>(n = 17)</th><th colspan="2" valign="top"><italic>Naa10<sup>-/-</sup></italic> <break/>(n = 1)</th></tr></thead><tbody><tr><td>4 sternebrae</td><td colspan="2" valign="top">7 (14.0%)</td><td colspan="2" valign="top">1 (10%)</td><td colspan="2" valign="top">3 (17.6%)</td><td colspan="2" valign="top">9 (52.9%)</td><td colspan="2" valign="top">1 (100%)</td></tr><tr><td>3 sternebrae</td><td colspan="2" valign="top">27 (54.0%)</td><td colspan="2" valign="top">8 (80%)</td><td colspan="2" valign="top">11 (64.7%)</td><td colspan="2" valign="top">5 (29.4%)</td><td colspan="2" valign="top">0 (0%)</td></tr><tr><td>4 sternebrae but with 3/4 fusion</td><td colspan="2" valign="top">16 (32%)</td><td colspan="2" valign="top">1 (10%)</td><td colspan="2" valign="top">3 (17.6%)</td><td colspan="2" valign="top">3 (17.6%)</td><td colspan="2" valign="top">0 (0%)</td></tr><tr><td>14 ribs total bilaterally</td><td colspan="2" valign="top">0 (0%)</td><td colspan="2" valign="top">0 (0%)</td><td colspan="2" valign="top">0 (0%)</td><td colspan="2" valign="top">17 (100%)</td><td colspan="2" valign="top">1 (100%)</td></tr><tr><td>13 ribs total bilaterally</td><td colspan="2" valign="top">50 (100%)</td><td colspan="2" valign="top">10 (100%)</td><td colspan="2" valign="top">17 (100%)</td><td colspan="2" valign="top">0 (0%)</td><td colspan="2" valign="top">0 (0%)</td></tr><tr><td>8 ribs attached to sternum bilaterally</td><td colspan="2" valign="top">0 (0%)</td><td colspan="2" valign="top">0 (0%)</td><td colspan="2" valign="top">0 (0%)</td><td colspan="2" valign="top">17 (100%)</td><td colspan="2" valign="top">1 (100%)</td></tr><tr><td>7 ribs attached to sternum bilaterally</td><td colspan="2" valign="top">50 (100%)</td><td colspan="2" valign="top">10 (100%)</td><td colspan="2" valign="top">17 (100%)</td><td colspan="2" valign="top">0 (0%)</td><td colspan="2" valign="top">0 (0%)</td></tr><tr><td>14 thoracic vertebrae</td><td colspan="2" valign="top">0 (0%)</td><td colspan="2" valign="top">0 (0%)</td><td colspan="2" valign="top">0 (0%)</td><td colspan="2" valign="top">17 (100%)</td><td colspan="2" valign="top">1 (100%)</td></tr><tr><td>13 thoracic vertebrae</td><td colspan="2" valign="top">50 (100%)</td><td colspan="2" valign="top">10 (100%)</td><td colspan="2" valign="top">17 (100%)</td><td colspan="2" valign="top">0 (0%)</td><td colspan="2" valign="top">0 (0%)</td></tr></tbody></table><table-wrap-foot><fn><p>Tabulation regarding the number of sternebrae found in skeletons, including ones in which there was partial fusions between the third and fourth sternebrae.</p></fn></table-wrap-foot></table-wrap><p>A majority of the <italic>Naa10<sup>-/Y</sup></italic> and <italic>Naa10<sup>-/-</sup></italic> mice also had four instead of the usual three sternebrae, which were sometimes fused (<xref ref-type="table" rid="table1">Table 1</xref>). Cervical vertebrae fusion was also demonstrated in <italic>Naa10<sup>-/Y</sup></italic> mice, particularly involving C1 and C2, suggesting possible anteriorization of C2 into a C1-like phenotype (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E, F</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>). The number of lumbar vertebrae remained the same, thus suggesting an anterior transformation of the first sacral vertebra to a lumbar-like phenotype. These combined observations suggest possible anterior transformations in the <italic>Naa10</italic> mutant skeletal phenotype, with an anteriorization of C2, a T8 transformation to a T7-like phenotype with ribs connecting to the sternum, an extra pair of ribs on L1 likely due to an L1 transformation to a T13-like phenotype, and an anterior transformation of the first sacral vertebra to a lumbar-like phenotype with loss of fusion to the sacral wings.</p><p>Out of 32 <italic>Naa10<sup>-/Y</sup></italic> that survived past the third day of life and which were then examined longitudinally, about 60% survived past 200 days of life (~7 months) (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>), with some of these then developing hydronephrosis (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, middle). They had some hollowed space in the kidney, which had been filled with fluid and their ureter was thickened already at P3 stage of prenatal development in some <italic>Naa10<sup>-/Y</sup></italic> mice (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). Commonly, hydronephrosis is caused by a blockage or obstruction in the urinary tract. We speculate that this swelling in <italic>Naa10</italic> KO (<italic>Naa10<sup>-/Y</sup></italic> and <italic>Naa10<sup>-/-</sup></italic>) mice is likely caused by ureteral defects rather than the kidney itself. Moreover, some <italic>Naa10</italic> KO mice displayed genital defects, such as seminal vesicle malformation and hydrometrocolpos, respectively (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, bottom). Many <italic>Naa10<sup>-/-</sup></italic> female mice appeared to have decreased fecundity, although they were fertile upon the first mating, and this decrease in fecundity is possibly due to the development of hydrometrocolpos (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, bottom), which might result from structural issues, like vaginal atresia or a retained vaginal septum, although this requires further investigation. Additionally, hydrocephaly became clinically apparent with a round-shaped head (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, upper) in ~40% of the <italic>Naa10<sup>-/Y</sup></italic> mice that had survived past 3 days of life (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>). CT scanning of some of these mice confirmed hydrocephaly as the primary cause of their rapid deteriorating condition, usually within the first three months of life (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B, C</xref>). CT scanning did not reveal any obstructive lesions (such as a tumor) in any of the ventricles that could account for the hydrocephaly. Taken together, these results indicate that <italic>Naa10</italic> contributes to overall development and is particularly important for viability.</p><p>Litter sizes and offspring from other matings were also investigated, as shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>. Matings were setup between <italic>Naa10<sup>-/-</sup></italic> females and C57bl6J WT (<italic>Naa10<sup>+/Y</sup></italic>) males, involving 11 mating pairs with seven unique females and seven unique males. Of a total of 127 pups that were born, 37 died in the first day of life and were degraded and/or cannibalized prior to any tail sample being retrieved, thus not being genotyped. This was a relatively high death rate in the first 24 hr of life (29%), more so than with the other matings, except for the one between <italic>Naa10<sup>-/-</sup></italic> females and <italic>Naa10<sup>-/Y</sup></italic> males (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>). However, this is substantially less than the death rate of 90% (46/51) reported for the same mating in the <xref ref-type="bibr" rid="bib46">Lee et al., 2017</xref> paper, and we currently do not have an explanation for this discrepancy. Of the remaining 90 pups that could be genotyped, 59 of these were <italic>Naa10<sup>+/-</sup></italic> females and 31 were <italic>Naa10<sup>-/Y</sup></italic> males. 7 of the 59 <italic>Naa10<sup>+/-</sup></italic> females and 2 of the 31 <italic>Naa10<sup>-/Y</sup></italic> males died in the first three days of life (for a total death rate in the first three days for all born pups of 46/127, or 36%), and after this time, none of the remaining <italic>Naa10<sup>+/-</sup></italic> females died in the first 10 weeks of life (52/59, or 88% overall survival), whereas 10 of the remaining 29 <italic>Naa10<sup>-/Y</sup></italic> males developed hydrocephaly and died in the first 10 weeks of life, for an overall survival of (19/31, or 61%). The death rate for all pups of 36% in the first three days of life is similar to the rate of 42.4% seen with the mating of <italic>Naa10<sup>-/-</sup></italic> females with <italic>Naa10<sup>-/Y</sup></italic> males (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>), whereas this rate is higher than that seen for <italic>Naa10<sup>+/-</sup></italic> females mated with <italic>Naa10<sup>+/Y</sup></italic> males (15.8%) or with <italic>Naa10<sup>-/Y</sup></italic> males (13.6%).</p></sec><sec id="s2-2"><title><italic>Naa10-</italic>deficient mice have a functionally active NatA complex</title><p>Prior experiments showed reduced in vivo protein amino-terminal acetylation of a few putative targets in patient cells (<xref ref-type="bibr" rid="bib56">Myklebust et al., 2015</xref>). Reduced Nt-acetylomes were also observed in the <italic>Naa10</italic> mutant yeast models (<xref ref-type="bibr" rid="bib80">Van Damme et al., 2014</xref>). Given these prior reports, we hypothesized that pleiotropic phenotypes in <italic>Naa10</italic>-deficient mice are due to a decrease in global N-terminal acetylation. To test our hypothesis, integrated N-terminal peptide enrichment method (iNrich) (<xref ref-type="bibr" rid="bib40">Ju et al., 2020</xref>) was used to analyze the level of protein amino-terminal acetylation in mouse embryonic fibroblast (MEF) lysates of <italic>Naa10<sup>+/Y</sup></italic> and <italic>Naa10<sup>-/Y</sup></italic>. Since the samples are treated with deuterated acetic anhydride prior to MS, unacetylated N-terminal site appears with +3 Da mass shift in the MS spectrum of the corresponding acetylated N-terminal site (<xref ref-type="bibr" rid="bib78">Van Damme et al., 2011a</xref>). The peak intensity ratios of acetyl/heavy acetyl pairs represent the degree of acetylation of the N-terminal site. We found 765 acetyl/heavy acetyl pairs of N-termini throughout five replicates of <italic>Naa10<sup>+/Y</sup></italic> and five replicates of <italic>Naa10<sup>-/Y</sup></italic> MEFs. Except for the sites detected only in either WT or mutant, 533 N-terminal sites could be compared (see tabs called ‘N-term’ and ‘Header Key’ in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2a, c</xref>). Approximately 98% (n = 522) of N-termini sites showed less than 10% variation in the degree of terminal acetylation, indicating that there is no major difference in amino-terminal acetylation between <italic>Naa10<sup>-/Y</sup></italic> and <italic>Naa10<sup>+/Y</sup></italic> MEFs (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). A more stringent analysis was also conducted in which peptides had to be detected in all 10 samples (i.e., tabs marked ‘N-term detected in all samples’ and ‘Header Key’ in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2b, c</xref>), and this resulted in 152 N-termini sites, of which only 3 (Rpl27, PPia, and Histone H1.0) had a slightly greater than 10% difference in the degree of acetylation between <italic>Naa10<sup>+/Y</sup></italic> and <italic>Naa10<sup>-/Y</sup></italic>. Although this was not a significant result statistically (p=0.09), it is worth noting that peptidyl-prolyl cis–trans isomerase A (PPIA), having a 10.3% decrease in amino-terminal acetylation, was previously identified with decreased amino-terminal acetylation in patient-derived B cells and fibroblasts in boys with the S37P mutation in NAA10 (<xref ref-type="bibr" rid="bib56">Myklebust et al., 2015</xref>), along with being decreased in siNatA knockdown HeLa cells (<xref ref-type="bibr" rid="bib5">Arnesen et al., 2009</xref>). PPIA also had decreased amino-terminal acetylation in one sample from homozygous null <italic>NAA15</italic><sup>L314*/L314*</sup>-induced pluripotent stem cells (<xref ref-type="bibr" rid="bib88">Ward et al., 2021</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Activity measurement of NatA from wildtype (WT) and <italic>Naa10</italic> knockout (KO) mice.</title><p>(<bold>A</bold>) Correlation of Naa10 alteration state on amino-terminal acetylation in mouse embryonic fibroblasts (MEFs). Each dot (n = 533) represents the average amino-terminal acetylation percentage of five replicates of <italic>Naa10<sup>+/Y</sup></italic> and <italic>Naa10<sup>-/Y</sup></italic>, respectively. Dashed lines are the borders of ±10% difference. Except for the 10 dots, 522 of the 533 dots are within the borders. The marginal histograms show the distribution of amino-terminal acetylation data points. (<bold>B</bold>) Immunoprecipitation of Naa15. Liver tissue from WT and <italic>Naa10</italic> KO mouse was lysed and incubated with anti-Naa15 antibody to retrieve NatA complexes. Proteins were separated by SDS-PAGE and immunoblots probed with anti-Naa15 antibody and anti-NAA10 antibody. (<bold>C</bold>) Catalytic activity of immunoprecipitated NatA. The catalytic activity of NatA precipitated from WT and <italic>Naa10</italic> KO mouse liver tissue by anti-Naa15 was measured towards the NatA substrate peptide SESS<sub>24</sub> in an in vitro [<sup>14</sup>C]-Ac-CoA–based acetylation assay. Control reactions were performed with no enzyme or no peptide to account for background signal. The immunoprecipitation (IP) and activity measurements were performed in three independent setups, each with three technical replicates per assay. One representative setup is shown.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Identification of a potential Naa10 homolog.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-65952-fig3-data1-v3.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Identification of a potential Naa10 homolog.</title><p>(<bold>A</bold>) Construction of <italic>Naa10</italic> Southern blot probe. (<bold>B</bold>) Southern blot membrane after hybridization with a <italic>Naa10</italic> probe. Expected size band, restricted with Apa I and Xba I, are shown. (<bold>C</bold>) Ribosome profiling traces for the potential <italic>Naa10</italic> paralog (Gm16286, UniProt: Q9CQX6). Picture was modified from GWIPS genome browser, Chr 18, 80206601–80212942.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Identification of a potential Naa10 homolog.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-65952-fig3-figsupp1-data1-v3.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig3-figsupp1-v3.tif"/></fig></fig-group><p>Overall, given the very minor differences with amino-terminal acetylation, we measured the in vitro amino-terminal acetylation activity of NatA via immunoprecipitation of the large auxiliary subunit Naa15 from mouse tissues. This analysis showed normal expression of Naa15 in <italic>Naa10</italic> KO liver tissue as in WT tissues (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), and we isolated a physical complex composed of Naa15 and undefined partners that retains NatA activity from <italic>Naa10</italic> KO tissues (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). These data suggest that despite the loss of <italic>Naa10</italic> in mice the NatA complex remains active, thus explaining the lack of major differences with amino-terminal acetylation.</p></sec><sec id="s2-3"><title>A <italic>Naa10</italic> paralog exists in mice</title><p><italic>Naa10</italic> disruption is lethal in a variety of organisms, including <italic>Drosophila melanogaster</italic> (<xref ref-type="bibr" rid="bib86">Wang et al., 2010</xref>)<italic>, C. elegans</italic> (<xref ref-type="bibr" rid="bib10">Chen et al., 2014</xref>), and <italic>Trypanosoma brucei</italic> (<xref ref-type="bibr" rid="bib37">Ingram et al., 2000</xref>). Given the relatively mild phenotype and no reduction of the Nt-acetylome in <italic>Naa10</italic> KO mice, we hypothesized that there might be a yet unidentified paralog of <italic>Naa10,</italic> which can compensate for loss of function in mice. A Blast search for genomic sequences with homology to <italic>Naa10</italic> exposed several <italic>Naa10</italic> pseudogenes on chromosomes 2, 3, 7, 12, 15, and 18. Additionally, Southern blot analysis from C57BL/6J DNA with <italic>Naa10</italic> cDNA probe detected bands of the expected sizes on the X chromosome (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A, B</xref>), while other bands of unexpected sizes appeared on other chromosomes 2, 5, 15, and 18. The previously identified <italic>Naa10</italic> paralog <italic>Naa11</italic> is located on chromosome 5; however, this paralog is only expressed in testes (<xref ref-type="bibr" rid="bib58">Pang et al., 2011</xref>). We found a predicted gene (Gm16286, UniProt: Q9CQX6) on chromosome 18, with high similarity to <italic>Naa10</italic>, which we name <italic>Naa12</italic>, and RiboSeq and mRNA traces of this region suggest possible transcription and translation of this gene (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). The protein sequence of <italic>Naa12</italic> is &gt;80% identical to <italic>Naa10</italic> and almost 90% identical with <italic>Naa11</italic> (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>).</p><p>Quantitative PCR (q-PCR) analysis also confirmed the expression of this transcript in all tested tissues (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>), with the expression of Naa12 unchanged in the corresponding <italic>Naa10</italic> KO tissues. We attempted to test for Naa12 expression in mouse tissues by developing an antibody specific for Naa12 by performing a sequence alignment of the two known mNaa10 isoforms, mNaa11 and mNaa12, and selecting a unique Naa12 peptide for immunization and antibody generation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). After generation and affinity purification, we validated the specificity and sensitivity of this Naa12 antibody with recombinant proteins purified from bacterial hosts (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C, D</xref>). However, multiple attempts to use this antibody to detect Naa12 in mouse tissues met with conflicting results, so that we were unable to consistently detect Naa12 even in WT liver, kidney, or brain tissue lysates, which could be due to a poor antibody and/or very low expression or post-translational modification of Naa12 in these tissues, thus making it difficult to detect. Furthermore, given that this antibody was raised against a peptide at the C-terminus of Naa12, such data could not be used anyway to completely exclude the possibility of truncated non-functional mini-protein expression, although the lack of any signal with RT-PCR (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>) likely means that nonsense-mediated decay occurred. Presently, the rabbit polyclonal antibody is no longer recognizing any consistent protein bands in western blotting, so we have abandoned any further attempts to use this antibody.</p><p>To test whether Naa12 has a similar enzymatic activity as Naa10, we performed a radioactive-based acetyltransferase assay using synthetic peptides (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Since monomeric Naa10 preferentially acetylates N-termini with acidic side chains (<xref ref-type="bibr" rid="bib29">Foyn et al., 2013</xref>; <xref ref-type="bibr" rid="bib79">Van Damme et al., 2011b</xref>; <xref ref-type="bibr" rid="bib50">Liszczak et al., 2013</xref>), we used peptides representing the N-termini of γ-actin (starting DDDIA-) and γ-actin (starting EEEIA-), which are two known Naa10 in vitro substrates. Additionally, we used a peptide starting with SESSSKS-, representing an in vitro NatA complex substrate high-mobility group protein A1. As expected for the monomeric proteins, we could not detect any activity towards the SESSSKS substrate. Importantly, both Naa10 and Naa12 significantly Nt-acetylated the acidic N-terminal peptides, demonstrating the intrinsic capacity of Naa12 to catalyze amino-terminal acetylation (<xref ref-type="fig" rid="fig4">Figure 4A</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Characterization of <italic>Naa12.</italic></title><p>(<bold>A</bold>) In vitro N-terminal acetyltransferase radioactive-based assay. Comparison of mouse Naa10 and Naa12 towards Naa10 peptide substrates, beta-actin (DDDIA-) and gamma-actin (EEEIA-), and the optimal NatA complex peptide substrate, SESSS-. Background control reactions were performed in the absence of either peptide or enzyme. Assays were performed in triplicate; error bars represent SEM. (<bold>B</bold>) Co-immunoprecipitation assay. HEK293 cells were transfected as indicated and lysed after 48 hr. Cell lysates were incubated with 1 μg anti-V5 antibody to precipitate V5-tagged Naa15. The isolated complexes were separated on SDS-PAGE and probed with the indicated antibodies. (<bold>C</bold>) Recombinant mouse Naa12/human Naa15 chimera complex activity. Radioactive acetyltransferase activity assay evaluating the activity of mNaa12-hNaa15 towards peptide (closed circles, ‘mNaa12-hNaa15’) and peptide chemical acetylation in the absence of enzyme (closed circles, ‘Buffer’) as well as chemical acetylation of the enzyme in the absence of peptide (open circles) assay and background (open circles). Error bars represent SD of two technical replicates. These are the same results from fraction #14 (both SESSS- and No Peptide) and both Buffer and Background used to illustrate the size-exclusion-purified mNaa12-hNaa15 complex activity in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F</xref>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Characterization of a potential Naa10 homolog.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-65952-fig4-data1-v3.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Characterization of a potential Naa10 homolog.</title><p>(<bold>A</bold>) qPCR analyses of mouse NATs (mNATs) in <italic>Naa10</italic> wildtype (WT) and knockout (KO) adult mouse tissue. (<bold>B</bold>) Sequence alignment of mNaa10 isoforms and paralogs, including the potential Naa10 paralog mNaa12 (Gm16286, UniProt: Q9CQX6) using Clustal Omega (EMBL-EBI). The peptide used for immunization of rabbits to generate a specific antibody is indicated in red. (<bold>C</bold>) Full-length mNAT cDNA from mouse was amplified and cloned into pGEX-4T1. Proteins were expressed in <italic>E. coli</italic> BL21 (DE3) and purified via GSH-Sepharose. Shown is a Coomassie stain of fraction 1–4. (<bold>D</bold>) Cross-reactivity and sensitivity of the used NAT antibodies. 1–20 pmol of GST-mNAT proteins were separated on SDS-PAGE followed by western blot, probed with the indicated antibodies. (<bold>E</bold>) Recombinant mouse Naa12/human Naa15 chimera complex. Silver-stained denaturing SDS-PAGE (left) containing fractions (#10–20) eluted from an S200 size-exclusion chromatography (SEC) column with fractions evaluated for NatA-type activity indicated (asterisks, below gel) with (<bold>F</bold>) corresponding radioactive acetyltransferase activity assay comparing the activity of indicated fractions and buffer control (chemical acetylation) towards the SESSS- peptide (filled circles), in the absence of peptide (open circles), and assay background (x). Error bars represent SD of two technical replicates.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Characterization of a potential Naa10 homolog.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-65952-fig4-figsupp1-data1-v3.pdf"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Characterization of a potential Naa10 homolog.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-65952-fig4-figsupp1-data2-v3.pdf"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata3"><label>Figure 4—figure supplement 1—source data 3.</label><caption><title>Characterization of a potential Naa10 homolog.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-65952-fig4-figsupp1-data3-v3.pdf"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata4"><label>Figure 4—figure supplement 1—source data 4.</label><caption><title>Characterization of a potential Naa10 homolog.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-65952-fig4-figsupp1-data4-v3.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig4-figsupp1-v3.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Confirmation and characterization of Naa12 knockout (KO) mice.</title><p>(<bold>A</bold>) Expression of <italic>Naa10</italic> and <italic>Naa12</italic> in wildtype (WT), <italic>Naa10</italic> KO and <italic>Naa12</italic> KO tissues, adult mice 13 weeks of age, (brain, heart, kidney, and testis) by RT-PCR. Expression of GAPDH was analyzed as an endogenous control. (<bold>B</bold>) Phenotypes in <italic>Naa12</italic> KO mice. Lack of hypopigmentation (upper; N = 29) and lack of supernumerary ribs (middle and bottom; E18.5; N = 7) in <italic>Naa12</italic> KO mouse.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig4-figsupp2-v3.tif"/></fig></fig-group><p>Across species, Naa10 is bound to its auxiliary subunit, Naa15, which links the catalytic subunit to the ribosome to facilitate co-translational amino-terminal acetylation of proteins as they emerge from the exit tunnel (<xref ref-type="bibr" rid="bib55">Mullen et al., 1989</xref>; <xref ref-type="bibr" rid="bib77">Sugiura et al., 2003</xref>; <xref ref-type="bibr" rid="bib59">Park and Szostak, 1992</xref>; <xref ref-type="bibr" rid="bib31">Gautschi et al., 2003</xref>; <xref ref-type="bibr" rid="bib52">Magin et al., 2017</xref>; <xref ref-type="bibr" rid="bib83">Varland and Arnesen, 2018</xref>). Due to its high sequence similarity (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), we suspected that Naa12 may also interact with Naa15. To test this hypothesis, we performed co-immunoprecipitation assays in HEK 293 cells. Apart from Naa10 (isoform 1, Naa10<sup>235</sup>) and Naa12, we also included the second isoform of mNaa10, mNaa10<sup>225</sup> that has been described earlier (<xref ref-type="bibr" rid="bib2">Arnesen et al., 2005</xref>; <xref ref-type="bibr" rid="bib59">Park and Szostak, 1992</xref>; <xref ref-type="bibr" rid="bib42">Kim et al., 2006</xref>) as well as Naa11. Both Naa10 isoforms as well as Naa11 and Naa12 co-precipitated with V5-Naa15 but not V5 alone, suggesting that all tested proteins could form a stable complex with Naa15 in mouse (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). As we have previously purified the human NatA complex composed of truncated human Naa10 (residues 1–160) and full-length human Naa15 complexes that had been expressed in insect cells (<xref ref-type="bibr" rid="bib33">Gottlieb and Marmorstein, 2018</xref>), we attempted to co-express a chimeric truncated mouse Naa12 (residues 1–160) with full-length human Naa15 complex in insect cells (human and mouse Naa15 are highly conserved with a sequence conservation of 98.2%). The complex was purified by a combination of affinity, ion exchange, and size-exclusion chromatography, and size-exclusion fractions harboring a clearly detectable band of Naa15 and a lighter band for Naa12, as determined by silver staining, were analyzed for activity towards a SESSSKS- peptide (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E, F</xref>). This analysis revealed that peak fractions containing the Naa12-Naa15 complex harbored detectable amino-terminal acetylation activity towards the SESSSKS- peptide (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F</xref>), thus demonstrating catalytic activity of a NatA complex with mouse Naa12.</p><p>In a mass spectrometry analysis of a similar setup to that shown in <xref ref-type="fig" rid="fig3">Figure 3B</xref>, NAA15 immunoprecipitates from WT or <italic>Naa10</italic>-KO mouse livers were analyzed by mass spectrometry. We found five distinct peptides derived from Naa12 (<xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2d</xref>). Three of these derive from the same part of the peptide sequence, RDLSQMADELRR, and all of these three peptides had one or two missed trypsin cleavages (DLSQMADELRR, RDLSQMADELR, and RDLSQMADELRR). The other two peptides, AMIENFSAK and ENQGSTLPGSEEASQQENLAGGDSGSDGK, are not the results of missed cleavages. None of these peptides are found in other sequences in the mouse genome and thus unambiguously identify Naa12 in our experiments. They have higher intensities in Naa15 IPs compared to Ctrl IPs, indicating that Naa12 is selectively enriched by Naa15 IP. Some peptides are additionally assigned to the Naa10/Naa11/Naa12 protein group as a large part of their sequences are identical. As expected, no unique Naa10 peptides are identified in the IPs from <italic>Naa10</italic>-KO mice. 12 peptides were ambiguously assigned to Naa12 or to major urinary proteins (Mup9, Mup8, Mup1, Mup17, Mup5, or Mup2), but these are as likely to be derived from Mups as from Naa12, as they have comparable intensities between Ctrl and Naa15 IPs.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Naa10, Naa11, and Naa12 peptides identified by LC-MS/MS analysis in Naa15 IP samples from WT and <italic>Naa10</italic>-KO mouse.</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top">Gene name</th><th rowspan="2" valign="top">Peptide sequence</th><th colspan="2" valign="top">Log2 LFQ intensity Naa15-IP</th></tr><tr><th valign="top">WT mouse</th><th valign="top"><italic>Naa10</italic>-KO mouse</th></tr></thead><tbody><tr><td valign="bottom"><italic>Naa12</italic></td><td valign="bottom">AMIENFSAK</td><td valign="bottom">23.8144</td><td valign="bottom">27.5563</td></tr><tr><td valign="bottom"><italic>Naa12</italic></td><td valign="bottom">DLSQMADELRR</td><td valign="bottom">25.2637</td><td valign="bottom">28.38</td></tr><tr><td valign="bottom"><italic>Naa12</italic></td><td valign="bottom">ENQGSTLPGSEEASQQENLAGGDSGSDGK</td><td valign="bottom">21.299</td><td valign="bottom">22.09</td></tr><tr><td valign="bottom"><italic>Naa12</italic></td><td valign="bottom">RDLSQMADELR</td><td valign="bottom">-</td><td valign="bottom">22.20</td></tr><tr><td valign="top"><italic>Naa12</italic></td><td valign="bottom">RDLSQMADELRR</td><td valign="bottom">-</td><td valign="bottom">27.77</td></tr><tr><td valign="top"><italic>Naa10</italic></td><td valign="bottom">AALHLYSNTLNFQISEVEPK</td><td valign="bottom">26.7672</td><td valign="top">-</td></tr><tr><td valign="bottom"><italic>Naa10</italic></td><td valign="bottom">AMIENFNAK</td><td valign="bottom">27.3981</td><td valign="top">-</td></tr><tr><td valign="bottom"><italic>Naa10</italic></td><td valign="bottom">DLTQMADELRR</td><td valign="bottom">25.5107</td><td valign="top">-</td></tr><tr><td valign="bottom"><italic>Naa10</italic></td><td valign="bottom">GNVLLSSGEACREEK</td><td valign="bottom">25.0717</td><td valign="top">-</td></tr><tr><td valign="bottom"><italic>Naa10</italic></td><td valign="bottom">HMVLAALENK</td><td valign="bottom">25.5293</td><td valign="top">-</td></tr><tr><td valign="bottom"><italic>Naa10</italic></td><td valign="bottom">NARPEDLMNMQHCNLLCLPENYQMK</td><td valign="bottom">25.8928</td><td valign="top">-</td></tr><tr><td valign="bottom"><italic>Naa10</italic></td><td valign="bottom">YYFYHGLSWPQLSYIAEDENGK</td><td valign="bottom">26.5915</td><td valign="top">-</td></tr><tr><td valign="top"><italic>Naa12;Naa11</italic></td><td valign="bottom">AALHLYSNTLNFQVSEVEPK</td><td valign="bottom">-</td><td valign="bottom">27.3833</td></tr><tr><td valign="top"><italic>Naa12;Naa11</italic></td><td valign="bottom">YYFYHGLSWPQLSYIAEDEDGKIVGYVLAK</td><td valign="bottom">-</td><td valign="bottom">25.2517</td></tr><tr><td valign="top"><italic>Naa12;Naa11;Naa10</italic></td><td valign="bottom">IVGYVLAK</td><td valign="bottom">28.0873</td><td valign="bottom">25.7753</td></tr><tr><td valign="top"><italic>Naa12;Naa11;Naa10</italic></td><td valign="bottom">MEEDPDDVPHGHITSLAVK</td><td valign="bottom">29.1069</td><td valign="bottom">29.265</td></tr><tr><td valign="top"><italic>Naa12;Naa11;Naa10</italic></td><td valign="bottom">MEEDPDDVPHGHITSLAVKR</td><td valign="bottom">24.7605</td><td valign="bottom">21.7784</td></tr><tr><td valign="top"><italic>Naa12;Naa11;Naa10</italic></td><td valign="bottom">YVSLHVR</td><td valign="bottom">22.8611</td><td valign="bottom">23.7383</td></tr><tr><td valign="top"><italic>Naa12;Naa11;Naa10</italic></td><td valign="bottom">YYADGEDAYAMK</td><td valign="bottom">-</td><td valign="bottom">27.2083</td></tr><tr><td valign="top"><italic>Naa12;Naa11;Naa10</italic></td><td valign="bottom">YYADGEDAYAMKR</td><td valign="bottom">27.2319</td><td valign="bottom">27.1689</td></tr></tbody></table><table-wrap-foot><fn><p>Samples were run in technical duplicates and the average log2 LFQ intensity of the peptides is presented.</p><p>IP: immunoprecipitation; WT: wildtype; KO: knockout; LFQ: label-free quantification.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-4"><title><italic>Naa12</italic> rescues loss of <italic>Naa10</italic> in mice</title><p>To investigate whether <italic>Naa12</italic> can rescue the loss of the function of Naa10 in vivo, <italic>Naa12</italic> KO mice were generated using CRISPR technology (<xref ref-type="bibr" rid="bib74">Singh et al., 2015</xref>). One 95-base pair deletion Δ131–225 in <italic>Naa12</italic> was characterized in depth (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). This mutation introduces a frameshift, leading to a termination codon at amino acid 67, which should either result in complete KO of the protein or, at best, the expression of a truncated mini-protein that would be far shorter than the usual 220 amino acid Naa12. We confirmed the deletion by PCR with genomic DNA (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). QPCR further showed deletion of <italic>Naa12</italic> in the tested tissues of <italic>Naa12</italic> KO mice (<xref ref-type="fig" rid="fig5">Figure 5C</xref>); however, it seemed that <italic>Naa12</italic> might be slightly expressed in testis. Due to the high similarity between <italic>Naa11</italic> and <italic>Naa12</italic>, the expression shown in <italic>Naa12</italic> KO testis could actually be <italic>Naa11</italic> rather than <italic>Naa12</italic>, and this was confirmed by RT-PCR showing definite deletion (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Generation of <italic>Naa12</italic> knockout (KO) mice.</title><p>(<bold>A</bold>) Scheme of <italic>Naa12</italic> (Gm16286, UniProt: Q9CQX6) deletion used to generate <italic>Naa12</italic> KO mouse. 95 base pairs (131–225) were deleted. F′: genomic DNA forward primer; F′′: cDNA forward primer; R: reverse primer. (<bold>B</bold>) Genotyping of <italic>Naa12</italic> KO mice by PCR. Wildtype (WT) allele size was 381 bp and targeted allele size was 287 bp. (<bold>C</bold>) mRNA level of <italic>Naa12</italic> was analyzed in selected tissues by qPCR. Relative expression level of WT (white bars) and <italic>Naa12</italic> KO (black bars) after normalizing to that of GAPDH.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Generation of <italic>Naa12</italic>KO mice.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-65952-fig5-data1-v3.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig5-v3.tif"/></fig><p>Paralogs are homologous genes that originate from the intragenomic duplication of an ancestral gene. Homologs that play a compensatory role can sometimes show similar phenotypes to each other when one of them is deficient (<xref ref-type="bibr" rid="bib60">Peng, 2019</xref>), whereas other homologs might only offer partial compensation when the primary gene is more widely expressed or has higher activity levels. We analyzed <italic>Naa12</italic> KO mice to see if they produced similar developmental defects to those in <italic>Naa10</italic> KO mice. KO mice for this gene were viable (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>). Although there was initially a question of decreased fertility for the male mice, larger numbers of matings and litters did not bear this out (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>), and necropsy and inspection of testes and seminal vesicles under a stereomicroscope did not reveal any macroscopic differences. Furthermore, the phenotypes (piebaldism and bilateral supernumerary ribs, <xref ref-type="fig" rid="fig2">Figure 2B</xref>) observed in <italic>Naa10</italic> KO mice with complete penetrance were not present in <italic>Naa12</italic> KO mice (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). Overall, there were not any obvious phenotypes in these mice.</p><p>Matings between <italic>Naa10<sup>+/-</sup> Naa12<sup>+/+</sup></italic> female mice and either <italic>Naa10<sup>+/y</sup> Naa12<sup>+/-</sup></italic> or <italic>Naa10<sup>+/y</sup> Naa12</italic><sup>-/-</sup> males produced zero male <italic>Naa10<sup>-/y</sup> Naa12</italic><sup>+/-</sup> progeny, while also suggesting that compound heterozygous (<italic>Naa10<sup>+/-</sup> Naa12)</italic> female mice are produced at a rate much less than predicted by Mendelian ratios (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f, g</xref>). Matings between surviving compound heterozygous (<italic>Naa10<sup>+/-</sup> Naa12<sup>+/-</sup></italic>) females and <italic>Naa10<sup>+/Y</sup> Naa12<sup>+/-</sup></italic> males demonstrate that no live births occurred for <italic>Naa10 Naa12</italic> double-knockout (DKO) males (<italic>Naa10<sup>-/Y</sup> Naa12</italic><sup>-/-</sup>) (<xref ref-type="fig" rid="fig6">Figure 6</xref>). In addition, the average litter size was small when compared to the control (WT × WT) matings, suggesting embryonic lethality (<xref ref-type="table" rid="table3">Table 3</xref>). In order to determine whether lethality occurs during the embryonic stage, we genotyped E18.5 litters – just before birth. Consistent with our previous observations, we could not obtain any <italic>Naa10<sup>-/Y</sup> Naa12</italic><sup>-/-</sup> embryos, and many embryos could not be genotyped because they were already in the midst of resorption (n = 23) (<xref ref-type="fig" rid="fig6">Figure 6</xref>). We checked an even earlier stage at E10.5 and also found zero <italic>Naa10<sup>-/Y</sup> Naa12</italic><sup>-/-</sup> embryos, and also with far fewer resorptions at this stage (N = 3). Interestingly, we did observe <italic>Naa10<sup>-/Y</sup> Naa12<sup>+/-</sup></italic> embryos where two of them displayed delayed developmental stage (appearing younger than E10.5) and another two embryos were lysed and had already begun degenerating (but despite this, we could at least genotype these embryos). This helps explain why only one <italic>Naa10<sup>-/Y</sup> Naa12<sup>+/-</sup></italic> embryo was observed at E18.5. Furthermore, <italic>Naa10<sup>+/-</sup> Naa12</italic><sup>-/-</sup> female embryos were also lysed/degenerating at E10.5 and were not observed from that day onward. Matings between compound heterozygous females and <italic>Naa10<sup>+/Y</sup> Naa12</italic><sup>-/-</sup> males also did not yield any <italic>Naa10<sup>-/Y</sup> Naa12</italic><sup>-/-</sup> male mice at any embryonic stage examined, and only a couple of <italic>Naa10<sup>+/-</sup> Naa12</italic><sup>-/-</sup> female mice at early stages of development (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>), and the litter sizes were even smaller, suggesting increased embryonic lethality (<xref ref-type="table" rid="table3">Table 3</xref>). Consistent with this, we noted many resorptions at E12.5 and E18.5 that could not be genotyped. The number of living postnatal compound heterozygous female mice was also considerably lower than the predicted Mendelian ratios (<xref ref-type="fig" rid="fig6">Figure 6</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>) and the surviving <italic>Naa10<sup>+/-</sup> Naa12<sup>+/-</sup></italic> females were smaller in size than littermate controls (<xref ref-type="fig" rid="fig7">Figure 7D</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Lethality in <italic>Naa10 Naa12</italic> double-knockout (DKO) mice.</title><p><italic>Naa10 Naa12</italic> DKO exhibit embryonic lethality. Pedigree and genotypes of pups and embryos at E10.5 and E18.5 from <italic>Naa10<sup>+/-</sup> Naa12<sup>+/-</sup></italic> female mice crossed to the <italic>Naa10<sup>+/Y</sup> Naa12<sup>+/-</sup></italic> male mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig6-v3.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Genotypes of offspring from <italic>Naa10<sup>+/-</sup> Naa12<sup>+/-</sup></italic> female mice crossed to the <italic>Naa10<sup>+/Y</sup> Naa12<sup>-/-</sup></italic> male mice.</title><p><italic>Naa10 Naa12</italic> double-knockout (DKO) exhibit embryonic lethality. Pedigree of mating and genotypes of pups and embryos at E8.5, E10.5, E12.5, and E18.5.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig6-figsupp1-v3.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Comparisons of Mendelian predicted, observed, and model D<sub>4</sub> predicted offspring numbers for female genotypes (#1–#6) at each age.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig6-figsupp2-v3.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Comparisons of Mendelian predicted, observed, and model D<sub>4</sub> predicted offspring numbers for male genotypes (#7–#12) at each age.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig6-figsupp3-v3.tif"/></fig><fig id="fig6s4" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 4.</label><caption><title>Comparisons of cumulative Mendelian predicted, observed, and model D<sub>4</sub> predicted offspring numbers for female genotypes (#1–#6) at each age.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig6-figsupp4-v3.tif"/></fig><fig id="fig6s5" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 5.</label><caption><title>Comparisons of cumulative Mendelian predicted, observed, and model D<sub>4</sub> predicted offspring numbers for male genotypes (#7–#12) at each age.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig6-figsupp5-v3.tif"/></fig></fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Decreased body weight in compound heterozygous females.</title><p>(<bold>A</bold>) Male body weight for the <italic>Naa10</italic> mice on inbred genetic background (eight backcrosses to C57bl6/J). (<bold>B</bold>) Female body weight for the <italic>Naa10</italic> mice on inbred genetic background (eight backcrosses to C57bl6/J). (<bold>C</bold>) Male body weight for the <italic>Naa10</italic> and <italic>Naa12</italic> mice on mixed genetic background. (<bold>D</bold>) Female body weight for the <italic>Naa10</italic> and <italic>Naa12</italic> mice on mixed genetic background.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65952-fig7-v3.tif"/></fig><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Litter size of Naa10 × Naa12 matings.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Genotypes of Naa10; Naa12 breeders (♀ x ♂)</th><th valign="top">Total number of pups</th><th valign="top">Total number of litters</th><th valign="top">Average litter size <break/>(pups/litters)</th><th valign="top">SD of litter size</th></tr></thead><tbody><tr><td><italic>Naa10<sup>+/+</sup> Naa12<sup>+/+</sup></italic> × <italic>Naa10<sup>+/Y</sup> Naa12<sup>+/+</sup></italic></td><td>206</td><td>24</td><td>8.6</td><td>1.6</td></tr><tr><td><italic>Naa10<sup>+/-</sup> Naa12<sup>+/-</sup></italic> × <italic>Naa10<sup>+/Y</sup> Naa12<sup>+/-</sup></italic></td><td>157</td><td>32</td><td>4.9</td><td>1.5</td></tr><tr><td><italic>Naa10<sup>+/-</sup> Naa12<sup>+/-</sup></italic> × <italic>Naa10<sup>+/Y</sup> Naa12<sup>-/- *</sup></italic></td><td>225</td><td>63</td><td>3.6</td><td>1.7</td></tr></tbody></table><table-wrap-foot><fn><p><sup>*</sup>This mating was performed at IBR in Staten Island, New York, whereas the other two matings were performed at Ewha Womans University, Seoul, Republic of Korea.</p><p>SD: standard deviation.</p></fn></table-wrap-foot></table-wrap><p>Due to the severe embryonic lethality observed in the <italic>Naa10 Naa12</italic> DKO male mice and the <italic>Naa10<sup>+/-</sup> Naa12</italic><sup>-/-</sup> female mice, which was not seen in each single KO (<italic>Naa10</italic> KO or <italic>Naa12</italic> KO), it seems likely that, without compensation by Naa12, amino-terminal acetylation is disrupted in <italic>Naa10 Naa12</italic> DKO mice. Together, these data support the compensatory role of Naa12 in vivo.</p></sec><sec id="s2-5"><title>Genotype distribution modeling of <italic>Naa10</italic>- and <italic>Naa12</italic>-deficient offspring</title><p>The discrepancies we noted between the observed offspring genotype distributions and the expected Mendelian frequencies prompted us to examine the results from four matings (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h–m</xref>) with the goal of understanding the effects of combined <italic>Naa10</italic> and <italic>Naa12</italic> mutations on embryonic and postnatal mortality. We created mathematical models to predict the observed genotype distribution at each age based on successive incorporation of assumptions of the lethality of specific offspring genotypes. Embryonic genotype data was obtained from two matings for which embryonic genotype data were obtained (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h, i</xref>). Those matings were (1) <italic>Naa10<sup>+/Y</sup>; Naa12<sup>+/-</sup></italic> males crossed with <italic>Naa10<sup>+/-</sup>; Naa12<sup>+/-</sup></italic> females (<xref ref-type="fig" rid="fig6">Figure 6</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>) and (2) <italic>Naa10<sup>+/Y</sup>; Naa12<sup>-/-</sup></italic> males crossed with <italic>Naa10<sup>+/-</sup>; Naa12<sup>+/-</sup></italic> females (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1i</xref>). The genotype numbering shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref> was used throughout this analysis, and the corresponding genotypes for all other crosses are aligned to have the same numbers. Each model described below adjusted the expected observed genotype frequencies at each age to account for loss of embryos or pups due to the predicted lethal effects of one or more genotypes by the method described in Materials and methods. Three stages of models (B–D) were compared with the expected Mendelian distribution (model A).</p><p>Model B assumed that the double KO male genotype 12 (<italic>Naa10<sup>-/Y</sup>; Naa12<sup>-/-</sup></italic>) is lethal from very early in development based on the observation that this genotype was not found in any embryos or pups out of 483 obtained genotypes from all litters. Specifically, 0 out of an expected 7.9 were detected at E10.5 or earlier, 0 out of an expected 14.5 were detected at E18.5 or earlier, and 0 out of an expected 46.7 were detected by P3. Thus, the survival for genotype 12 was 0% for all ages examined.</p><p>Model C was developed from model B in two stages by incorporating separately observations that the male genotype 11 (<italic>Naa10<sup>-/Y</sup>; Naa12<sup>+/-</sup></italic>) and the female genotype 6 (<italic>Naa10<sup>+/-</sup>; Naa12<sup>-/-</sup></italic>) were lethal during mid to late fetal development. Based on the Mendelian model, 5 of 9.8 (51%) expected genotype 11 were detected by E10.5 but only 1 of expected 8.6 (11.6%) were identified on E12.5 or E18.5 and none were detected at P3. The five embryos that were present at E10.5 were noted to be lysed and/or developmentally delayed; the single E18.5 genotype 11 embryo was not observed to be abnormal. Based on the Mendelian model for genotype 6, 1 of 2.6 expected E8.5 embryos and 3 of 5.3 expected E10.5 embryos were identified. All three E10.5 embryos were identified as lysed. Genotype 6 was not identified after age E10.5. Cumulatively, 4 of 7.9 expected embryos detected by E10.5 and 0 of 38.8 expected embryos/pups thereafter.</p><p>Model D incorporated the assumptions of models B and C and added adjustments to the survival rates of genotype 5 (<italic>Naa10<sup>+/-</sup>; Naa12<sup>+/-</sup></italic>) and genotype 10 (<italic>Naa10<sup>-/Y</sup>; Naa12<sup>+/+</sup></italic>) based on the observations that these genotypes were underrepresented at late fetal ages or early postpartum. Genotype 5 was overrepresented during embryogenesis (31 identified but only 18.4 expected for all embryonic ages) but was underrepresented at P3 (17 of 42 expected) based on the expected Mendelian frequencies. A better analysis was achieved by comparing the observed genotype frequencies with those predicted by model C because the expected distributions are significantly affected by the lethal effects of the three genotypes considered in that model. In that case, the genotype overrepresentation during embryogenesis is somewhat less (31 identified but only 22.1 expected) but the underrepresentation at P3 is significantly increased (17 identified of 62 expected, or 27%). Using a model (D<sub>3</sub>) that incorporated adjusted survival rates for genotypes 12, 11, 6, and 5, we found that genotype 10 remained underrepresented in the observed postnatal offspring counts. The subsequent model (D<sub>4</sub>) incorporated adjustments to genotype 10 survival rates at E18.5 and P3 to account for this and then was slightly refined by adjusting other genotype survival rates to maximize the fit of all genotypes at all ages. The survival values for model D<sub>4</sub> are shown in <xref ref-type="table" rid="table4">Table 4</xref>. A comparison of the observed offspring numbers with those predicted by the Mendelian distribution and model D<sub>4</sub>is shown in <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplements 2</xref>–<xref ref-type="fig" rid="fig6s5">5</xref>.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Model D<sub>4 </sub>genotype survival by age.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">#*</th><th valign="top">Genotype</th><th valign="top">E8.5 (%)</th><th valign="top">E10.5 (%)</th><th valign="top">E12.5 (%)</th><th valign="top">E18.5 (%)</th><th valign="top">Postnatal (%)</th></tr></thead><tbody><tr><td>12</td><td><italic>Naa10<sup>-/Y</sup>; Naa12<sup>-/-</sup></italic></td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>11</td><td><italic>Naa10<sup>-/Y</sup>; Naa12<sup>+/-</sup></italic></td><td>40</td><td>35</td><td>10</td><td>10</td><td>0</td></tr><tr><td>6</td><td><italic>Naa10<sup>+/-</sup>; Naa12<sup>-/-</sup></italic></td><td>40</td><td>33</td><td>0</td><td>0</td><td>0</td></tr><tr><td>5</td><td><italic>Naa10<sup>+/-</sup>; Naa12<sup>+/-</sup></italic></td><td>100</td><td>100</td><td>100</td><td>100</td><td>35</td></tr><tr><td>10</td><td><italic>Naa10<sup>-/Y</sup>; Naa12<sup>+/+</sup></italic></td><td>100</td><td>100</td><td>100</td><td>55</td><td>55</td></tr><tr><td/><td>All Others</td><td>100</td><td>100</td><td>100</td><td>100</td><td>100</td></tr></tbody></table><table-wrap-foot><fn><p><sup>*</sup>Genotype number according to <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>.</p><p>E: embryonic day.</p></fn></table-wrap-foot></table-wrap><p>The observations of reduced survival for selected <italic>Naa10</italic>/<italic>Naa12</italic> mutants suggests that <italic>Naa10</italic> is the more dominant function (e.g., is able to provide <italic>Naa12</italic> functions more successfully than <italic>Naa12</italic> can provide <italic>Naa10</italic> functions) but that two copies of <italic>Naa10</italic> are required to replace complete loss of <italic>Naa12</italic> in females, possibly due to X-linked inactivation of <italic>Naa10</italic> during development. The stochastic nature of X-linked inactivation in time and space may make <italic>Naa10</italic> functionality somewhat unpredictable during development in a background having a mixture of <italic>Naa10</italic> and <italic>Naa12</italic> mutations.</p></sec><sec id="s2-6"><title>Statistical examination of weight data in <italic>Naa10</italic>- and <italic>Naa12</italic>-deficient mice</title><p>To determine whether Naa10 and Naa12 are essential for viability and development, we examined the survival, weights, and growth rates of 688 <italic>Naa10</italic> and <italic>Naa12</italic> KO and WT mice. The genotypes of mice examined are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1n</xref>. To avoid potential survival biases, only weights taken during the first 180 days were included. Growth curves are shown in <xref ref-type="fig" rid="fig7">Figure 7</xref>. Age and age-squared (the quadratic term) are both entered in the analyses; the quadratic term shows the degree to which the effect of age itself changes with age.</p><p><xref ref-type="supplementary-material" rid="supp1">Supplementary file 1o</xref> shows the results in which the weight of <italic>Naa10</italic> mice in grams is regressed upon age, Naa10 KO status, and their interaction. Unsurprisingly, age predicts weight for males and females strongly, with growth slowing with age (first column). Though a strong negative effect of the KO is seen in for both males and females (second column), when both age and KO status are modeled together (third column), this effect all but disappears in females. Moreover, in females there is no interaction of KO status with age (fourth column), suggesting that the <italic>Naa10</italic> KO status itself has no significant effect on the growth rate in females. For males, however, the main effect of the KO remains when age is included in the model (third column) and the interaction is significant (fourth column), indicating that the <italic>Naa10</italic> KO both reduces weight of males overall and lowers the rate of growth.</p><p>Results of analyses of mixed-genetic background Naa10/Naa12 mice are shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1p</xref>. Effects of age and KOs on weight comprise the upper portion of the table, while the lower portion shows their effect on the rate of weight gain. Among females, a significant reduction of weight (above, second column) and in the rate of growth (below, first column) is seen among mice heterozygous for the Naa10 KO. There were no homozygous Naa10 KO female mixed-breed mice available to analyze as the matings were not setup to yield any such mice (so breeding patterns, not mortality in utero, are the reason for this absence). No significant effect on growth rate is seen for heterozygous or homozygous Naa12 KO (above, third column) or for their interactions with age (below, second column), and only the effects of the heterozygous Naa10 KO and its interaction with age are seen in the full model (below, third column). Thus, the Naa12 KO, whether heterozygous or homozygous, does not appear to reduce the weight or growth rate of females, while a heterozygous Naa10 KO is sufficient to reduce both weight and growth rate. Interestingly, when modeled together, both the Naa10 and the <italic>Naa12</italic> KOs significantly reduced weight (above, fourth column) and the interaction of the Naa10 and the <italic>Naa12</italic> heterozygous KOs significantly reduced weight (above, fifth column). As no female mice were both KO for <italic>Naa10</italic> and homozygous KO for <italic>Naa12</italic>, the effect of the interaction of those two factors could not be determined. The triple interaction of heterozygous <italic>Naa10</italic> KO, <italic>Naa12</italic> KO, and age was weakly significant, suggesting that the presence of both KOs affects growth rate above and beyond the effects of each KO independently (below, fourth column). No males with KOs of both <italic>Naa10</italic> and <italic>Naa12</italic> were born, so no test of their interaction was possible. An effect was seen for the Naa10 KO on weight when modeled with age and age<sup>2</sup> (second column), and the significant interaction of the <italic>Naa10</italic> KO with age and age<sup>2</sup> (third column) shows that the <italic>Naa10</italic> KO in males reduces the growth rate. As with females, no significant effect of a <italic>Naa12 KO</italic>, whether heterozygous or homozygous, was seen in males, nor is there a significant interaction with age (fourth column). When the interactions of age with both <italic>Naa10</italic> and <italic>Naa12</italic> KO status are entered in one model, <italic>Naa10</italic> alone is seen to reduce growth rates (fifth column).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We have shown that Naa10 deficiency results in pleotropic developmental defects in two different Naa10-deficient mouse models. Similar to infant mortality in some OS males, the lethality of <italic>Naa10</italic> KO mice increased dramatically in pups in the first three days of life (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Defects in kidney, brain, pigmentation (piebaldism), and ribs were observed during embryonic or early postnatal stages in some mice (<xref ref-type="fig" rid="fig2">Figure 2B, C</xref>). These observed phenotypes overlap with some of the phenotypes found in surviving humans with OS, including supernumerary vertebrae and hydrocephaly, although piebaldism has not been reported to date in any humans. However, the puzzling lack of embryonic lethality in the <italic>Naa10</italic> KO mice prompted us to discover <italic>Naa12</italic> as a possible compensatory NAT, with Naa10-like amino-terminal acetylation activity (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), with an interaction between Naa15 and Naa12 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), and with enzymatic activity in a chimeric complex with human NAA15 (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). In addition, co-immunoprecipitation of endogenous Naa15 from Naa10 KO mouse tissues followed by mass spectrometry analysis (<xref ref-type="table" rid="table2">Table 2</xref>) and amino-terminal acetylation assays (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) fully supports that the endogenous Naa12-Naa15 complexes produces NatA activity. Finally, we found genetic proof of the compensatory activity of Naa12 in mice when we observed embryonic lethality in in <italic>Naa10 Naa12</italic> DKO male and <italic>Naa10<sup>+/-</sup> Naa12</italic><sup>-/-</sup> female mice (<xref ref-type="fig" rid="fig6">Figure 6</xref>). This compensation by Naa12 explains the mouse proteomics data indicating normal amino-terminal acetylation in Naa10 KO mice (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We have confirmed the expression of Naa12 in various tissues using qPCR (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>).</p><p>Gene duplication has long been believed to be a major driving force in evolution that provides genetic novelty in organisms. Paralogous genes, originating by small-scale or whole-genome duplication, overlap functional roles for each other and can completely or partially compensate for the loss of the duplicate gene (<xref ref-type="bibr" rid="bib60">Peng, 2019</xref>; <xref ref-type="bibr" rid="bib84">Veitia, 2017</xref>). There is not yet any human reported with complete KO for <italic>NAA10</italic>. There is one published truncating variant in the C-terminal portion of NAA10 in a male patient with microphthalmia (<xref ref-type="bibr" rid="bib14">Cheng et al., 2019</xref>), but unfortunately there are no cell lines available from this family to confirm whether any truncated NAA10 protein is expressed, as was shown with a splice-site mutation in a Lenz microphthalmia family (<xref ref-type="bibr" rid="bib27">Esmailpour et al., 2014</xref>). NAA10 was also identified in screens for essential genes in human cell lines (<xref ref-type="bibr" rid="bib7">Blomen et al., 2015</xref>; <xref ref-type="bibr" rid="bib87">Wang et al., 2015</xref>), so it seems unlikely that an unknown NAA10-like paralogous gene exists in humans, other than the already known NAA11.</p><p>The pleiotropic phenotypes shown in <italic>Naa10</italic> KO mice, including hypopigmentation and supernumerary ribs with a penetrance of 100%, were not observed in the <italic>Naa12</italic> KO mice. Naa10 itself has been described to have N-ɛ-acetyl-activity towards internal lysine residues of proteins involved in various disease- and development-related signaling pathways (<xref ref-type="bibr" rid="bib47">Lee et al., 2018</xref>), although its acetylation of some substrates is controversial (<xref ref-type="bibr" rid="bib51">Magin et al., 2016</xref>; <xref ref-type="bibr" rid="bib85">Vo, 2020</xref>). Since the Nt-acetylome appears to be globally intact in MEFs from <italic>Naa10</italic> KO mice (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), it is possible that the presented phenotypes could be due to the loss of Naa10-specific N-ɛ-acetyl-activity or non-catalytic roles of Naa10 (<xref ref-type="bibr" rid="bib1">Aksnes et al., 2019</xref>). Alternatively, the quantitative expression of Naa10 and Naa12 might be different within or between tissues, which might then explain why there is clearly a phenotype for <italic>Naa10<sup>+/-</sup> Naa12<sup>+/-</sup></italic> female mice (not born at Mendelian ratios and the few that are born are usually much smaller) but no apparent phenotype in <italic>Naa10<sup>+/+</sup> Naa12</italic><sup>-/-</sup> female mice. It seems likely that the mechanism cannot be simply additive between two equally expressed proteins, because if the expression of each protein is theoretically set at an arbitrary unit of 10, then <italic>Naa10<sup>+/-</sup> Naa12<sup>+/-</sup></italic> female mice might possibly have half as much of each protein, so that the total dose of both proteins together would be 10, instead of 20. Likewise, the total dose of both proteins together would also be predicted to be 10 in a <italic>Naa10<sup>+/+</sup> Naa12<sup>-</sup></italic><sup>/-</sup> female. Yet, the <italic>Naa10<sup>+/-</sup> Naa12<sup>+/-</sup></italic> female mice have a phenotype, whereas the <italic>Naa10<sup>+/+</sup> Naa12</italic><sup>-/-</sup> female mice do not (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Therefore, other explanations could include different tissue-specific dosages of each protein, different expression between different tissues, possible X-chromosome skewing for the X-linked <italic>Naa10</italic> in different tissues, or different functions of the two enzymes, including Naa10-specific N-ɛ-acetyl-activity or non-catalytic roles of Naa10 (<xref ref-type="bibr" rid="bib1">Aksnes et al., 2019</xref>). These questions remain unanswered and are worth exploring in future studies. It is worth highlighting that X-chromosome inactivation could certainly be one explanation, given that males that are <italic>Naa10<sup>+/Y</sup></italic> with <italic>Naa12<sup>+/-</sup></italic> or <italic>Naa12<sup>-/-</sup></italic> show expected survival rates, whereas females that are <italic>Naa10<sup>+/-</sup></italic> with <italic>Naa12<sup>+/-</sup></italic> show ~35% survival but with <italic>Naa12<sup>-/-</sup></italic> show 0% survival (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>There are several clinical features that were presented in the original description of OS (<xref ref-type="bibr" rid="bib70">Rope et al., 2011</xref>) which can now be better understood in light of the phenotypes found in the KO mouse model. For example, all of the affected children in the first families with OS were noted to have large and, in some cases, persistently open fontanels (<xref ref-type="bibr" rid="bib56">Myklebust et al., 2015</xref>; <xref ref-type="bibr" rid="bib70">Rope et al., 2011</xref>). For one child (family 1, individual II-1), CT scanning revealed cerebral atrophy with enlarged ventricles, and in another child (family 1, individual III-4), there was evidence on magnetic resonance imaging (MRI) of ‘moderate lateral and third ventricular dilatation without identified cause.’ Lastly, all of the children had respiratory depression and apneic episodes, along with varying course of hypotonia and/or hypertonia (including documented hyperreflexia in at least one case [family 2, individual III-2]). In retrospect, it seems that these clinical features could be consistent with mild hydrocephaly in these probands with OS, which resolved over time. This is also consistent with the ventriculomegaly reported in several female OS probands with missense mutations in <italic>NAA10</italic>, along with ventriculomegaly in one other male proband who died in the first week of life, with generalized hypotonia and lack of spontaneous respirations (<xref ref-type="bibr" rid="bib71">Saunier et al., 2016</xref>). One of the female patients with an Arg83Cys mutation in Naa10 (#9 in Table 1 of that paper) was reported as having intraventricular hemorrhage in the occipital horn, hypoxic-ischemic encephalopathy, and a ventriculo-peritoneal shunt. It is possible that this sequence of events is compatible with hydrocephaly with clinical signs and symptoms that required the placement of the shunt.</p><p>There are additional cardiac and skeletal features that are also worth re-examining in light of these new findings. In some of the original cases of OS, there were varying levels of pulmonary valve stenosis detected on echocardiography, along with some documentation of pulmonary hypoplasia (<xref ref-type="bibr" rid="bib70">Rope et al., 2011</xref>). For example, individual III-7 in family 1 was found on echocardiography to have small persistent ductus arteriosus, a mildly decreased left ventricular systolic function, an abnormal appearing aortic valve, an enlargement of the right ventricle, decreased right ventricular systolic function, and persistence of the foramen ovale. Individual III-6 from this same extended family was found on echocardiography to have a thickened bicuspid aortic valve and mild pulmonary hypertension. One of the OS female patients with an Arg83Cys mutation in <italic>NAA10</italic> was reported to have ‘supernumerary vertebrae’ (<xref ref-type="bibr" rid="bib71">Saunier et al., 2016</xref>). Prompted by our findings of supernumerary ribs in the mice, we obtained an MRI report for this patient, in which the radiologist concluded that there appeared to be 25 distinct vertebrae, as opposed to the usual 24, with a suggestion of a 13th rib, at least on the right. The report went on to state that “the vertebrae represent seven cervical vertebrae, 13 rib-bearing thoracic vertebrae, and five lumbar vertebrae, and the L1 vertebra is mildly dysmorphic, with a suggestion of anterior breaking.” In addition, chest and abdominal X-rays from two of the brothers in generation VI of a family with microphthalmia demonstrated the presence of 13 rib-bearing thoracic vertebrae, alongside the dramatic scoliosis in both individuals. Four other females carrying mutations in Naa10 were reported as having either pectus carinatum or excavatum (<xref ref-type="bibr" rid="bib71">Saunier et al., 2016</xref>), one of the boys with OS (family 1, individual III-4) was noted to have pectus excavatum, and retrospective review of some of the clinical photographs appears to show mild pectus excavatum in individual III-6 of the same family. Studies of human populations have shown that the levels of transition may be shifted cephalad, resulting in 23 mobile vertebrae, or shifted caudad, resulting in 25 presacral vertebrae. Such variations may occur in 2–11% of the population (<xref ref-type="bibr" rid="bib8">Bornstein and Peterson, 1966</xref>). In addition, the number of ribs can also vary in mice as a result of teratogenic and genetic influences (<xref ref-type="bibr" rid="bib53">Mclaren and Michie, 1958</xref>; <xref ref-type="bibr" rid="bib15">Chernoff and Rogers, 2004</xref>). However, the complete penetrance for supernumerary ribs in the <italic>Naa10</italic>-deficient mice, along with the presence of extras ribs in some of the patients, suggests that there is a pathway common to humans and mice that is altered by mutations involving <italic>NAA10</italic>.</p><p>Several mouse mutants show similar cardiac or skeletal phenotypes to the <italic>Naa10</italic>-deficient mice. <italic>Pax3</italic> mutants phenocopy our <italic>Naa10<sup>-/-</sup></italic> mutants as <italic>Pax3<sup>+/-</sup></italic> adults exhibit 100% piebaldism and exhibit neural crest (NC)-related PTA/DORV with concomitant VSDs (<xref ref-type="bibr" rid="bib17">Conway et al., 1997a</xref>; <xref ref-type="bibr" rid="bib18">Conway et al., 1997b</xref>; <xref ref-type="bibr" rid="bib82">van den Hoff and Moorman, 2000</xref>; <xref ref-type="bibr" rid="bib57">Olaopa et al., 2011</xref>). <italic>Pax3</italic> systemic nulls also have skeletal defects due to abnormal somite morphogenesis (<xref ref-type="bibr" rid="bib34">Henderson et al., 1999</xref>; <xref ref-type="bibr" rid="bib23">Dickman et al., 1999</xref>). Moreover, <italic>Pax3</italic> cKOs demonstrated that NC-specific deletion is sufficient to cause DORV/VSDs and death at birth (<xref ref-type="bibr" rid="bib57">Olaopa et al., 2011</xref>; <xref ref-type="bibr" rid="bib44">Koushik et al., 2002</xref>), and that restricted deletion within the neuroepithelium causes congenital hydrocephalus (<xref ref-type="bibr" rid="bib93">Zhou and Conway, 2016</xref>). While <italic>Pax7</italic> systemic deletion does not cause NC-associated defects, it does exhibit overlapping expression, and Pax3-Pax7 compound heterozygous mice develop hydrocephalus (<xref ref-type="bibr" rid="bib93">Zhou and Conway, 2016</xref>), suggesting combinatorial function. <italic>Hox C8</italic><sup>-/-</sup> mice exhibit an extra rib and an extra rib articulating with the sternum (<xref ref-type="bibr" rid="bib45">Le Mouellic et al., 1992</xref>; <xref ref-type="bibr" rid="bib41">Juan and Ruddle, 2003</xref>), and an unfused sacral vertebra, which lead to 27 presacral vertebrae (<xref ref-type="bibr" rid="bib81">van den Akker et al., 2001</xref>), as seen in our model. <italic>Hox A4</italic><sup>-/-</sup> mice described in <xref ref-type="bibr" rid="bib36">Horan et al., 1994</xref> show cervical fusions of C2/C3, a rib on C7 not fully penetrant and sternal defects with bone ossification anomalies. <italic>Hox A5</italic><sup>-/-</sup> mice display numerous cervico-thoracic defects such as a rib process coming from the seventh cervical vertebra, an increase in the number of sternebrae and total number of ribs (<xref ref-type="bibr" rid="bib38">Jeannotte et al., 1993</xref>). Both <italic>Hox A4</italic><sup>-/-</sup> and <italic>A5</italic><sup>-/-</sup> mice exhibit an extra rib articulating with the sternum. <italic>Hox D3</italic><sup>-/-</sup> mice are the only Hox gene mutation leading to cervical fusion of both the atlas and axis (<xref ref-type="bibr" rid="bib16">Condie and Capecchi, 1993</xref>). <italic>Hox A9</italic><sup>-/-</sup> mice have anteriorization of both sacral and lumbar parts, with an extra pair of ribs at the lumbar level. <italic>Hox A9</italic><sup>-/-</sup> mice do not have any relevant sternal defect (<xref ref-type="bibr" rid="bib30">Fromental-Ramain et al., 1996</xref>). <italic>Hox B9</italic><sup>-/-</sup> mice have an extra rib articulating with the sternum and 14 pairs of rib (<xref ref-type="bibr" rid="bib12">Chen and Capecchi, 1997</xref>). These phenotypes, especially <italic>Hox C8</italic>, share common features with the <italic>Naa10</italic>-deficient mice. This phenotype is also close to the <italic>Rpl38</italic><sup>-/-</sup> phenotype (<xref ref-type="bibr" rid="bib43">Kondrashov et al., 2011</xref>), except for the sacral fusion described in <italic>Rpl38</italic><sup>-/-</sup> mice. Interestingly, it was shown that <italic>Hox</italic> genes were dysregulated in this genotype. The skeletal findings and comparison to other mutant mice suggest a pattern consistent with a homeotic anterior transformation hypothesis.</p><p>The developmental role of Naa10 in mice has been previously described (<xref ref-type="bibr" rid="bib46">Lee et al., 2017</xref>). Lee et al. reported embryonic lethality at E12.5–14.5 and beyond (due to placental defects), hydrocephaly, postnatal growth retardation, and maternal effect lethality in <italic>Naa10</italic> KO mice and suggested that genomic imprinting dysregulation is associated with those developmental phenotypes. In the present study, hydrocephaly and postnatal growth retardation were also apparent, but embryonic lethality was not observed, which prompted the search for and discovery of Naa12. The previous paper (<xref ref-type="bibr" rid="bib46">Lee et al., 2017</xref>) did not report the piebaldism, homeotic anterior transformation, hydronephrosis, and genital defects (such as seminal vesicle malformation and hydrometrocolpos), nor did it explain the cause of death in the first day of life, which is at least partly due to congenital heart defects, as reported herein. A more recent paper from the same group reported that conventional and adipose-specific Naa10p deletions in mice resulted in increased energy expenditure, thermogenesis, and beige adipocyte differentiation in the surviving mice (<xref ref-type="bibr" rid="bib48">Lee et al., 2019</xref>), although the authors do not comment on whether any of the male mice used in that study starting at age 5 weeks ended up developing hydrocephaly and/or hydronephrosis, which we have observed in older mice. Although the <xref ref-type="bibr" rid="bib46">Lee et al., 2017</xref> paper reported a very high maternal effect lethality rate of 90% (46/51) (otherwise stated as a survival rate of 10% [5/51]) for newborns in matings following <italic>Naa10<sup>-/-</sup></italic> female and C57BL/6J WT male intercrossing, this rate was only 29% (37/127) in this same mating herein in the first 24 hr of life and with a total death rate in the first three days for all newborns of 46/127, or 36% (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>), with this result deriving from a larger number of mating pairs, litters, and pups. Although this rate of 36% is higher than that seen with matings involving <italic>Naa10<sup>+/-</sup></italic> females (15.8% and 13.6%) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>), the explanation for this ~20% difference in survival in the first three days of life could involve differences in maternal care provided by the <italic>Naa10<sup>+/-</sup></italic> and <italic>Naa10<sup>-/-</sup></italic> females, but this would have to be investigated in future studies, involving detailed behavioral and cognitive assessment of the dams.</p><p>The reasons for the differences between the studies in regards to maternal effect lethality and in utero lethality are unknown at present. Whilst Lee et al. deleted <italic>Naa10</italic> exons 2–6 (<xref ref-type="bibr" rid="bib46">Lee et al., 2017</xref>), the current study deleted <italic>Naa10</italic> exons 1–4 <italic>or used an allele Naa10<sup>tm1a</sup></italic> expressing β-galactosidase instead of the <italic>Naa10</italic> gene (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>), and there was not any significant embryonic lethality in either line (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a, b</xref>). All three of these mouse models were made using 129Sv/Ev ES cells, and all three are nulls lacking Naa10 protein. It is the case that the previous study used the Cre/loxP system to generate the <italic>Naa10</italic> KO mice, where a floxed Naa10 female mouse was crossed with the Ella-Cre transgenic male mouse expressing Cre recombinase for germ line deletion of loxP-flanked <italic>Naa10</italic>, whereas our mice were made using standard gene-targeting methods without the use of Cre recombinase, but it is not clear how this would have resulted in embryonic lethality, particularly as these mice were only used after ‘at least six generations of backcross with C57BL/6 mice,’ which are noted by the authors to be the substrain C57BL/6JNarl, first established at the Animal Center of National Research Institute from the Jackson Laboratory (JAX) in 1995. The explanation for differences in embryonic lethality might be more likely due to different combinations of modifying alleles that are present in the different C57BL/6J substrain genetic backgrounds, rather than differences in our model systems, and future plans will address this after back-crossing more than 20 generations to C57BL/6J (imported annually from JAX) to achieve an entirely inbred line. The impact of genetic background is supported by the observation that additional null alleles on mixed genetic backgrounds, made during the process of generating missense mouse models for OS, have far less penetrance for a range of the various phenotypes, including much less perinatal lethality (unpublished observations).</p><p>In conclusion, our study provides strong evidence that Naa10, the catalytic subunit of NatA, is critical for normal development in mice. Furthermore, this study explains the puzzle regarding the lack of complete embryonic lethality in the <italic>Naa10</italic> KO mice due to the discovery of a second mouse <italic>Naa10</italic> paralog, which, unlike <italic>Naa11</italic>, is expressed in the heart as well as other tissues. Taken together, our findings suggest that the newly identified Naa12 can functionally rescue Naa10 loss and act as a catalytic subunit in mouse NatA complexes.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or <break/>resource</th><th valign="top">Designation</th><th valign="top">Source or <break/>reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Gene (<italic>Mus musculus</italic>)</td><td valign="top">Naa10</td><td valign="top">GenBank</td><td valign="top">MGI:MGI:1915255</td><td valign="top"/></tr><tr><td valign="top">Gene (<italic>M. musculus</italic>)</td><td valign="top">Naa15</td><td valign="top">GenBank</td><td valign="top">MGI:MGI:1922088</td><td valign="top"/></tr><tr><td valign="top">Gene (<italic>M. musculus</italic>)</td><td valign="top">Naa11</td><td valign="top">GenBank</td><td valign="top">MGI:MGI:2141314</td><td valign="top"/></tr><tr><td valign="top">Gene (<italic>M. musculus</italic>)</td><td valign="top">Naa12</td><td valign="top">This paper</td><td valign="top">Gm16286, UniProt: Q9CQX6</td><td valign="top">Provided by corresponding author, Gholson J. Lyon</td></tr><tr><td valign="top">Genetic reagent (<italic>M. musculus</italic>)</td><td valign="top">Naa10<sup>-/-</sup></td><td valign="top">Nature Communication <xref ref-type="bibr" rid="bib91">Yoon et al., 2014</xref></td><td valign="top"/><td valign="top">Provided by corresponding author, Goo Taeg Oh</td></tr><tr><td valign="top">Genetic reagent (<italic>M. musculus</italic>)</td><td valign="top">Naa12-/-</td><td valign="top">This paper</td><td valign="top">Gm16286, UniProt: Q9CQX6</td><td valign="top">Provided by corresponding author, Gholson J. Lyon</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HEK293 (normal, embryonic kidney cells)</td><td valign="top">ATCC</td><td valign="top">CRL-1573</td><td valign="top"/></tr><tr><td valign="top">Biological sample (<italic>M. musculus</italic>)</td><td valign="top">Primary mouse embryonic fibroblasts</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Freshly isolated from mouse embryos (E13.5)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Naa10 (rabbit polyclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab155687</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Naa10 (rabbit polyclonal)</td><td valign="top">Protein Tech</td><td valign="top">Cat# 14803-1-AP</td><td valign="top">(1:3000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Naa10 (rabbit monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 13357</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Naa10 (goat polyclonal)</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-33256</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Naa10 (rabbit polyclonal)</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-33820</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Naa11 (rabbit polyclonal)</td><td valign="top">Novus Biologicals</td><td valign="top">Cat# NBP1-90853</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Naa15/NARG1 (mouse monoclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab60065</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-NAA15 (rabbit polyclonal)</td><td valign="top">Biochemical Journal (reference 12 in this paper) <break/><xref ref-type="bibr" rid="bib2">Arnesen et al., 2005</xref></td><td valign="top"/><td valign="top">(1:2000) <break/>Provided by author Thomas Arnesen,</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-NAA50 (rabbit polyclonal)</td><td valign="top">LifeSpan BioSciences</td><td valign="top">Cat# LS-C81324-100</td><td valign="top">(1:3000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-FLAG (rabbit polyclonal)</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# F7425</td><td valign="top">(2 μg/mL)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-GAPDH (mouse monoclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab9484</td><td valign="top">(1:3000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-actin (goat polyclonal)</td><td valign="top">Santa Cruz</td><td valign="top">Cat# 1615</td><td valign="top">(1:3000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-GST (mouse monoclonal)</td><td valign="top">GenScript</td><td valign="top">Cat# A00865</td><td valign="top">(1 µg/mL)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-V5 (mouse monoclonal)</td><td valign="top">Life Technologies</td><td valign="top">Cat# R960-25</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Naa12 (rabbit polyclonal)</td><td valign="top">This paper</td><td valign="top">Gm16286, UniProt: Q9CQX6</td><td valign="top">C-terminus (aa191-205: QENLAGGDSGSDGKD-C) conjugated to OVA by PrimmBiotech <break/>Provided by corresponding author, Gholson J. Lyon</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mNaa10-Exon2/3_F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">ctcttggccccagctttctt <break/>Provided by corresponding author, Goo Taeg Oh</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mNaa10-Exon3/4_R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">tcgtctgggtcctcttccat <break/>Provided by corresponding author, Goo Taeg Oh</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mNaa11_F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">accccacaagcaaagacagtg <break/>Provided by corresponding author, Goo Taeg Oh</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mNaa11_R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">agcgatgctcaggaaatgctct <break/>Provided by corresponding author, Goo Taeg Oh</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mNaa12(Gm16286)_F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">acgcgtatgctatgaagcga <break/>Provided by corresponding author, Gholson J. Lyon</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mNaa12(Gm16286)__R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">ccaggaagtgtgctaccctg <break/>Provided by corresponding author, Gholson J. Lyon</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mNaa15_F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">gcagagcatggagaaaccct <break/>Provided by corresponding author, Gholson J. Lyon</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mNaa15_R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">tctcaaacctctgcgaacca <break/>Provided by corresponding author, Gholson J. Lyon</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mNaa50_F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">taggatgccttgcaccttacc <break/>Provided by corresponding author, Gholson J. Lyon</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mNaa50_R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">gtcaatcgctgactcattgct <break/>Provided by corresponding author, Gholson J. Lyon</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mGAPDH_F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">aggtcggtgtgaacggatttg <break/>Provided by corresponding author, Gholson J. Lyon</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mGAPDH_R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">tgtagaccatgtagttgaggtca <break/>Provided by corresponding author, Gholson J. Lyon</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mACTB_F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">ggctgtattcccctccatcg <break/>Provided by corresponding author, Gholson J. Lyon</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">mACTB_R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="top">ccagttggtaacaatgccatgt <break/>Provided by corresponding author, Gholson J. Lyon</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Zen 3.0 SR</td><td valign="top">ZEISS</td><td valign="top">Version 16.0.1.306</td><td valign="top">Black 64bit edition</td></tr><tr><td valign="top">Other</td><td valign="top">Alcian Blue 8GX</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# A5268</td><td valign="top">0.03%</td></tr><tr><td valign="top">Other</td><td valign="top">Alizarin Red</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# A5533</td><td valign="top">0.05%</td></tr><tr><td valign="top">Other</td><td valign="top">Hematoxylin</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# MHS80</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Eosin</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# HT110116</td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>All experiments were performed in accordance with guidelines of International Animal Care and Use Committee (IACUC) of Ewha Womans University (protocol #18-012), Cold Spring Harbor Laboratory (CSHL) protocol #579961-18, and Institute for Basic Research in Developmental Disabilities (IBR) (protocol #456). At CSHL and IBR, any matings that required genotyping were screened on a daily basis by animal husbandry staff, with notation of how many newborn pups were present each morning, but with paw tattoo and tail genotyping not being performed until day 3 of life, so as to not disturb the litters and thus to not increase the risk for maternal rejection of the litter. The stock of C57BL/6J was replenished annually from Jackson Laboratory so as to avoid genetic drift from the JAX inbred line.</p></sec><sec id="s4-2"><title>Generation of <italic>Naa10-</italic>deficient mice</title><p>The <italic>Naa10</italic> KO mice were generated as previously described (<xref ref-type="bibr" rid="bib91">Yoon et al., 2014</xref>). <italic>Naa10<sup>tm1a</sup></italic> [B6;129P2-Ard1<sup>tm1a(Eucomm)Gto</sup>/J] (<italic>Naa10<sup>tm1a</sup></italic>) mice, used for <italic>Naa10</italic> reporter mouse, were generated using standard method based on a standard gene-targeting in E14 embryonic stem (ES) cells (129/Sv) by using a targeting vector from EUCOMM. Correctly targeted ES clones were used for blastocyst microinjection and generation of chimeric mice. Chimeric mice were crossed to C57BL/6J mice, and then the progeny were backcrossed to C57BL/6J for more than 10 generations. The <italic>Naa10</italic>-deficient mice used in the weight analyses were derived from mice backcrossed eight times to a C57BL/6J inbred genetic background, and this was confirmed with genome scanning at the Jackson Laboratory, showing heterozygosity for only one marker for 129S1/SvImJ out of 290 autosomal markers tested, thus giving a percentage of C57BL/6J of 99.66%.</p></sec><sec id="s4-3"><title>Generation of <italic>Naa12</italic> (Gm16286, UniProt: Q9CQX6) KO mice</title><p>The mice were made using standard methods by microinjection of CRISPR reagent mix into zygotes obtained from the mating of B6D2F1 females (i.e., 50% C57BL/6J, 50% DBA/2J [D2]) females to inbred C57BL/6J males. The guide RNA was produced and validated from Sigma using a Cel1-nuclease assay, and the most active guide was selected, which was Naa12_0_125 (C9587), with a target sequence of <named-content content-type="sequence">GAGCGTTTCACAGCCAGCG</named-content> and including the targeting cr-RNA sequence and the tracrRNA portion. The indels were transmitted by breeding again to inbred C57BL/6J males, and the resulting progeny were interbred on a mixed genetic background of approximately 12.5% DBA/2J (D2)/87.5% C57BL/6J, for use in the reported experiments, including the weight analyses. Progeny from these mice have been backcrossed to C57BL/6J for more than 10 generations, with no discernible new phenotypes emerging. Genomic DNA was isolated from paw and tail. DNA was screened for mutations using PCR and Surveyor assay (<xref ref-type="bibr" rid="bib65">Qiu et al., 2004</xref>), followed by Sanger sequencing of selected clones and the use of CRISP-ID (<xref ref-type="bibr" rid="bib22">Dehairs et al., 2016</xref>) to identify putative deletions.</p></sec><sec id="s4-4"><title>Primers for mice genotyping</title><p>The primers used for <italic>Naa10 KO</italic> and <italic>Naa10<sup>tm1a</sup></italic> genotyping were Naa10-F: 5′-<named-content content-type="sequence">cctcacgtaatgctctgcaa</named-content>-3′, Naa10-neo-F: 5′-<named-content content-type="sequence">acgcgtcaccttaat</named-content>-<named-content content-type="sequence">atgcg</named-content>-3′, Naa10-R: 5′-<named-content content-type="sequence">tgaaagttgagggtgttgga</named-content>-3′, Naa10<sup>tm1a</sup>-F: 5′-<named-content content-type="sequence">gcacactctctgaattggac</named-content>-3′, Naa10<sup>tm1a</sup>-neo-F: 5′-<named-content content-type="sequence">ggccgcttttctggattcat</named-content>-3′, and Naa10<sup>tm1a</sup>-R: 5′-<named-content content-type="sequence">gcaggggaataaggcattgg</named-content>-3′. The primers used for Naa12 KO were Naa12 Surveyor F: 5′-<named-content content-type="sequence">gctccacctcgctaacctgg</named-content>-3′, Naa12 Surveyor R: 5′-<named-content content-type="sequence">gccagatgacctgatgaacatgc</named-content>-3′ and HEX-Naa12 Surveyor F: 5′-<named-content content-type="sequence">gctccacctcgctaacctgg</named-content>-3′.</p></sec><sec id="s4-5"><title>Antibodies</title><p>The following antibodies were used: rabbit anti-Naa10 (Abcam #ab155687), rabbit anti-Naa10 (Protein Tech #14803-1-AP), rabbit monoclonal anti-NAA10 (Cell Signaling, #13357), goat anti-Naa10 (Santa Cruz, #sc-33256), rabbit anti-Naa10 (Santa Cruz, #sc-33820), rabbit anti-Naa11 (Novus Biologicals; #NBP1-90853), mouse anti-Naa15/NARG1 (Abcam; #ab60065), rabbit polyclonal anti-NAA15 (<xref ref-type="bibr" rid="bib2">Arnesen et al., 2005</xref>), rabbit anti-Naa50 (LifeSpan BioSciences; #LS-C81324-100), rabbit anti-FLAG (Sigma; #F7425), mouse anti-GAPDH (Abcam; #ab9484), goat anti-actin (Santa Cruz, #1615), mouse anti-GST (GenScript; #A00865), and mouse anti-V5 (Life Technologies; #R960-25). The antibody against the potential mNaa10 paralog mNaa12 (Gm16286, UniProt: Q9CQX6) was raised in rabbits after immunization with a synthetic peptide of the Naa12 C-terminus (aa191-205: QENLAGGDSGSDGKD-C) conjugated to OVA by PrimmBiotech.</p></sec><sec id="s4-6"><title>Alcian Blue and Alizarin Red co-staining of skeletons</title><p>After the skin and internal organs were removed, embryos were fixed in 95% ethanol (EtOH) for 4 hr, then in 100% acetone for overnight. Embryos were stained with 0.03% Alcian Blue 8GX in ethanol/acetic acid (4:1 v/v) for overnight and kept in 1% KOH for 2 days until they became clearly visible, followed by staining with 0.05% Alizarin Red in 1% KOH for 4 hr. After washing with 100% glycerol/1% KOH (1:1 v/v), skeletons were kept in 100% glycerol.</p></sec><sec id="s4-7"><title>Isolation and imaging of mouse embryos</title><p>Timed matings were performed either by using the presence of a vaginal plug to assess fertilization. The morning vaginal plug was designated E0.5. Pregnant mice were sacrificed at several time points after conception. The embryos were isolated in ice-cold PBS with 1% FBS and washed three times in ice-cold PBS. Embryos were imaged using a Zeiss Axiozoom V16 with Zen software and merged 50 slides between Z-stack intervals.</p></sec><sec id="s4-8"><title>β-Galactosidase staining</title><p>Isolated E10.5 embryos were incubated in fixation solution (4% paraformaldehyde) at 4°C for 25 min. Samples were washed in ice-cold PBS and then incubated in permeabilization solution (PBS containing 0.01% Na deoxycholate, 0.02% Nonidet-P40, 2 mM MgCl<sub>2</sub>) for 20 min at 4°C. Subsequently, samples were incubated in β<bold>-</bold>gal staining solution (PBS containing 1 mg/mL X-Gal, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 0.02% Nonidet-P40, 2 mM MgCl<sub>2</sub>) at 37°C overnight. Following β-gal staining, samples were washed with PBS and incubated in fixation solution at 4°C for storage.</p></sec><sec id="s4-9"><title>Hematoxylin and eosin staining</title><p>Isolated kidney tissues at E18.5 and P3 were fixed with 4% paraformaldehyde at 4°C for overnight and embedded in paraffin. Samples were sectioned at 8 μm thick and stained with hematoxylin (MHS80, Sigma) and eosin (HT110116, Sigma) for morphology.</p></sec><sec id="s4-10"><title>Cloning</title><p>Full-length mouse Naa10 and Naa12 (Gm16286, UniProt: Q9CQX6) expression vectors were separately constructed using a pMAL-c5x vector. In both cases, the catalytic subunit contained an N-terminal uncleavable MBP-tag. Bacterial expression vectors of mNATs were cloned from cDNA generated from mouse liver or testes. mRNA was isolated using the Oligotex direct mRNA kit (Qiagen) according to the manufacturer's recommendations. 1 µg RNA was reverse transcribed with Superscript IV reverse transcriptase (Thermo Fisher) and Oligo dT(18) primer. The PCR product was digested and cloned into BamHI restriction sites of pGEX-4T1 (GE Healthcare), pMAL-p5X and p3xFLAG-CMV10 (Sigma-Aldrich) using standard techniques. All constructs were sequenced to validate correct insert and orientation.</p></sec><sec id="s4-11"><title>Primers for cloning</title><p>cDNA was amplified using the primers <named-content content-type="sequence">CCG GGA TCC ATG AAC ATC CGC AAT</named-content> and <named-content content-type="sequence">CTG GGA TCC CTA GGA GGC AGA GTC AGA</named-content> for mNaa10 variants, <named-content content-type="sequence">CCG GGA TCC ATG AAC ATC CGC AAT GC</named-content> and <named-content content-type="sequence">CTG GGA TCC CTA GGA GAT GGA ATC CAA GTC</named-content> for mNaa11, <named-content content-type="sequence">CCG GGA TCC ATG AAC ATC CGC CGG</named-content> and <named-content content-type="sequence">CTG GGA TCC CTA GGA GGC GGA CCC TAG</named-content> for mNaa12.</p></sec><sec id="s4-12"><title>Peptide competition assay</title><p>To determine the specificity of the mNaa12 antibody, a peptide competition assay was performed using the same peptide as used for immunization (aa 191–205: QENLAGGDSGSDGKD-C). 100 µg antibody were bound to 50 mg peptide-coupled CNBr-Sepharose (10 mg peptide/g Sepharose) in PBS + 0.2% Triton X-100 for 1 hr at 4° C on an orbital shaker. The beads were pelleted by centrifugation at 2.700 × g for 3 min at 4°C and 250 µL of the antibody-depleted supernatant diluted in 5 mL TST for detection (1:100 final antibody dilution). Western blots of mouse lysates were probed with the depleted antibody or untreated antibody as control (1:100 dilution in TST).</p></sec><sec id="s4-13"><title>Cell lines</title><p>HEK293 cells were purchased from ATCC, authenticated via STR profiling, and confirmed mycoplasma free.</p></sec><sec id="s4-14"><title>Co-immunoprecipitation assay</title><p>Protein-protein interaction studies were performed in HEK293 cells. Briefly, 8 × 10<sup>5</sup> cells were seeded per well in 6-well plates. After 24 hr, cells were co-transfected with pcDNA3.1/V5-His-mNaa15 and p3xFLAG-CMV10-Naa10<sup>235</sup> (isoform 1), -Naa10<sup>225</sup> (isoform 2), -Naa11, or -Naa12 or the corresponding empty vectors. Cells were lysed after 48 hr in 200 µL PBS-X per well and cellular debris pelleted at 20.800 × g for 10 min at 4°C. 350 µL of the generated lysate was incubated with 1 µg anti-V5 antibody for 1 hr at 4°C, followed by a 30 min incubation with 30 µL protein-A Sepharose (Sigma-Aldrich). Protein complexes were washed three times by centrifugation (2.700 × g, 2 min) and eluted in 30 µL 2×SDS sample buffer.</p><p>Proteins were separated by SDS-PAGE and transferred onto a nitrocellulose membrane (Amersham Protran 0.2 µM NC) by immunoblotting. The membrane was blocked in 5% non-fat dry milk and incubated overnight with rabbit polyclonal anti-NAA15 (<xref ref-type="bibr" rid="bib2">Arnesen et al., 2005</xref>) (1:2000, BioGenes) and rabbit monoclonal anti-NAA10 (anti-ARD1A, 1:1000, Cell Signaling, #13357) diluted in 1× PBS containing 1% non-fat dry milk and 0.1% Tween. The immunoblots were washed and incubated for 1 hr at room temperature (RT) with HRP-linked secondary antibody donkey anti-rabbit IgG (GE Healthcare, NA934). The HRP-signal was detected using SuperSignalTM West Pico PLUS Chemiluminescent Substrate Kit (Thermo Scientific) and ChemiDocTM XRS+ system (Bio-Rad) and visualized by ImageLab Software (Bio-Rad).</p></sec><sec id="s4-15"><title>Immunoprecipitation of Naa15 to form NatA complex</title><p>For immunoprecipitation of Naa15, 90–120 mg liver tissue from a WT- and Naa10 KO mouse was lysed in 500 µL IPH lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM) NaCl, 5 mM EDTA, 0.5% NP-40, 1× complete EDTA-free protease inhibitor cocktail (Roche) using Kontes Pellet Pestle Motor and incubated on ice for 40 min. Cell debris was pelleted by centrifugation (17,000 × g, 4°C, 10 min) and the supernatants transferred to new Eppendorf tubes. The protein concentration was determined by BCA Protein Assay Kit (Thermo Scientific) and the tissue lysates were subsequently diluted with IPH lysis buffer to an equal protein concentration of 25 µg/µL. The WT- and Naa10 KO tissue lysates were then divided in two, whereof one half was mixed with 15 µg of anti-Naa15 antibody and the other half with 15 µg of anti-V5 antibody as a negative control. The mixtures were incubated at 4°C for 3 hr on a rotator. Afterwards, 180 µL of Protein A/G magnetic beads (Millipore) pre-washed in IPH lysis buffer was added to each sample and incubated overnight. Then, the magnetic beads were washed three times in IPH lysis buffer and two times in 1× acetylation buffer (100 mM Tris-HCl pH 8.5, 2 mM EDTA, 20% glycerol) prior to being resuspended in 90 µL of 2× acetylation buffer and used in a [<sup>14</sup>C]-Ac-CoA-based acetylation assay.</p></sec><sec id="s4-16"><title>[<sup>14</sup>C]-Ac-CoA-based acetylation assay of immunoprecipitated samples</title><p>Three positive replicates were prepared for each IP sample containing 10 µL IP beads, 200 µM synthetic oligopeptide SESS<sub>24</sub> (BioGenes), 100 µM [<sup>14</sup>C]-Ac-CoA (Perkin-Elmer), and dH<sub>2</sub>O to a final volume of 25 µL. In addition, two replicates for each IP sample were prepared without synthetic oligopeptide as negative controls. The samples were incubated at 37°C for 45 min in a thermomixer with shaking at 1400 rpm. Finally, the magnetic beads were isolated and 23 µL of the supernatant transferred to P81 phosphocellulose filter disks (Millipore). The filter disks were washed three times for 5 min in 10 mM HEPES buffer (pH 7.4) and air dried. To determine the amount of incorporated [<sup>14</sup>C]-Ac, the filter disks were added to 5 mL Ultima Gold F scintillation mixture (Perkin-Elmer) and analyzed by a Perkin-Elmer TriCarb 2900TR Liquid Scintillation Analyzer.</p></sec><sec id="s4-17"><title>Proteomics sample preparation</title><p>Immunoprecipitation of Naa15 from a WT- and Naa10 KO mouse was performed as described above. Bound proteins were eluted from the magnetic beads using 60 µL of elution buffer (2% SDS, 100 mM Tris-HCl pH 7.6, 0.1 M DTT) and heated for 5 min at 95°C. The eluates were processed for LC-MS/MS analysis using filter-aided sample preparation (FASP) method (<xref ref-type="bibr" rid="bib89">Wiśniewski et al., 2009</xref>). The eluted protein mixtures were mixed with UA buffer (8 M urea, 100 Mm Tris-HCl pH 8.0) and centrifuged through Microcon 30 kDa MWCO filters followed by Cys-alkylation with 50 mM iodoacetamide dissolved in UA buffer. Afterwards, the buffer was exchanged with 50 mM ammonium bicarbonate through sequential centrifugation, proteins were trypsinized (Sequencing Grade Modified Trypsin, Promega), and digested peptides were collected by centrifugation. Peptides were acidified using 5% formic acid and desalted using C18-stagetips according to protocol (<xref ref-type="bibr" rid="bib66">Rappsilber et al., 2007</xref>). Briefly, 40 µg peptides from each sample were loaded onto C18-stagetips pre-conditioned with buffer A (1% formic acid). The C18-stagetips were then washed with buffer A, before peptides were eluted with buffer B (80% acetonitrile [ACN], 1% formic acid). The final eluate was concentrated by Speedvac to evaporate ACN and diluted to desired volume with 5% formic acid.</p></sec><sec id="s4-18"><title>Mass spectrometric analysis for immunoprecipitate</title><p>1 µg of the peptide samples were injected into an Ultimate 3000 RSLC system (Thermo Scientific) connected to a Q-Exactive HF mass spectrometer (Thermo Scientific) equipped with EASY-spray nano-electrospray ion source (Thermo Scientific). Trapping and desalting was performed with 0.1% TFA (flow rate 5 µL/min, 5 min) on a pre-column (Acclaim PepMap 100, 2 cm × 75 µm ID nanoViper column, 3 µm C18 beads). Peptides were separated on an analytical column (PepMap RSLC, 50 cm × 75 µm i.d. EASY-spray column, 2 µm C18 beads) during a biphasic ACN gradient with a flow rate of 200 nL/min. Solvent A (0.1% FA [vol/vol] in water) and B (100% ACN) were used for the following gradient composition: 5% B for 5 min, 5–8% B for 0.5 min, 8–24% B for 109.5 min, 24–35% B for 25 min and 35–80% B for 15 min, 80% B for 15 min, and conditioning with 5% B for 20 min. The mass spectrometer was operated in data-dependent mode to automatically switch between full-scan MS and MS/MS acquisition. MS spectra (m/z 375–1500) were acquired with a resolution of 120,000 at m/z 200, automatic gain control (AGC) target of 3 × 10<sup>6</sup>, and maximum injection time (IT) of 100 ms. The 12 most intense peptides above an intensity threshold (50,000 counts, charge states 2–5) were sequentially isolated to an AGC target of 1 × 10<sup>5</sup> and maximum IT of 100 ms and isolation width maintained at 1.6 m/z, before fragmentation at a normalized collision energy of 28%. Fragments were detected in the orbitrap at a resolution of 15,000 at m/z 200, with first mass fixed at m/z 100. Dynamic exclusion was utilized with an exclusion time of 25 s and ‘exclude isotopes’ enabled. Lock-mass internal calibration (m/z 445.12003) was used. Raw files were processed with MaxQuant v. 1.6.17.0 (<xref ref-type="bibr" rid="bib21">Cox and Mann, 2008</xref>) and searched against a database of Swiss-Prot annotated mouse protein sequences (retrieved 22.06.2018) in which the NAA12 sequence was added manually, and with a reverse decoy database. MaxQuant was run with default settings. Peptide and protein identifications were filtered to a 1% false discovery rate (FDR). Minimum peptide length was set to 7. Modifications included in protein quantification were oxidation (M), Nt-acetylation, acetylation (K), and phosphorylation (STY). Other parameters: match between runs – true, matching time window – 0.7 min, alignment time window – 20 min, find dependent peptides – true, mass bin size – 0.0065. Protein and peptide intensities were quantified by label-free quantification (LFQ) (<xref ref-type="bibr" rid="bib20">Cox et al., 2014</xref>). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD026684.</p></sec><sec id="s4-19"><title>Whole-body CT scanning</title><p>CT scans were acquired on a Nanoscan PET/CT scanner from Mediso using Nucline v2.01 software. All mice were kept sedated under isoflurane anesthesia for the duration of the scan. Scans were acquired with an X-ray tube energy and current of 70 kVp and 280 uA, respectively. 720 projections were acquired per rotation, for three rotations, with a scan time of approximately 11 min, followed by reconstruction with a RamLak filter and voxel size 40 × 40 × 122 µm. For ex vivo analyses, mouse heads were fixed in 10% formalin buffered saline, followed by scanning and reconstruction with 1440 projections per revolution. Cranial volume was measured using VivoQuant software (v2.50patch2) using the spline tool to manually and accurately draw around the circumference of the cranium on multiple stepwise 2D slices.</p></sec><sec id="s4-20"><title>Integrated N-terminal peptide enrichment (iNrich) assay</title><p>iNrich assays were performed as described (<xref ref-type="bibr" rid="bib40">Ju et al., 2020</xref>). MEFs were made from E13.5 embryos, using standard techniques, with DMEM media supplemented with 10% fetal bovine serum (FBS), L-glutamine, and penicillin/streptomycin. Cells were harvested by trypsinization, washed twice with ice-cold phosphate-buffered saline (PBS, pH 7.4; Gibco), and resuspended in ice-cold lysis buffer containing 0.2 M EPPS (pH 8.0), 6 M guanidine, 10 mM TCEP (Thermo Fisher Scientific), and 40 mM 2-chloroacetamide (Sigma-Aldrich). After 10 min of incubation on 95°C, cells were lysed by ultrasonication by a BranSonic 400B. The proteins from the cell lysate were isolated by transferring supernatant after centrifugation at 12,000 g for 10 min at 4°C. The protein concentration of the collected supernatant was determined by bicinchoninic acid (BCA) protein assay. After enrichment of the N-terminal peptides, the peptide samples were analyzed by LC–MS/MS on an LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific) without further fractionation. Mass spectrometry data were uploaded to PRIDE under project name: Naa10 mutant mouse N-terminome LC-MS, project accession: PXD026410. Data analysis used unpaired, equal variance algorithm for Student’s <italic>t</italic>-test.</p></sec><sec id="s4-21"><title>RNA and protein isolation and assays</title><p>70–120 mg tissues were lysed in 5 μL/mg tissue RIPA buffer (Sigma) with 1× Complete protease inhibitors and 1 U/μL Superase In RNase inhibitor (Thermo Scientific) using Fisherbrand Pellet Pestle Cordless Motor. Afterwards, homogenization debris was removed by centrifugation at 20.800 × g for 10 min at 4°C. Protein concentration was determined using APA assay (Cytoskeleton Inc) and 50 μg total protein were separated on SDS-PAGE followed by western blot. Membranes were stained with anti-Naa10, anti-Naa15, and anti-GAPDH antibodies (all Abcam).</p><p>For RNA purification, 30 μL clarified lysates were mixed with 70 μL RNase free water and RNA isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturers recommendations, including on-column Dnase digest. 1 μg RNA was reverse transcribed using the TaqMan Reverse transcription kit and gene level detection performed using SYBR Green Master Mix (all Thermo Scientific). Relative expression was normalized to GAPDH and ACTB.</p><p>For the characterization of the mNaa12 antibody, tissue was lysed in 2 µL per mg tissue PBS-X (PBS + 0.2% [v/v] Triton X-100 + 1× Complete protease inhibitor cocktail). 10–200 µg lysate were subjected to SDS-PAGE and western blot.</p></sec><sec id="s4-22"><title>Primers for mice qPCR</title><p>The following primers pairs were used: mNaa10-Exon2/3 F: 5′-<named-content content-type="sequence">ctcttggccccagctttctt</named-content>-3′ and mNaa10-Exon3/4 R: 5′- <named-content content-type="sequence">tcgtctgggtcctcttccat</named-content>-3′, mNaa11-F: 5′-<named-content content-type="sequence">accccacaagcaaagacagtg</named-content>-3′ and mNaa11-R: 5′-<named-content content-type="sequence">agcgatgctcaggaaatgctct</named-content>-3′, mNaa12(Gm16286)-F: 5′-<named-content content-type="sequence">acgcgtatgctatgaagcga</named-content>-3′ and mNaa12(Gm16286)-R: 5′-<named-content content-type="sequence">ccaggaagtgtgctaccctg</named-content>-3′, mNaa15-F: 5′-<named-content content-type="sequence">gcagagcatggagaaaccct</named-content>-3′ and mNaa15-R: 5′-<named-content content-type="sequence">tctcaaacctctgcgaacca</named-content>-3′, mNaa50-F: 5′-<named-content content-type="sequence">taggatgccttgcaccttacc</named-content>-3′ and mNaa50-R: 5′-<named-content content-type="sequence">gtcaatcgctgactcattgct</named-content>-3′, mGAPDH-F: 5′-<named-content content-type="sequence">aggtcggtgtgaacggatttg</named-content>-3′ and mGAPDH-R: 5′-<named-content content-type="sequence">tgtagaccatgtagttgaggtca</named-content>-3′, mACTB-F: 5′-<named-content content-type="sequence">ggctgtattcccctccatcg</named-content>-3′ and mACTB-R: 5′-<named-content content-type="sequence">ccagttggtaacaatgccatgt</named-content>-3′.</p></sec><sec id="s4-23"><title>Expression and purification of WT mouse, Naa10, and Naa12</title><p>All constructs were expressed in Rosetta (DE3)pLysS competent <italic>Escherichia coli</italic> cells. Cells were grown in LB-media to OD<sub>600 </sub>0.6–0.7 prior to inducing protein expression with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 18°C for ~16 hr. All subsequent purification steps were carried out at 4°C. Cells were isolated by centrifugation and lysed in lysis buffer containing 25 mM Tris, pH 8.0, 150 mM NaCl, 10 mM β-mercaptoethanol (β-ME), 10 µg/mL phenylmethanesulfonylfluoride (PMSF), and DNase. The lysate was clarified by centrifugation and incubated with amylose agarose resin (New England Biolabs) for 1 hr before washing the resin with ≥100 column volumes of lysis buffer and then eluted with 10-column volumes of lysis buffer supplemented with 20 mM maltose. The resulting eluent was pooled and concentrated to ~10 mg/mL (30 kDa concentrator; Amicon Ultra, Millipore) such that 500 µL was loaded onto a Superdex 200 Increase 10/300 GL gel filtration column (GE Healthcare). The gel filtration run was performed in sizing buffer containing 25 mM HEPES, pH 7.0, 200 mM NaCl, and 1 mM TCEP. After confirming the purity of the peak fractions at ~14 mL by denaturing SDS-PAGE (15% acrylamide), peak fractions were concentrated to 0.6 (6.1 µM) WT mouse Naa10 and 0.3 mg/mL (3.5 µM) WT mouse Naa12, as measured by UV<sub>280</sub> (Nanodrop 2000; Thermo Fisher Scientific), and stored at 4°C.</p></sec><sec id="s4-24"><title>Expression and purification of recombinant mNaa12 (1–160)-hNaa15 constructs</title><sec id="s4-24-1"><title>Subcloning</title><p>Both full-length and truncated (1–160) mouse Naa12 were amplified from the pMAL-c5x Naa12 plasmid using Q5 HF Master Mix (NEB), <named-content content-type="sequence">AAAACCCGGGTATGAACATCCGCCGGGCTCGGC</named-content> as the forward primer, and either <named-content content-type="sequence">AAAAGGTACCCTAGGAGGCGGACCCTAGGGTCTG</named-content> (full-length) or <named-content content-type="sequence">AAAAGGTACCTCACCGTCTCAGCTCATCGGCCATCTG</named-content> (1-160) as the reverse primer. An <italic>Spodoptera frugiperda</italic> (<italic>Sf</italic>9) pFastBac dual vector containing the sequence for the N-terminally 6xHis-tagged human Naa15 and truncated human Naa10 (residues 1–160) sequences was digested using KpnI-HF (NEB) and XmaI (NEB) to remove the human Naa10 sequence. The PCR product was also digested using the same restriction enzymes and ligated into the corresponding restriction sites using Mighty mix (Takara) using standard techniques. Both constructs were sequenced to validate the insert sequence and directionality.</p><p>Sf9 cells were grown to a density of 1 × 10<sup>6</sup> cells/ml and infected using the amplified baculoviruses to a multiplicity of infection (MOI) of ~1–2. Because the full-length mNaa12 construct did not produce protein, cells transfected with mNaa12<sub>1-160</sub>/hNaa15 were grown at 27°C and harvested 48 hr post infection. All subsequent purification steps were carried out at 4°C. Following centrifugation of the cells, the pellet was resuspended and lysed in buffer containing 25 mM Tris, pH 8.0, 500 mM NaCl, 10 mM Imidazole, 10 mM β-ME, 10 µg/mL PMSF, DNase, and complete, EDTA-free protease inhibitor tablet (Roche). The lysate was clarified by centrifugation and incubated with nickel resin (Thermo Scientific) for 1 hr before washing the resin with ~125 column volumes of lysis buffer and then eluted with 10-column volumes of elution buffer (25 mM Tris, pH 8.0, 500 mM NaCl, 200 mM imidazole, 10 mM β-ME). Eluted protein was diluted to a final salt concentration of 200 mM NaCl and loaded onto a 5 mL HiTrap SP ion-exchange column (GE Healthcare). The protein was eluted in the same buffer with a salt gradient (200 mM to 1 M NaCl) over the course of 20 column volumes. Using the resulting peak fractions, the remainder of the purification was performed as described for the recombinant monomeric mNaa10 and mNaa12. However, resulting size-exclusion fractions were analyzed by denaturing SDS-PAGE using a 12% acrylamide gel, which was then silver stained (Bio-Rad) according to the manufacturer's instructions.</p></sec></sec><sec id="s4-25"><title>In vitro radioactive acetyltransferase assays with recombinant protein</title><p>For recombinant mNaa12 and mNaa10 constructs, the assays were carried out in 40 mM HEPES, pH 7.5, 200 mM NaCl, where reactions were incubated with 150 nM of the gel-filtration purified WT mouse Naa10 or Naa12 in a 30 µL reaction volume containing each 250 µM substrate peptide and radiolabeled [<sup>14</sup>C]acetyl-CoA (4 mCi/mmol; PerkinElmer Life Sciences) for 12 min (Naa12) or 13 min (Naa10) at 25°C. Respective time points were selected to ensure detection of sufficient activity within the linear range as determined by a time-course experiment. The substrate peptides used in the assay correspond to the first seven amino acids of β-actin (DDDIAAL-), γ-actin (EEEIAAL-), or the in vivo NatA complex substrate high-mobility group protein A1 (SESSS-), along with C-terminal positively charged residues for capture to the anion exchange paper. Background control reactions were performed in the absence of enzyme or in the absence of substrate peptide to ensure that any possible signal due to chemical acetylation was negligible. Each reaction was performed in triplicate.</p><p>To quench the reaction, 20 µL of the reaction mixture was added to negatively charged P81 phosphocellulose squares (EMD Millipore), and the paper disks were immediately placed in wash buffer (10 mM HEPES, pH 7.5). The paper disks were washed three times, at 5 min per wash, to remove unreacted acetyl-CoA. The papers were then dried with acetone and added to 4 mL of scintillation fluid, and the signal was measured with a PerkinElmer Life Sciences Tri-Carb 2810 TR liquid scintillation analyzer. The counts per minute were converted to molar units using a standard curve of known [<sup>14</sup>C]acetyl-CoA concentrations in scintillation fluid.</p><p>Full peptide sequences:</p><list list-type="simple"><list-item><p>β-actin: NH2-DDDIAALRWGRPVGRRRRPVRVYP-COOH</p></list-item><list-item><p>γ-actin: NH2-EEEIAALRWGRPVGRRRRPVRVYP-COOH</p></list-item><list-item><p>High-mobility group protein A1: NH2-SESSSKSRWGRPVGRRRRPVRVYP-COOH</p></list-item></list><p>For mNaa12-hNaa15, reactions were carried out similar to the monomeric mNaa12 and mNaa10, with the following exceptions: reactions were prepared by combining 21 µL of the respective fraction or sizing buffer with 5 µL of 10X buffer (500 mM HEPES, pH 7.5) to yield a buffer composed of 50 mM HEPES, pH 7.5, 140 mM NaCl, 0.7 mM TCEP, and 250 µM of each substrate upon reaction initiation. The reactions were allowed to incubate overnight at ambient temperatures (~25°C) and then quenched as described above. Control reactions were conducted in parallel as described above without conversion to molar units. Two technical replicates of the reactions were performed.</p></sec><sec id="s4-26"><title>Statistical analyses</title><p>Significant differences (p&lt;0.05) are indicated by asterisks. Weight analyses were performed using generalized estimating equations (GEEs) (<xref ref-type="bibr" rid="bib92">Zeger and Liang, 1986</xref>), an extension of generalized linear models that adjusts for the effects of autocorrelation resulting from multiple measurements, and implemented within version 15.1 of Stata (StataCorp 2017).</p></sec><sec id="s4-27"><title>Genotype distribution analyses and modeling</title><p>Genotype distributions for several <italic>Naa10/Naa12</italic> KO crosses were analyzed and models were created to estimate the number of the live (or at least intact) embryos or pups that are expected to be observed based on the assumptions and rules that follow. (1) Genotype survival rates are the fractional value, from 0 to 1 (or 0–100%), of the expected Mendelian fraction for that genotype in the cross being evaluated. (2) Genotype survival rates cannot exceed 1 (or 100%). (3) Genotype survival rates can decrease with age but not increase. (4) WT genotypes (<italic>Naa10<sup>+/Y</sup>; Naa12<sup>+/+</sup></italic> and <italic>Naa10<sup>+/+</sup>; Naa12<sup>+/+</sup></italic>) are expected to have 100% survival at all ages because the models predict the number of embryos or pups relative to WT survival. Reductions in overall in litter sizes for crosses were estimated through other calculations. (5) The biological basis for a reduced survival rate assumes that loss of one or more copies of either <italic>Naa10</italic> or <italic>Naa12</italic> removes or reduces functions that are required for successful embryonic development or postnatal life. Reduced survival rates for non-WT genotypes were estimated based on differences (delta) between the expected number of embryos or pups based on the Mendelian proportion (or the current best model) and the observed number of embryos or pups. Separate comparisons were made using deltas for each specific age and for the cumulative numbers at each age. (6) Genotype frequencies for each model were calculated as described in the section below. (7) The fit between a model and the observed data was determined by calculating the relative standard deviation (SD) for the deltas across all genotypes, for example, the SD across genotypes divided by the number of animals observed (either age-specific or cumulative). Each model was evaluated at each age by minimizing the relative SD for all genotypes at that age and over all ages. The final model (D<sub>4</sub>) was created by refining the assumptions for model D<sub>3</sub> in a sequential series of comparisons of survival rates for genotypes 12, 11, 6, 10, and 5 in that order.</p></sec><sec id="s4-28"><title>Genotype frequency calculations</title><p>The models described adjust the expected observed genotype frequencies at each age to account for loss of embryos or pups due to the presumed lethal effects of one or more genotypes. The models account directly for the effect of genotype-specific mortality by reducing the number (or frequency) observed for that genotype in the sample and thus increasing the expected proportion of other genotypes. This also indirectly implies a larger theoretical litter size at conception, which can be used to determine the theoretical litter sizes had there been no mortality in the affected genotypes. The predicted proportion for each genotype is calculated at each age as the genotype Mendelian frequency multiplied by the fractional genotype survival at that age divided by the expected total fractional survival (i.e., one minus the sum of all genotype fractional losses). The formula is</p><p>For all ‘n’ possible genotypes:<disp-formula id="equ1"><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi mathvariant="normal">G</mml:mi><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub><mml:mo>∗</mml:mo><mml:msub><mml:mi mathvariant="normal">S</mml:mi><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>–</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>–</mml:mo><mml:msub><mml:mi mathvariant="normal">S</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>∗</mml:mo><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>–</mml:mo><mml:msub><mml:mi mathvariant="normal">S</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>∗</mml:mo><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo>…</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>–</mml:mo><mml:msub><mml:mi mathvariant="normal">S</mml:mi><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>∗</mml:mo><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula>where</p><list list-type="simple"><list-item><p>G<sub>x</sub> = model genotype fractional value (frequency) for genotype ‘x’ (G<sub>x</sub> value from 0 to 1),</p></list-item><list-item><p>M<sub>x</sub> = Mendelian fractional value (frequency) for genotype ‘x’ for the cross, and</p></list-item><list-item><p>S<sub>x</sub> = fractional survival between 0 and 1.</p></list-item></list><p>(1 – S<sub>n</sub>) * M<sub>n</sub> is the fractional reduction due to survival &lt; 100% for genotype ‘n’, for example, when S<sub>n</sub> = 1 (e.g., 100% survival), the loss is zero; when S<sub>n</sub> = 0 (e.g., 0% survival), the loss is M<sub>n</sub> or the entire Mendelian fraction.</p><p>Note that the sum of all G<sub>x</sub> for all genotypes at any age is always equal to 1 (or 100%).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>GTO thanks Huiju Jo for supporting mouse genotyping. GJL would like to thank Ryan Driscoll for mouse genotyping, Fatima Inusa for embryo dissection, Jemima Kadima for mouse husbandry, Leyi Li for transgenic mouse assistance, Melissa Nashat, Jodi Coblentz, Rachel Rubino, and Lisa Bianco for veterinary advice, and Vicky Brandt for editorial assistance.</p><p>This work was supported by National Research Foundation of Korea (NRF) grants funded by the Korean Government (2020R1A3B2079811 (GO), 2017RIDIAB03032286 (ML), and 2020RICIC1007686 (ML)). Research reported in this publication was also supported by the National Institute of General Medical Sciences of the National Institutes of Health (NIH) under Award Numbers R35GM133408 (GJL) and R35GM118090 (RM), and NIH grant HL148165 (SJC). The work was also supported by the Research Council of Norway (Project 249843), the Norwegian Health Authorities of Western Norway (projects 912176 and F-12540-D11382), and the Norwegian Cancer Society (PR-2009-0222). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding was also provided by the Stanley Institute for Cognitive Genomics at Cold Spring Harbor Laboratory, the George A Jervis Clinic and the Department of Human Genetics, Laboratory of Genomic Medicine at the New York State Institute for Basic Research in Developmental Disabilities (IBR), New York State Office for People with Developmental Disabilities. Part of the work was carried out at the Proteomics Unit at University of Bergen (PROBE).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Supervision, Investigation, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Investigation</p></fn><fn fn-type="con" id="con12"><p>Investigation</p></fn><fn fn-type="con" id="con13"><p>Investigation</p></fn><fn fn-type="con" id="con14"><p>Investigation</p></fn><fn fn-type="con" id="con15"><p>Investigation</p></fn><fn fn-type="con" id="con16"><p>Investigation</p></fn><fn fn-type="con" id="con17"><p>Investigation</p></fn><fn fn-type="con" id="con18"><p>Investigation</p></fn><fn fn-type="con" id="con19"><p>Investigation</p></fn><fn fn-type="con" id="con20"><p>Investigation</p></fn><fn fn-type="con" id="con21"><p>Investigation</p></fn><fn fn-type="con" id="con22"><p>Investigation</p></fn><fn fn-type="con" id="con23"><p>Investigation</p></fn><fn fn-type="con" id="con24"><p>Investigation</p></fn><fn fn-type="con" id="con25"><p>Investigation</p></fn><fn fn-type="con" id="con26"><p>Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con27"><p>Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con28"><p>Funding acquisition, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con29"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Animal experimentation: All experiments were performed in accordance with guidelines of International Animal Care and Use Committee (IACUC) of Ewha Womans University (protocol #18-012), Cold Spring Harbor L aboratory (CSHL) protocol # 579961 18, and Institute for Basic Research in Developmental Disabilities (IBR) (protocol #456).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Tables related to genotypes, phenotypes and Mendelian ratios.</title><p>(<bold>a</bold>) Genotypes of offspring from <italic>Naa10<sup>+/-</sup></italic> female mice crossed to the <italic>Naa10<sup>+/Y</sup></italic> male mice. Expected and observed Mendelian ratio of genotypes in offspring at E10.5, E13.5, E18.5 and adults from crosses of <italic>Naa10<sup>+/-</sup></italic> female and <italic>Naa10<sup>+/Y</sup></italic> male mice. The percentage of adult <italic>Naa10<sup>-/Y</sup></italic> mice significantly decreases. (<bold>b</bold>) Genotypes of offspring from <italic>Naa10<sup>+/tm1a</sup></italic> female mice crossed to the <italic>Naa10<sup>+/Y</sup></italic> male mice. Expected and observed Mendelian ratio of genotypes in offspring at E10.5, E13.5, E18.5 and adults from crosses of <italic>Naa10<sup>+/tm1a</sup></italic> female and <italic>Naa10<sup>+/Y</sup></italic> male mice. The percentage of adults <italic>Naa10<sup>tm1a/Y</sup></italic> mice significantly decreases. (<bold>c</bold>) Cervical fusion skeletal analyses in <italic>Naa10</italic> knockout (KO) mice. (<bold>d</bold>) Matings and litter size analyses. (<bold>e</bold>) Genotypes of offspring from <italic>Naa12<sup>+/-</sup></italic> female mice crossed to the <italic>Naa12<sup>+/-</sup></italic> male mice. Expected and observed Mendelian ratio of genotypes in offspring from crosses. (<bold>f</bold>) Genotypes of offspring from <italic>Naa10<sup>+/-</sup> Naa12<sup>+/+</sup></italic> female mice crossed to the <italic>Naa10<sup>+/y</sup> Naa12<sup>+/-</sup></italic> male mice. Expected and observed Mendelian ratio of genotypes in offspring from crosses. (<bold>g</bold>) Genotypes of offspring from <italic>Naa10<sup>+/-</sup> Naa12<sup>+/+</sup></italic> female mice crossed to the <italic>Naa10<sup>+/y</sup> Naa12<sup>-/-</sup></italic> male mice. Expected and observed Mendelian ratio of genotypes in offspring from crosses. (<bold>h</bold>) Mendelian and observed offspring distributions from Naa10(+/Y); Naa12(+/-) male and Naa10(+/-); Naa12(+/-) female breeding. (<bold>i</bold>) Mendelian and observed offspring distributions from Naa10(+/Y); Naa12(-/-) male and Naa10(+/-); Naa12(+/-) female breeding. (<bold>j</bold>) Mendelian and observed postnatal offspring distributions from Naa10(+/Y); Naa12(+/-) male and Naa10(+/-); Naa12(+/+) female breeding. (<bold>k</bold>) Mendelian and observed postnatal offspring distributions from Naa10(+/Y); Naa12(-/-) male and Naa10(+/-); Naa12(+/+) female breeding. (<bold>l</bold>) Mendelian and observed age-specific offspring distributions from four crosses. (<bold>m</bold>) Mendelian and observed cumulative offspring distributions from all four crosses. (<bold>n</bold>) Mice analyzed by weighing, according to genotype. (<bold>o</bold>) Effects of <italic>Naa10</italic> KO on growth rate of <italic>Naa10</italic> mice on pure genetic background. (<bold>p</bold>) Effects of <italic>Naa10</italic> and <italic>Naa12</italic> KOs on growth rate on mixed genetic background.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-65952-supp1-v3.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Mass spectrometry analyses.</title><p>(<bold>a</bold>) N-termini detected in mouse embryonic fibroblasts (MEFs) (Excel sheet). (<bold>b</bold>) N-termini detected in all MEF samples (Excel sheet). (<bold>c</bold>) Header Key, showing the abbreviation meanings for (<bold>a</bold>) and (<bold>b</bold>) (Excel sheet). (<bold>d</bold>) Mass spectrometry of immunoprecipitated Naa15 complexes (Excel sheet).</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65952-supp2-v3.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-65952-transrepform-v3.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Mass spectrometry data were uploaded to PRIDE under Project Name: Naa10 mutant mouse N-terminome LC-MS, Project accession: PXD026410 and Project Name: mNaa10-KO liver immunoprecipitation, Project accession: PXD026684.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Naa10 mutant mouse N-terminome LC-MS</data-title><source>PRIDE</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD026410">PXD026410</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Ree</surname><given-names>R</given-names></name><name><surname>Arnesen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>mNaa10-KO liver immunoprecipitation</data-title><source>PRIDE</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD026684">PXD026684</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksnes</surname> <given-names>H</given-names></name><name><surname>Ree</surname> <given-names>R</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Co-translational, Post-translational, and Non-catalytic roles of N-Terminal acetyltransferases</article-title><source>Molecular Cell</source><volume>73</volume><fpage>1097</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.02.007</pub-id><pub-id pub-id-type="pmid">30878283</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Anderson</surname> <given-names>D</given-names></name><name><surname>Baldersheim</surname> <given-names>C</given-names></name><name><surname>Lanotte</surname> <given-names>M</given-names></name><name><surname>Varhaug</surname> <given-names>JE</given-names></name><name><surname>Lillehaug</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Identification and characterization of the human ARD1-NATH protein acetyltransferase complex</article-title><source>Biochemical Journal</source><volume>386</volume><fpage>433</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1042/BJ20041071</pub-id><pub-id pub-id-type="pmid">15496142</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Gromyko</surname> <given-names>D</given-names></name><name><surname>Pendino</surname> <given-names>F</given-names></name><name><surname>Ryningen</surname> <given-names>A</given-names></name><name><surname>Varhaug</surname> <given-names>JE</given-names></name><name><surname>Lillehaug</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2006">2006a</year><article-title>Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex</article-title><source>Oncogene</source><volume>25</volume><fpage>4350</fpage><lpage>4360</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209469</pub-id><pub-id pub-id-type="pmid">16518407</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Betts</surname> <given-names>MJ</given-names></name><name><surname>Pendino</surname> <given-names>F</given-names></name><name><surname>Liberles</surname> <given-names>DA</given-names></name><name><surname>Anderson</surname> <given-names>D</given-names></name><name><surname>Caro</surname> <given-names>J</given-names></name><name><surname>Kong</surname> <given-names>X</given-names></name><name><surname>Varhaug</surname> <given-names>JE</given-names></name><name><surname>Lillehaug</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2006">2006b</year><article-title>Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase</article-title><source>BMC Biochemistry</source><volume>7</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2091-7-13</pub-id><pub-id pub-id-type="pmid">16638120</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Van Damme</surname> <given-names>P</given-names></name><name><surname>Polevoda</surname> <given-names>B</given-names></name><name><surname>Helsens</surname> <given-names>K</given-names></name><name><surname>Evjenth</surname> <given-names>R</given-names></name><name><surname>Colaert</surname> <given-names>N</given-names></name><name><surname>Varhaug</surname> <given-names>JE</given-names></name><name><surname>Vandekerckhove</surname> <given-names>J</given-names></name><name><surname>Lillehaug</surname> <given-names>JR</given-names></name><name><surname>Sherman</surname> <given-names>F</given-names></name><name><surname>Gevaert</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans</article-title><source>PNAS</source><volume>106</volume><fpage>8157</fpage><lpage>8162</lpage><pub-id pub-id-type="doi">10.1073/pnas.0901931106</pub-id><pub-id pub-id-type="pmid">19420222</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Starheim</surname> <given-names>KK</given-names></name><name><surname>Van Damme</surname> <given-names>P</given-names></name><name><surname>Evjenth</surname> <given-names>R</given-names></name><name><surname>Dinh</surname> <given-names>H</given-names></name><name><surname>Betts</surname> <given-names>MJ</given-names></name><name><surname>Ryningen</surname> <given-names>A</given-names></name><name><surname>Vandekerckhove</surname> <given-names>J</given-names></name><name><surname>Gevaert</surname> <given-names>K</given-names></name><name><surname>Anderson</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The chaperone-like protein HYPK acts together with NatA in Cotranslational N-terminal acetylation and prevention of huntingtin aggregation</article-title><source>Molecular and Cellular Biology</source><volume>30</volume><fpage>1898</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.1128/MCB.01199-09</pub-id><pub-id pub-id-type="pmid">20154145</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blomen</surname> <given-names>VA</given-names></name><name><surname>Májek</surname> <given-names>P</given-names></name><name><surname>Jae</surname> <given-names>LT</given-names></name><name><surname>Bigenzahn</surname> <given-names>JW</given-names></name><name><surname>Nieuwenhuis</surname> <given-names>J</given-names></name><name><surname>Staring</surname> <given-names>J</given-names></name><name><surname>Sacco</surname> <given-names>R</given-names></name><name><surname>van Diemen</surname> <given-names>FR</given-names></name><name><surname>Olk</surname> <given-names>N</given-names></name><name><surname>Stukalov</surname> <given-names>A</given-names></name><name><surname>Marceau</surname> <given-names>C</given-names></name><name><surname>Janssen</surname> <given-names>H</given-names></name><name><surname>Carette</surname> <given-names>JE</given-names></name><name><surname>Bennett</surname> <given-names>KL</given-names></name><name><surname>Colinge</surname> <given-names>J</given-names></name><name><surname>Superti-Furga</surname> <given-names>G</given-names></name><name><surname>Brummelkamp</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Gene essentiality and synthetic lethality in haploid human cells</article-title><source>Science</source><volume>350</volume><fpage>1092</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1126/science.aac7557</pub-id><pub-id pub-id-type="pmid">26472760</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bornstein</surname> <given-names>PE</given-names></name><name><surname>Peterson</surname> <given-names>RR</given-names></name></person-group><year iso-8601-date="1966">1966</year><article-title>Numerical variation of the presacral vertebral column in three population groups in North America</article-title><source>American Journal of Physical Anthropology</source><volume>25</volume><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1002/ajpa.1330250205</pub-id><pub-id pub-id-type="pmid">5971115</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casey</surname> <given-names>JP</given-names></name><name><surname>Støve</surname> <given-names>SI</given-names></name><name><surname>McGorrian</surname> <given-names>C</given-names></name><name><surname>Galvin</surname> <given-names>J</given-names></name><name><surname>Blenski</surname> <given-names>M</given-names></name><name><surname>Dunne</surname> <given-names>A</given-names></name><name><surname>Ennis</surname> <given-names>S</given-names></name><name><surname>Brett</surname> <given-names>F</given-names></name><name><surname>King</surname> <given-names>MD</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Lynch</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>NAA10 mutation causing a novel intellectual disability syndrome with long QT due to N-terminal acetyltransferase impairment</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>16022</elocation-id><pub-id pub-id-type="doi">10.1038/srep16022</pub-id><pub-id pub-id-type="pmid">26522270</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Minnerly</surname> <given-names>J</given-names></name><name><surname>Kaul</surname> <given-names>T</given-names></name><name><surname>Riddle</surname> <given-names>DL</given-names></name><name><surname>Jia</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title><italic>daf-31</italic> encodes the catalytic subunit of N Alpha-Acetyltransferase that regulates <italic>Caenorhabditis elegans</italic> development, metabolism and adult lifespan</article-title><source>PLOS Genetics</source><volume>10</volume><elocation-id>e1004699</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1004699</pub-id><pub-id pub-id-type="pmid">25330189</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Wu</surname> <given-names>W</given-names></name><name><surname>Ke</surname> <given-names>X</given-names></name><name><surname>Zou</surname> <given-names>W</given-names></name><name><surname>Zhao</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nα-Acetyltransferases 10 and 15 are required for the correct initiation of endosperm cellularization in Arabidopsis</article-title><source>Plant and Cell Physiology</source><volume>59</volume><fpage>2113</fpage><lpage>2128</lpage><pub-id pub-id-type="doi">10.1093/pcp/pcy135</pub-id><pub-id pub-id-type="pmid">30020502</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>F</given-names></name><name><surname>Capecchi</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Targeted mutations in hoxa-9 and hoxb-9 reveal synergistic interactions</article-title><source>Developmental Biology</source><volume>181</volume><fpage>186</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1006/dbio.1996.8440</pub-id><pub-id pub-id-type="pmid">9013929</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>H</given-names></name><name><surname>Dharmadhikari</surname> <given-names>AV</given-names></name><name><surname>Varland</surname> <given-names>S</given-names></name><name><surname>Ma</surname> <given-names>N</given-names></name><name><surname>Domingo</surname> <given-names>D</given-names></name><name><surname>Kleyner</surname> <given-names>R</given-names></name><name><surname>Rope</surname> <given-names>AF</given-names></name><name><surname>Yoon</surname> <given-names>M</given-names></name><name><surname>Stray-Pedersen</surname> <given-names>A</given-names></name><name><surname>Posey</surname> <given-names>JE</given-names></name><name><surname>Crews</surname> <given-names>SR</given-names></name><name><surname>Eldomery</surname> <given-names>MK</given-names></name><name><surname>Akdemir</surname> <given-names>ZC</given-names></name><name><surname>Lewis</surname> <given-names>AM</given-names></name><name><surname>Sutton</surname> <given-names>VR</given-names></name><name><surname>Rosenfeld</surname> <given-names>JA</given-names></name><name><surname>Conboy</surname> <given-names>E</given-names></name><name><surname>Agre</surname> <given-names>K</given-names></name><name><surname>Xia</surname> <given-names>F</given-names></name><name><surname>Walkiewicz</surname> <given-names>M</given-names></name><name><surname>Longoni</surname> <given-names>M</given-names></name><name><surname>High</surname> <given-names>FA</given-names></name><name><surname>van Slegtenhorst</surname> <given-names>MA</given-names></name><name><surname>Mancini</surname> <given-names>GMS</given-names></name><name><surname>Finnila</surname> <given-names>CR</given-names></name><name><surname>van Haeringen</surname> <given-names>A</given-names></name><name><surname>den Hollander</surname> <given-names>N</given-names></name><name><surname>Ruivenkamp</surname> <given-names>C</given-names></name><name><surname>Naidu</surname> <given-names>S</given-names></name><name><surname>Mahida</surname> <given-names>S</given-names></name><name><surname>Palmer</surname> <given-names>EE</given-names></name><name><surname>Murray</surname> <given-names>L</given-names></name><name><surname>Lim</surname> <given-names>D</given-names></name><name><surname>Jayakar</surname> <given-names>P</given-names></name><name><surname>Parker</surname> <given-names>MJ</given-names></name><name><surname>Giusto</surname> <given-names>S</given-names></name><name><surname>Stracuzzi</surname> <given-names>E</given-names></name><name><surname>Romano</surname> <given-names>C</given-names></name><name><surname>Beighley</surname> <given-names>JS</given-names></name><name><surname>Bernier</surname> <given-names>RA</given-names></name><name><surname>Küry</surname> <given-names>S</given-names></name><name><surname>Nizon</surname> <given-names>M</given-names></name><name><surname>Corbett</surname> <given-names>MA</given-names></name><name><surname>Shaw</surname> <given-names>M</given-names></name><name><surname>Gardner</surname> <given-names>A</given-names></name><name><surname>Barnett</surname> <given-names>C</given-names></name><name><surname>Armstrong</surname> <given-names>R</given-names></name><name><surname>Kassahn</surname> <given-names>KS</given-names></name><name><surname>Van Dijck</surname> <given-names>A</given-names></name><name><surname>Vandeweyer</surname> <given-names>G</given-names></name><name><surname>Kleefstra</surname> <given-names>T</given-names></name><name><surname>Schieving</surname> <given-names>J</given-names></name><name><surname>Jongmans</surname> <given-names>MJ</given-names></name><name><surname>de Vries</surname> <given-names>BBA</given-names></name><name><surname>Pfundt</surname> <given-names>R</given-names></name><name><surname>Kerr</surname> <given-names>B</given-names></name><name><surname>Rojas</surname> <given-names>SK</given-names></name><name><surname>Boycott</surname> <given-names>KM</given-names></name><name><surname>Person</surname> <given-names>R</given-names></name><name><surname>Willaert</surname> <given-names>R</given-names></name><name><surname>Eichler</surname> <given-names>EE</given-names></name><name><surname>Kooy</surname> <given-names>RF</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>JC</given-names></name><name><surname>Lupski</surname> <given-names>JR</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Cooper</surname> <given-names>GM</given-names></name><name><surname>Chung</surname> <given-names>WK</given-names></name><name><surname>Gecz</surname> <given-names>J</given-names></name><name><surname>Stessman</surname> <given-names>HAF</given-names></name><name><surname>Meng</surname> <given-names>L</given-names></name><name><surname>Lyon</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Truncating variants in NAA15 are associated with variable levels of intellectual disability, autism spectrum disorder, and congenital anomalies</article-title><source>The American Journal of Human Genetics</source><volume>102</volume><fpage>985</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2018.03.004</pub-id><pub-id pub-id-type="pmid">29656860</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>H</given-names></name><name><surname>Gottlieb</surname> <given-names>L</given-names></name><name><surname>Marchi</surname> <given-names>E</given-names></name><name><surname>Kleyner</surname> <given-names>R</given-names></name><name><surname>Bhardwaj</surname> <given-names>P</given-names></name><name><surname>Rope</surname> <given-names>AF</given-names></name><name><surname>Rosenheck</surname> <given-names>S</given-names></name><name><surname>Moutton</surname> <given-names>S</given-names></name><name><surname>Philippe</surname> <given-names>C</given-names></name><name><surname>Eyaid</surname> <given-names>W</given-names></name><name><surname>Alkuraya</surname> <given-names>FS</given-names></name><name><surname>Toribio</surname> <given-names>J</given-names></name><name><surname>Mena</surname> <given-names>R</given-names></name><name><surname>Prada</surname> <given-names>CE</given-names></name><name><surname>Stessman</surname> <given-names>H</given-names></name><name><surname>Bernier</surname> <given-names>R</given-names></name><name><surname>Wermuth</surname> <given-names>M</given-names></name><name><surname>Kauffmann</surname> <given-names>B</given-names></name><name><surname>Blaumeiser</surname> <given-names>B</given-names></name><name><surname>Kooy</surname> <given-names>RF</given-names></name><name><surname>Baralle</surname> <given-names>D</given-names></name><name><surname>Mancini</surname> <given-names>GMS</given-names></name><name><surname>Conway</surname> <given-names>SJ</given-names></name><name><surname>Xia</surname> <given-names>F</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Meng</surname> <given-names>L</given-names></name><name><surname>Mihajlovic</surname> <given-names>L</given-names></name><name><surname>Marmorstein</surname> <given-names>R</given-names></name><name><surname>Lyon</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Phenotypic and biochemical analysis of an international cohort of individuals with variants in NAA10 and NAA15</article-title><source>Human Molecular Genetics</source><volume>28</volume><fpage>2900</fpage><lpage>2919</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddz111</pub-id><pub-id pub-id-type="pmid">31127942</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chernoff</surname> <given-names>N</given-names></name><name><surname>Rogers</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Supernumerary ribs IN developmental toxicity bioassays and IN human populations: incidence and biological significance</article-title><source>Journal of Toxicology and Environmental Health, Part B</source><volume>7</volume><fpage>437</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1080/10937400490512447</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Condie</surname> <given-names>BG</given-names></name><name><surname>Capecchi</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Mice homozygous for a targeted disruption of Hoxd-3 (Hox-4.1) exhibit anterior transformations of the first and second cervical vertebrae, the atlas and the axis</article-title><source>Development</source><volume>119</volume><fpage>579</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1242/dev.119.3.579</pub-id><pub-id pub-id-type="pmid">7910549</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname> <given-names>SJ</given-names></name><name><surname>Henderson</surname> <given-names>DJ</given-names></name><name><surname>Copp</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="1997">1997a</year><article-title>Pax3 is required for cardiac neural crest migration in the mouse: evidence from the splotch (Sp2H) mutant</article-title><source>Development</source><volume>124</volume><fpage>505</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1242/dev.124.2.505</pub-id><pub-id pub-id-type="pmid">9053326</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname> <given-names>SJ</given-names></name><name><surname>Henderson</surname> <given-names>DJ</given-names></name><name><surname>Kirby</surname> <given-names>ML</given-names></name><name><surname>Anderson</surname> <given-names>RH</given-names></name><name><surname>Copp</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="1997">1997b</year><article-title>Development of a lethal congenital heart defect in the splotch (Pax3) mutant mouse</article-title><source>Cardiovascular Research</source><volume>36</volume><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(97)00172-7</pub-id><pub-id pub-id-type="pmid">9463628</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname> <given-names>SJ</given-names></name><name><surname>Kruzynska-Frejtag</surname> <given-names>A</given-names></name><name><surname>Kneer</surname> <given-names>PL</given-names></name><name><surname>Machnicki</surname> <given-names>M</given-names></name><name><surname>Koushik</surname> <given-names>SV</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>What cardiovascular defect does my prenatal mouse mutant have, and why?</article-title><source>Genesis</source><volume>35</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1002/gene.10152</pub-id><pub-id pub-id-type="pmid">12481294</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname> <given-names>J</given-names></name><name><surname>Hein</surname> <given-names>MY</given-names></name><name><surname>Luber</surname> <given-names>CA</given-names></name><name><surname>Paron</surname> <given-names>I</given-names></name><name><surname>Nagaraj</surname> <given-names>N</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Accurate Proteome-wide Label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>13</volume><fpage>2513</fpage><lpage>2526</lpage><pub-id pub-id-type="doi">10.1074/mcp.M113.031591</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname> <given-names>J</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title><italic>MaxQuant enables high peptide identification rates, individualized</italic> p.p.<italic>b.-range mass accuracies and proteome-wide protein quantification</italic></article-title><source>Nature Biotechnology</source><volume>26</volume><fpage>1367</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1038/nbt.1511</pub-id><pub-id pub-id-type="pmid">19029910</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehairs</surname> <given-names>J</given-names></name><name><surname>Talebi</surname> <given-names>A</given-names></name><name><surname>Cherifi</surname> <given-names>Y</given-names></name><name><surname>Swinnen</surname> <given-names>JV</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CRISP-ID: decoding CRISPR mediated indels by Sanger sequencing</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>28973</elocation-id><pub-id pub-id-type="doi">10.1038/srep28973</pub-id><pub-id pub-id-type="pmid">27363488</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickman</surname> <given-names>ED</given-names></name><name><surname>Rogers</surname> <given-names>R</given-names></name><name><surname>Conway</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Abnormal skeletogenesis occurs coincident with increased apoptosis in the splotch (Sp2H) mutant: putative roles for Pax3 and PDGFRalpha in rib patterning</article-title><source>The Anatomical Record</source><volume>255</volume><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0185(19990701)255:3&lt;353::AID-AR11&gt;3.0.CO;2-H</pub-id><pub-id pub-id-type="pmid">10411402</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dikiy</surname> <given-names>I</given-names></name><name><surname>Eliezer</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>N-terminal acetylation stabilizes N-terminal helicity in lipid- and micelle-bound α-synuclein and increases its affinity for physiological membranes</article-title><source>Journal of Biological Chemistry</source><volume>289</volume><fpage>3652</fpage><lpage>3665</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.512459</pub-id><pub-id pub-id-type="pmid">24338013</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dörfel</surname> <given-names>MJ</given-names></name><name><surname>Fang</surname> <given-names>H</given-names></name><name><surname>Crain</surname> <given-names>J</given-names></name><name><surname>Klingener</surname> <given-names>M</given-names></name><name><surname>Weiser</surname> <given-names>J</given-names></name><name><surname>Lyon</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Proteomic and genomic characterization of a yeast model for ogden syndrome</article-title><source>Yeast</source><volume>34</volume><fpage>19</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1002/yea.3211</pub-id><pub-id pub-id-type="pmid">27668839</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dörfel</surname> <given-names>MJ</given-names></name><name><surname>Lyon</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The biological functions of Naa10 - From amino-terminal acetylation to human disease</article-title><source>Gene</source><volume>567</volume><fpage>103</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2015.04.085</pub-id><pub-id pub-id-type="pmid">25987439</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esmailpour</surname> <given-names>T</given-names></name><name><surname>Riazifar</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Donkervoort</surname> <given-names>S</given-names></name><name><surname>Huang</surname> <given-names>VH</given-names></name><name><surname>Madaan</surname> <given-names>S</given-names></name><name><surname>Shoucri</surname> <given-names>BM</given-names></name><name><surname>Busch</surname> <given-names>A</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Towbin</surname> <given-names>A</given-names></name><name><surname>Chadwick</surname> <given-names>RB</given-names></name><name><surname>Sequeira</surname> <given-names>A</given-names></name><name><surname>Vawter</surname> <given-names>MP</given-names></name><name><surname>Sun</surname> <given-names>G</given-names></name><name><surname>Johnston</surname> <given-names>JJ</given-names></name><name><surname>Biesecker</surname> <given-names>LG</given-names></name><name><surname>Kawaguchi</surname> <given-names>R</given-names></name><name><surname>Sun</surname> <given-names>H</given-names></name><name><surname>Kimonis</surname> <given-names>V</given-names></name><name><surname>Huang</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A splice donor mutation in NAA10 results in the dysregulation of the retinoic acid signalling pathway and causes lenz microphthalmia syndrome</article-title><source>Journal of Medical Genetics</source><volume>51</volume><fpage>185</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2013-101660</pub-id><pub-id pub-id-type="pmid">24431331</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>R</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Ma</surname> <given-names>S</given-names></name><name><surname>Wu</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Cao</surname> <given-names>Y</given-names></name><name><surname>Ma</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Protein N-terminal acetylation is required for embryogenesis in Arabidopsis</article-title><source>Journal of Experimental Botany</source><volume>67</volume><fpage>4779</fpage><lpage>4789</lpage><pub-id pub-id-type="doi">10.1093/jxb/erw257</pub-id><pub-id pub-id-type="pmid">27385766</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foyn</surname> <given-names>H</given-names></name><name><surname>Jones</surname> <given-names>JE</given-names></name><name><surname>Lewallen</surname> <given-names>D</given-names></name><name><surname>Narawane</surname> <given-names>R</given-names></name><name><surname>Varhaug</surname> <given-names>JE</given-names></name><name><surname>Thompson</surname> <given-names>PR</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Design, synthesis, and kinetic characterization of protein N-terminal acetyltransferase inhibitors</article-title><source>ACS Chemical Biology</source><volume>8</volume><fpage>1121</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1021/cb400136s</pub-id><pub-id pub-id-type="pmid">23557624</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fromental-Ramain</surname> <given-names>C</given-names></name><name><surname>Warot</surname> <given-names>X</given-names></name><name><surname>Lakkaraju</surname> <given-names>S</given-names></name><name><surname>Favier</surname> <given-names>B</given-names></name><name><surname>Haack</surname> <given-names>H</given-names></name><name><surname>Birling</surname> <given-names>C</given-names></name><name><surname>Dierich</surname> <given-names>A</given-names></name><name><surname>Doll e</surname> <given-names>P</given-names></name><name><surname>Chambon</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Specific and redundant functions of the paralogous Hoxa-9 and Hoxd-9 genes in forelimb and axial skeleton patterning</article-title><source>Development</source><volume>122</volume><fpage>461</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1242/dev.122.2.461</pub-id><pub-id pub-id-type="pmid">8625797</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautschi</surname> <given-names>M</given-names></name><name><surname>Just</surname> <given-names>S</given-names></name><name><surname>Mun</surname> <given-names>A</given-names></name><name><surname>Ross</surname> <given-names>S</given-names></name><name><surname>Rücknagel</surname> <given-names>P</given-names></name><name><surname>Dubaquié</surname> <given-names>Y</given-names></name><name><surname>Ehrenhofer-Murray</surname> <given-names>A</given-names></name><name><surname>Rospert</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The yeast N(alpha)-acetyltransferase NatA is quantitatively anchored to the ribosome and interacts with nascent polypeptides</article-title><source>Molecular and Cellular Biology</source><volume>23</volume><fpage>7403</fpage><lpage>7414</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.20.7403-7414.2003</pub-id><pub-id pub-id-type="pmid">14517307</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gendron</surname> <given-names>RL</given-names></name><name><surname>Laver</surname> <given-names>NV</given-names></name><name><surname>Good</surname> <given-names>WV</given-names></name><name><surname>Grossniklaus</surname> <given-names>HE</given-names></name><name><surname>Miskiewicz</surname> <given-names>E</given-names></name><name><surname>Whelan</surname> <given-names>MA</given-names></name><name><surname>Walker</surname> <given-names>J</given-names></name><name><surname>Paradis</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Loss of tubedown expression as a contributing factor in the development of age-related retinopathy</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>51</volume><fpage>5267</fpage><lpage>5277</lpage><pub-id pub-id-type="doi">10.1167/iovs.09-4527</pub-id><pub-id pub-id-type="pmid">20463314</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname> <given-names>L</given-names></name><name><surname>Marmorstein</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure of human NatA and its regulation by the huntingtin interacting protein HYPK</article-title><source>Structure</source><volume>26</volume><fpage>925</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1016/j.str.2018.04.003</pub-id><pub-id pub-id-type="pmid">29754825</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname> <given-names>DJ</given-names></name><name><surname>Conway</surname> <given-names>SJ</given-names></name><name><surname>Copp</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Rib truncations and fusions in the Sp2H mouse reveal a role for Pax3 in specification of the ventro-lateral and posterior parts of the somite</article-title><source>Developmental Biology</source><volume>209</volume><fpage>143</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1006/dbio.1999.9215</pub-id><pub-id pub-id-type="pmid">10208749</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname> <given-names>WM</given-names></name><name><surname>Mannakee</surname> <given-names>BK</given-names></name><name><surname>Gutenkunst</surname> <given-names>RN</given-names></name><name><surname>Serio</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Loss of amino-terminal acetylation suppresses a prion phenotype by modulating global protein folding</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>4383</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms5383</pub-id><pub-id pub-id-type="pmid">25023910</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horan</surname> <given-names>GS</given-names></name><name><surname>Wu</surname> <given-names>K</given-names></name><name><surname>Wolgemuth</surname> <given-names>DJ</given-names></name><name><surname>Behringer</surname> <given-names>RR</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Homeotic transformation of cervical vertebrae in Hoxa-4 mutant mice</article-title><source>PNAS</source><volume>91</volume><fpage>12644</fpage><lpage>12648</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.26.12644</pub-id><pub-id pub-id-type="pmid">7809093</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingram</surname> <given-names>AK</given-names></name><name><surname>Cross</surname> <given-names>GA</given-names></name><name><surname>Horn</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Genetic manipulation indicates that ARD1 is an essential N(alpha)-acetyltransferase in <italic>Trypanosoma brucei</italic></article-title><source>Molecular and Biochemical Parasitology</source><volume>111</volume><fpage>309</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/S0166-6851(00)00322-4</pub-id><pub-id pub-id-type="pmid">11163439</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeannotte</surname> <given-names>L</given-names></name><name><surname>Lemieux</surname> <given-names>M</given-names></name><name><surname>Charron</surname> <given-names>J</given-names></name><name><surname>Poirier</surname> <given-names>F</given-names></name><name><surname>Robertson</surname> <given-names>EJ</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Specification of axial identity in the mouse: role of the Hoxa-5 (Hox1.3) gene</article-title><source>Genes &amp; Development</source><volume>7</volume><fpage>2085</fpage><lpage>2096</lpage><pub-id pub-id-type="doi">10.1101/gad.7.11.2085</pub-id><pub-id pub-id-type="pmid">7901120</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname> <given-names>JJ</given-names></name><name><surname>Williamson</surname> <given-names>KA</given-names></name><name><surname>Chou</surname> <given-names>CM</given-names></name><name><surname>Sapp</surname> <given-names>JC</given-names></name><name><surname>Ansari</surname> <given-names>M</given-names></name><name><surname>Chapman</surname> <given-names>HM</given-names></name><name><surname>Cooper</surname> <given-names>DN</given-names></name><name><surname>Dabir</surname> <given-names>T</given-names></name><name><surname>Dudley</surname> <given-names>JN</given-names></name><name><surname>Holt</surname> <given-names>RJ</given-names></name><name><surname>Ragge</surname> <given-names>NK</given-names></name><name><surname>Schäffer</surname> <given-names>AA</given-names></name><name><surname>Sen</surname> <given-names>SK</given-names></name><name><surname>Slavotinek</surname> <given-names>AM</given-names></name><name><surname>FitzPatrick</surname> <given-names>DR</given-names></name><name><surname>Glaser</surname> <given-names>TM</given-names></name><name><surname>Stewart</surname> <given-names>F</given-names></name><name><surname>Black</surname> <given-names>GC</given-names></name><name><surname>Biesecker</surname> <given-names>LG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>NAA10</italic> polyadenylation signal variants cause syndromic microphthalmia</article-title><source>Journal of Medical Genetics</source><volume>56</volume><fpage>444</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2018-105836</pub-id><pub-id pub-id-type="pmid">30842225</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname> <given-names>S</given-names></name><name><surname>Kwon</surname> <given-names>Y</given-names></name><name><surname>Kim</surname> <given-names>JM</given-names></name><name><surname>Park</surname> <given-names>D</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>JW</given-names></name><name><surname>Hwang</surname> <given-names>CS</given-names></name><name><surname>Lee</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>iNrich, rapid and robust method to enrich N-Terminal proteome in a highly multiplexed platform</article-title><source>Analytical Chemistry</source><volume>92</volume><fpage>6462</fpage><lpage>6469</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.9b05653</pub-id><pub-id pub-id-type="pmid">32267142</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juan</surname> <given-names>AH</given-names></name><name><surname>Ruddle</surname> <given-names>FH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Enhancer timing of hox gene expression: deletion of the endogenous Hoxc8 early enhancer</article-title><source>Development</source><volume>130</volume><fpage>4823</fpage><lpage>4834</lpage><pub-id pub-id-type="doi">10.1242/dev.00672</pub-id><pub-id pub-id-type="pmid">12917291</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>SH</given-names></name><name><surname>Park</surname> <given-names>JA</given-names></name><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Lee</surname> <given-names>JW</given-names></name><name><surname>Seo</surname> <given-names>JH</given-names></name><name><surname>Jung</surname> <given-names>BK</given-names></name><name><surname>Chun</surname> <given-names>KH</given-names></name><name><surname>Jeong</surname> <given-names>JW</given-names></name><name><surname>Bae</surname> <given-names>MK</given-names></name><name><surname>Kim</surname> <given-names>KW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Characterization of ARD1 variants in mammalian cells</article-title><source>Biochemical and Biophysical Research Communications</source><volume>340</volume><fpage>422</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.12.018</pub-id><pub-id pub-id-type="pmid">16376303</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondrashov</surname> <given-names>N</given-names></name><name><surname>Pusic</surname> <given-names>A</given-names></name><name><surname>Stumpf</surname> <given-names>CR</given-names></name><name><surname>Shimizu</surname> <given-names>K</given-names></name><name><surname>Hsieh</surname> <given-names>AC</given-names></name><name><surname>Ishijima</surname> <given-names>J</given-names></name><name><surname>Shiroishi</surname> <given-names>T</given-names></name><name><surname>Barna</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Ribosome-mediated specificity in hox mRNA translation and vertebrate tissue patterning</article-title><source>Cell</source><volume>145</volume><fpage>383</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.03.028</pub-id><pub-id pub-id-type="pmid">21529712</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koushik</surname> <given-names>SV</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Conway</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Generation of a conditional loxP allele of the Pax3 transcription factor that enables selective deletion of the homeodomain</article-title><source>Genesis</source><volume>32</volume><fpage>114</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1002/gene.10051</pub-id><pub-id pub-id-type="pmid">11857794</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Mouellic</surname> <given-names>H</given-names></name><name><surname>Lallemand</surname> <given-names>Y</given-names></name><name><surname>Brûlet</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Homeosis in the mouse induced by a null mutation in the Hox-3.1 gene</article-title><source>Cell</source><volume>69</volume><fpage>251</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90406-3</pub-id><pub-id pub-id-type="pmid">1348969</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>CC</given-names></name><name><surname>Peng</surname> <given-names>SH</given-names></name><name><surname>Shen</surname> <given-names>L</given-names></name><name><surname>Lee</surname> <given-names>CF</given-names></name><name><surname>Du</surname> <given-names>TH</given-names></name><name><surname>Kang</surname> <given-names>ML</given-names></name><name><surname>Xu</surname> <given-names>GL</given-names></name><name><surname>Upadhyay</surname> <given-names>AK</given-names></name><name><surname>Cheng</surname> <given-names>X</given-names></name><name><surname>Yan</surname> <given-names>YT</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Juan</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The role of N-α-acetyltransferase 10 protein in DNA methylation and genomic imprinting</article-title><source>Molecular Cell</source><volume>68</volume><fpage>89</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.08.025</pub-id><pub-id pub-id-type="pmid">28943313</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>M-N</given-names></name><name><surname>Kweon</surname> <given-names>HY</given-names></name><name><surname>Oh</surname> <given-names>GT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>N-α-acetyltransferase 10 (NAA10) in development: the role of NAA10</article-title><source>Experimental &amp; Molecular Medicine</source><volume>50</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/s12276-018-0105-2</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>CC</given-names></name><name><surname>Shih</surname> <given-names>YC</given-names></name><name><surname>Kang</surname> <given-names>ML</given-names></name><name><surname>Chang</surname> <given-names>YC</given-names></name><name><surname>Chuang</surname> <given-names>LM</given-names></name><name><surname>Devaraj</surname> <given-names>R</given-names></name><name><surname>Juan</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Naa10p inhibits beige Adipocyte-Mediated thermogenesis through N-α-acetylation of Pgc1α</article-title><source>Molecular Cell</source><volume>76</volume><fpage>500</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.07.026</pub-id><pub-id pub-id-type="pmid">31422874</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linster</surname> <given-names>E</given-names></name><name><surname>Stephan</surname> <given-names>I</given-names></name><name><surname>Bienvenut</surname> <given-names>WV</given-names></name><name><surname>Maple-Grødem</surname> <given-names>J</given-names></name><name><surname>Myklebust</surname> <given-names>LM</given-names></name><name><surname>Huber</surname> <given-names>M</given-names></name><name><surname>Reichelt</surname> <given-names>M</given-names></name><name><surname>Sticht</surname> <given-names>C</given-names></name><name><surname>Møller</surname> <given-names>SG</given-names></name><name><surname>Meinnel</surname> <given-names>T</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Giglione</surname> <given-names>C</given-names></name><name><surname>Hell</surname> <given-names>R</given-names></name><name><surname>Wirtz</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Downregulation of N-terminal acetylation triggers ABA-mediated drought responses in Arabidopsis</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7640</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8640</pub-id><pub-id pub-id-type="pmid">26184543</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liszczak</surname> <given-names>G</given-names></name><name><surname>Goldberg</surname> <given-names>JM</given-names></name><name><surname>Foyn</surname> <given-names>H</given-names></name><name><surname>Petersson</surname> <given-names>EJ</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Marmorstein</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular basis for N-terminal acetylation by the heterodimeric NatA complex</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>20</volume><fpage>1098</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2636</pub-id><pub-id pub-id-type="pmid">23912279</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magin</surname> <given-names>RS</given-names></name><name><surname>March</surname> <given-names>ZM</given-names></name><name><surname>Marmorstein</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The N-terminal acetyltransferase Naa10/ARD1 does not acetylate lysine residues</article-title><source>Journal of Biological Chemistry</source><volume>291</volume><fpage>5270</fpage><lpage>5277</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.709428</pub-id><pub-id pub-id-type="pmid">26755727</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magin</surname> <given-names>RS</given-names></name><name><surname>Deng</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Cooperman</surname> <given-names>B</given-names></name><name><surname>Marmorstein</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Probing the interaction between NatA and the ribosome for co-translational protein acetylation</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0186278</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0186278</pub-id><pub-id pub-id-type="pmid">29016658</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mclaren</surname> <given-names>A</given-names></name><name><surname>Michie</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1958">1958</year><article-title>Factors affecting vertebral variation in mice. 4. experimental proof of the uterine basis of a maternal effect</article-title><source>Journal of Embryology and Experimental Morphology</source><volume>6</volume><fpage>645</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">13611143</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McTiernan</surname> <given-names>N</given-names></name><name><surname>Støve</surname> <given-names>SI</given-names></name><name><surname>Aukrust</surname> <given-names>I</given-names></name><name><surname>Mårli</surname> <given-names>MT</given-names></name><name><surname>Myklebust</surname> <given-names>LM</given-names></name><name><surname>Houge</surname> <given-names>G</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>NAA10 dysfunction with normal NatA-complex activity in a girl with non-syndromic ID and a de novo NAA10 p.(V111G) variant - a case report</article-title><source>BMC Medical Genetics</source><volume>19</volume><elocation-id>47</elocation-id><pub-id pub-id-type="doi">10.1186/s12881-018-0559-z</pub-id><pub-id pub-id-type="pmid">29558889</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullen</surname> <given-names>JR</given-names></name><name><surname>Kayne</surname> <given-names>PS</given-names></name><name><surname>Moerschell</surname> <given-names>RP</given-names></name><name><surname>Tsunasawa</surname> <given-names>S</given-names></name><name><surname>Gribskov</surname> <given-names>M</given-names></name><name><surname>Colavito-Shepanski</surname> <given-names>M</given-names></name><name><surname>Grunstein</surname> <given-names>M</given-names></name><name><surname>Sherman</surname> <given-names>F</given-names></name><name><surname>Sternglanz</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast</article-title><source>The EMBO Journal</source><volume>8</volume><fpage>2067</fpage><lpage>2075</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1989.tb03615.x</pub-id><pub-id pub-id-type="pmid">2551674</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myklebust</surname> <given-names>LM</given-names></name><name><surname>Van Damme</surname> <given-names>P</given-names></name><name><surname>Støve</surname> <given-names>SI</given-names></name><name><surname>Dörfel</surname> <given-names>MJ</given-names></name><name><surname>Abboud</surname> <given-names>A</given-names></name><name><surname>Kalvik</surname> <given-names>TV</given-names></name><name><surname>Grauffel</surname> <given-names>C</given-names></name><name><surname>Jonckheere</surname> <given-names>V</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Swensen</surname> <given-names>J</given-names></name><name><surname>Kaasa</surname> <given-names>H</given-names></name><name><surname>Liszczak</surname> <given-names>G</given-names></name><name><surname>Marmorstein</surname> <given-names>R</given-names></name><name><surname>Reuter</surname> <given-names>N</given-names></name><name><surname>Lyon</surname> <given-names>GJ</given-names></name><name><surname>Gevaert</surname> <given-names>K</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Biochemical and cellular analysis of ogden syndrome reveals downstream Nt-acetylation defects</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>1956</fpage><lpage>1976</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu611</pub-id><pub-id pub-id-type="pmid">25489052</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olaopa</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>HM</given-names></name><name><surname>Snider</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Schwartz</surname> <given-names>RJ</given-names></name><name><surname>Moon</surname> <given-names>AM</given-names></name><name><surname>Conway</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Pax3 is essential for normal cardiac neural crest morphogenesis but is not required during migration nor outflow tract septation</article-title><source>Developmental Biology</source><volume>356</volume><fpage>308</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2011.05.583</pub-id><pub-id pub-id-type="pmid">21600894</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname> <given-names>AL</given-names></name><name><surname>Clark</surname> <given-names>J</given-names></name><name><surname>Chan</surname> <given-names>WY</given-names></name><name><surname>Rennert</surname> <given-names>OM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Expression of human NAA11 (ARD1B) gene is tissue-specific and is regulated by DNA methylation</article-title><source>Epigenetics</source><volume>6</volume><fpage>1391</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.4161/epi.6.11.18125</pub-id><pub-id pub-id-type="pmid">22048246</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>EC</given-names></name><name><surname>Szostak</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>ARD1 and NAT1 proteins form a complex that has N-terminal acetyltransferase activity</article-title><source>The EMBO Journal</source><volume>11</volume><fpage>2087</fpage><lpage>2093</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1992.tb05267.x</pub-id><pub-id pub-id-type="pmid">1600941</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Gene redundancy and gene compensation: an updated view</article-title><source>Journal of Genetics and Genomics</source><volume>46</volume><fpage>329</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/j.jgg.2019.07.001</pub-id><pub-id pub-id-type="pmid">31377237</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polevoda</surname> <given-names>B</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Sherman</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A synopsis of eukaryotic Nalpha-terminal acetyltransferases: nomenclature, subunits and substrates</article-title><source>BMC Proceedings</source><volume>3</volume><elocation-id>S2</elocation-id><pub-id pub-id-type="doi">10.1186/1753-6561-3-s6-s2</pub-id><pub-id pub-id-type="pmid">19660095</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polevoda</surname> <given-names>B</given-names></name><name><surname>Sherman</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Composition and function of the eukaryotic N-terminal acetyltransferase subunits</article-title><source>Biochemical and Biophysical Research Communications</source><volume>308</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(03)01316-0</pub-id><pub-id pub-id-type="pmid">12890471</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popp</surname> <given-names>B</given-names></name><name><surname>Støve</surname> <given-names>SI</given-names></name><name><surname>Endele</surname> <given-names>S</given-names></name><name><surname>Myklebust</surname> <given-names>LM</given-names></name><name><surname>Hoyer</surname> <given-names>J</given-names></name><name><surname>Sticht</surname> <given-names>H</given-names></name><name><surname>Azzarello-Burri</surname> <given-names>S</given-names></name><name><surname>Rauch</surname> <given-names>A</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Reis</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>De novo missense mutations in the NAA10 gene cause severe non-syndromic developmental delay in males and females</article-title><source>European Journal of Human Genetics</source><volume>23</volume><fpage>602</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2014.150</pub-id><pub-id pub-id-type="pmid">25099252</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pun</surname> <given-names>A</given-names></name><name><surname>Cervantes</surname> <given-names>I</given-names></name><name><surname>Nieto</surname> <given-names>B</given-names></name><name><surname>Salgado</surname> <given-names>C</given-names></name><name><surname>Pérez-Cabal</surname> <given-names>MA</given-names></name><name><surname>Ibáñez-Escriche</surname> <given-names>N</given-names></name><name><surname>Gutiérrez</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genetic parameters for birthweight environmental variability in mice</article-title><source>Journal of Animal Breeding and Genetics</source><volume>130</volume><fpage>404</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1111/jbg.12021</pub-id><pub-id pub-id-type="pmid">24074177</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname> <given-names>P</given-names></name><name><surname>Shandilya</surname> <given-names>H</given-names></name><name><surname>D'Alessio</surname> <given-names>JM</given-names></name><name><surname>O'Connor</surname> <given-names>K</given-names></name><name><surname>Durocher</surname> <given-names>J</given-names></name><name><surname>Gerard</surname> <given-names>GF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mutation detection using surveyor nuclease</article-title><source>BioTechniques</source><volume>36</volume><fpage>702</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.2144/04364PF01</pub-id><pub-id pub-id-type="pmid">15088388</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rappsilber</surname> <given-names>J</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name><name><surname>Ishihama</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips</article-title><source>Nature Protocols</source><volume>2</volume><fpage>1896</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.261</pub-id><pub-id pub-id-type="pmid">17703201</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ree</surname> <given-names>R</given-names></name><name><surname>Myklebust</surname> <given-names>LM</given-names></name><name><surname>Thiel</surname> <given-names>P</given-names></name><name><surname>Foyn</surname> <given-names>H</given-names></name><name><surname>Fladmark</surname> <given-names>KE</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The N-terminal acetyltransferase Naa10 is essential for zebrafish development</article-title><source>Bioscience Reports</source><volume>35</volume><elocation-id>e00249</elocation-id><pub-id pub-id-type="doi">10.1042/BSR20150168</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ree</surname> <given-names>R</given-names></name><name><surname>Varland</surname> <given-names>S</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Spotlight on protein N-terminal acetylation</article-title><source>Experimental &amp; Molecular Medicine</source><volume>50</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/s12276-018-0116-z</pub-id><pub-id pub-id-type="pmid">30054468</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ree</surname> <given-names>R</given-names></name><name><surname>Geithus</surname> <given-names>AS</given-names></name><name><surname>Tørring</surname> <given-names>PM</given-names></name><name><surname>Sørensen</surname> <given-names>KP</given-names></name><name><surname>Damkjær</surname> <given-names>M</given-names></name><name><surname>Lynch</surname> <given-names>SA</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name><collab>DDD study</collab></person-group><year iso-8601-date="2019">2019</year><article-title><italic>A novel NAA10</italic> p.(<italic>R83H) variant with impaired acetyltransferase activity identified in two boys with ID and microcephaly</italic></article-title><source>BMC Medical Genetics</source><volume>20</volume><elocation-id>101</elocation-id><pub-id pub-id-type="doi">10.1186/s12881-019-0803-1</pub-id><pub-id pub-id-type="pmid">31174490</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rope</surname> <given-names>AF</given-names></name><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Evjenth</surname> <given-names>R</given-names></name><name><surname>Xing</surname> <given-names>J</given-names></name><name><surname>Johnston</surname> <given-names>JJ</given-names></name><name><surname>Swensen</surname> <given-names>JJ</given-names></name><name><surname>Johnson</surname> <given-names>WE</given-names></name><name><surname>Moore</surname> <given-names>B</given-names></name><name><surname>Huff</surname> <given-names>CD</given-names></name><name><surname>Bird</surname> <given-names>LM</given-names></name><name><surname>Carey</surname> <given-names>JC</given-names></name><name><surname>Opitz</surname> <given-names>JM</given-names></name><name><surname>Stevens</surname> <given-names>CA</given-names></name><name><surname>Jiang</surname> <given-names>T</given-names></name><name><surname>Schank</surname> <given-names>C</given-names></name><name><surname>Fain</surname> <given-names>HD</given-names></name><name><surname>Robison</surname> <given-names>R</given-names></name><name><surname>Dalley</surname> <given-names>B</given-names></name><name><surname>Chin</surname> <given-names>S</given-names></name><name><surname>South</surname> <given-names>ST</given-names></name><name><surname>Pysher</surname> <given-names>TJ</given-names></name><name><surname>Jorde</surname> <given-names>LB</given-names></name><name><surname>Hakonarson</surname> <given-names>H</given-names></name><name><surname>Lillehaug</surname> <given-names>JR</given-names></name><name><surname>Biesecker</surname> <given-names>LG</given-names></name><name><surname>Yandell</surname> <given-names>M</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Lyon</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency</article-title><source>The American Journal of Human Genetics</source><volume>89</volume><fpage>28</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2011.05.017</pub-id><pub-id pub-id-type="pmid">21700266</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunier</surname> <given-names>C</given-names></name><name><surname>Støve</surname> <given-names>SI</given-names></name><name><surname>Popp</surname> <given-names>B</given-names></name><name><surname>Gérard</surname> <given-names>B</given-names></name><name><surname>Blenski</surname> <given-names>M</given-names></name><name><surname>AhMew</surname> <given-names>N</given-names></name><name><surname>de Bie</surname> <given-names>C</given-names></name><name><surname>Goldenberg</surname> <given-names>P</given-names></name><name><surname>Isidor</surname> <given-names>B</given-names></name><name><surname>Keren</surname> <given-names>B</given-names></name><name><surname>Leheup</surname> <given-names>B</given-names></name><name><surname>Lampert</surname> <given-names>L</given-names></name><name><surname>Mignot</surname> <given-names>C</given-names></name><name><surname>Tezcan</surname> <given-names>K</given-names></name><name><surname>Mancini</surname> <given-names>GM</given-names></name><name><surname>Nava</surname> <given-names>C</given-names></name><name><surname>Wasserstein</surname> <given-names>M</given-names></name><name><surname>Bruel</surname> <given-names>AL</given-names></name><name><surname>Thevenon</surname> <given-names>J</given-names></name><name><surname>Masurel</surname> <given-names>A</given-names></name><name><surname>Duffourd</surname> <given-names>Y</given-names></name><name><surname>Kuentz</surname> <given-names>P</given-names></name><name><surname>Huet</surname> <given-names>F</given-names></name><name><surname>Rivière</surname> <given-names>JB</given-names></name><name><surname>van Slegtenhorst</surname> <given-names>M</given-names></name><name><surname>Faivre</surname> <given-names>L</given-names></name><name><surname>Piton</surname> <given-names>A</given-names></name><name><surname>Reis</surname> <given-names>A</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Thauvin-Robinet</surname> <given-names>C</given-names></name><name><surname>Zweier</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Expanding the phenotype associated with NAA10-Related N-Terminal acetylation deficiency</article-title><source>Human Mutation</source><volume>37</volume><fpage>755</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1002/humu.23001</pub-id><pub-id pub-id-type="pmid">27094817</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname> <given-names>DC</given-names></name><name><surname>Monda</surname> <given-names>JK</given-names></name><name><surname>Bennett</surname> <given-names>EJ</given-names></name><name><surname>Harper</surname> <given-names>JW</given-names></name><name><surname>Schulman</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>N-terminal acetylation acts as an avidity enhancer within an interconnected multiprotein complex</article-title><source>Science</source><volume>334</volume><fpage>674</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1126/science.1209307</pub-id><pub-id pub-id-type="pmid">21940857</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shemorry</surname> <given-names>A</given-names></name><name><surname>Hwang</surname> <given-names>CS</given-names></name><name><surname>Varshavsky</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Control of protein quality and stoichiometries by N-terminal acetylation and the N-end rule pathway</article-title><source>Molecular Cell</source><volume>50</volume><fpage>540</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.03.018</pub-id><pub-id pub-id-type="pmid">23603116</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname> <given-names>P</given-names></name><name><surname>Schimenti</surname> <given-names>JC</given-names></name><name><surname>Bolcun-Filas</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A mouse geneticist's practical guide to CRISPR applications</article-title><source>Genetics</source><volume>199</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1534/genetics.114.169771</pub-id><pub-id pub-id-type="pmid">25271304</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starheim</surname> <given-names>KK</given-names></name><name><surname>Gevaert</surname> <given-names>K</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Protein N-terminal acetyltransferases: when the start matters</article-title><source>Trends in Biochemical Sciences</source><volume>37</volume><fpage>152</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2012.02.003</pub-id><pub-id pub-id-type="pmid">22405572</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Støve</surname> <given-names>SI</given-names></name><name><surname>Blenski</surname> <given-names>M</given-names></name><name><surname>Stray-Pedersen</surname> <given-names>A</given-names></name><name><surname>Wierenga</surname> <given-names>KJ</given-names></name><name><surname>Jhangiani</surname> <given-names>SN</given-names></name><name><surname>Akdemir</surname> <given-names>ZC</given-names></name><name><surname>Crawford</surname> <given-names>D</given-names></name><name><surname>McTiernan</surname> <given-names>N</given-names></name><name><surname>Myklebust</surname> <given-names>LM</given-names></name><name><surname>Purcarin</surname> <given-names>G</given-names></name><name><surname>McNall-Knapp</surname> <given-names>R</given-names></name><name><surname>Wadley</surname> <given-names>A</given-names></name><name><surname>Belmont</surname> <given-names>JW</given-names></name><name><surname>Kim</surname> <given-names>JJ</given-names></name><name><surname>Lupski</surname> <given-names>JR</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A novel NAA10 variant with impaired acetyltransferase activity causes developmental delay, intellectual disability, and hypertrophic cardiomyopathy</article-title><source>European Journal of Human Genetics</source><volume>26</volume><fpage>1294</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1038/s41431-018-0136-0</pub-id><pub-id pub-id-type="pmid">29748569</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiura</surname> <given-names>N</given-names></name><name><surname>Adams</surname> <given-names>SM</given-names></name><name><surname>Corriveau</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronal development</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><fpage>40113</fpage><lpage>40120</lpage><pub-id pub-id-type="doi">10.1074/jbc.M301218200</pub-id><pub-id pub-id-type="pmid">12888564</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Damme</surname> <given-names>P</given-names></name><name><surname>Hole</surname> <given-names>K</given-names></name><name><surname>Pimenta-Marques</surname> <given-names>A</given-names></name><name><surname>Helsens</surname> <given-names>K</given-names></name><name><surname>Vandekerckhove</surname> <given-names>J</given-names></name><name><surname>Martinho</surname> <given-names>RG</given-names></name><name><surname>Gevaert</surname> <given-names>K</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011a</year><article-title>NatF contributes to an evolutionary shift in protein N-terminal acetylation and is important for normal chromosome segregation</article-title><source>PLOS Genetics</source><volume>7</volume><elocation-id>e1002169</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002169</pub-id><pub-id pub-id-type="pmid">21750686</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Damme</surname> <given-names>P</given-names></name><name><surname>Evjenth</surname> <given-names>R</given-names></name><name><surname>Foyn</surname> <given-names>H</given-names></name><name><surname>Demeyer</surname> <given-names>K</given-names></name><name><surname>De Bock</surname> <given-names>PJ</given-names></name><name><surname>Lillehaug</surname> <given-names>JR</given-names></name><name><surname>Vandekerckhove</surname> <given-names>J</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Gevaert</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011b</year><article-title>Proteome-derived peptide libraries allow detailed analysis of the substrate specificities of N(alpha)-acetyltransferases and point to hNaa10p as the post-translational actin N(alpha)-acetyltransferase</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>10</volume><elocation-id>M110.004580</elocation-id><pub-id pub-id-type="doi">10.1074/mcp.M110.004580</pub-id><pub-id pub-id-type="pmid">21383206</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Damme</surname> <given-names>P</given-names></name><name><surname>Støve</surname> <given-names>SI</given-names></name><name><surname>Glomnes</surname> <given-names>N</given-names></name><name><surname>Gevaert</surname> <given-names>K</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A <italic>Saccharomyces cerevisiae</italic> model reveals in vivo functional impairment of the ogden syndrome N-terminal acetyltransferase NAA10 Ser37Pro mutant</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>13</volume><fpage>2031</fpage><lpage>2041</lpage><pub-id pub-id-type="doi">10.1074/mcp.M113.035402</pub-id><pub-id pub-id-type="pmid">24408909</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Akker</surname> <given-names>E</given-names></name><name><surname>Fromental-Ramain</surname> <given-names>C</given-names></name><name><surname>de Graaff</surname> <given-names>W</given-names></name><name><surname>Le Mouellic</surname> <given-names>H</given-names></name><name><surname>Brûlet</surname> <given-names>P</given-names></name><name><surname>Chambon</surname> <given-names>P</given-names></name><name><surname>Deschamps</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Axial skeletal patterning in mice lacking all paralogous group 8 hox genes</article-title><source>Development</source><volume>128</volume><fpage>1911</fpage><lpage>1921</lpage><pub-id pub-id-type="doi">10.1242/dev.128.10.1911</pub-id><pub-id pub-id-type="pmid">11311170</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Hoff</surname> <given-names>MJ</given-names></name><name><surname>Moorman</surname> <given-names>AF</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cardiac neural crest: the holy grail of cardiac abnormalities?</article-title><source>Cardiovascular Research</source><volume>47</volume><fpage>212</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(00)00127-9</pub-id><pub-id pub-id-type="pmid">10946058</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varland</surname> <given-names>S</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Investigating the functionality of a ribosome-binding mutant of NAA15 using <italic>Saccharomyces cerevisiae</italic></article-title><source>BMC Research Notes</source><volume>11</volume><elocation-id>404</elocation-id><pub-id pub-id-type="doi">10.1186/s13104-018-3513-4</pub-id><pub-id pub-id-type="pmid">29929531</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veitia</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Gene duplicates: agents of robustness or fragility?</article-title><source>Trends in Genetics</source><volume>33</volume><fpage>377</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2017.03.006</pub-id><pub-id pub-id-type="pmid">28434610</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vo</surname> <given-names>TTL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Characterization of lysine acetyltransferase activity of recombinant human ARD1/NAA10</article-title><source>Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry</source><volume>25</volume><elocation-id>588</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25030588</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Mijares</surname> <given-names>M</given-names></name><name><surname>Gall</surname> <given-names>MD</given-names></name><name><surname>Turan</surname> <given-names>T</given-names></name><name><surname>Javier</surname> <given-names>A</given-names></name><name><surname>Bornemann</surname> <given-names>DJ</given-names></name><name><surname>Manage</surname> <given-names>K</given-names></name><name><surname>Warrior</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Drosophila <italic>variable nurse cells</italic> encodes arrest defective 1 (ARD1), the catalytic subunit of the major N-terminal acetyltransferase complex</article-title><source>Developmental Dynamics</source><volume>239</volume><fpage>2813</fpage><lpage>2827</lpage><pub-id pub-id-type="doi">10.1002/dvdy.22418</pub-id><pub-id pub-id-type="pmid">20882681</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Birsoy</surname> <given-names>K</given-names></name><name><surname>Hughes</surname> <given-names>NW</given-names></name><name><surname>Krupczak</surname> <given-names>KM</given-names></name><name><surname>Post</surname> <given-names>Y</given-names></name><name><surname>Wei</surname> <given-names>JJ</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Identification and characterization of essential genes in the human genome</article-title><source>Science</source><volume>350</volume><fpage>1096</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1126/science.aac7041</pub-id><pub-id pub-id-type="pmid">26472758</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname> <given-names>T</given-names></name><name><surname>Tai</surname> <given-names>W</given-names></name><name><surname>Morton</surname> <given-names>S</given-names></name><name><surname>Impens</surname> <given-names>F</given-names></name><name><surname>Van Damme</surname> <given-names>P</given-names></name><name><surname>Van Haver</surname> <given-names>D</given-names></name><name><surname>Timmerman</surname> <given-names>E</given-names></name><name><surname>Venturini</surname> <given-names>G</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name><name><surname>Jang</surname> <given-names>MY</given-names></name><name><surname>Willcox</surname> <given-names>JAL</given-names></name><name><surname>Haghighi</surname> <given-names>A</given-names></name><name><surname>Gelb</surname> <given-names>BD</given-names></name><name><surname>Chung</surname> <given-names>WK</given-names></name><name><surname>Goldmuntz</surname> <given-names>E</given-names></name><name><surname>Porter</surname> <given-names>GA</given-names></name><name><surname>Lifton</surname> <given-names>RP</given-names></name><name><surname>Brueckner</surname> <given-names>M</given-names></name><name><surname>Yost</surname> <given-names>HJ</given-names></name><name><surname>Bruneau</surname> <given-names>BG</given-names></name><name><surname>Gorham</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>Y</given-names></name><name><surname>Pereira</surname> <given-names>A</given-names></name><name><surname>Homsy</surname> <given-names>J</given-names></name><name><surname>Benson</surname> <given-names>CC</given-names></name><name><surname>DePalma</surname> <given-names>SR</given-names></name><name><surname>Varland</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>CS</given-names></name><name><surname>Arnesen</surname> <given-names>T</given-names></name><name><surname>Gevaert</surname> <given-names>K</given-names></name><name><surname>Seidman</surname> <given-names>C</given-names></name><name><surname>Seidman</surname> <given-names>JG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mechanisms of congenital heart disease caused by NAA15 haploinsufficiency</article-title><source>Circulation Research</source><volume>128</volume><fpage>1156</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.316966</pub-id><pub-id pub-id-type="pmid">33557580</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiśniewski</surname> <given-names>JR</given-names></name><name><surname>Zougman</surname> <given-names>A</given-names></name><name><surname>Nagaraj</surname> <given-names>N</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Universal sample preparation method for proteome analysis</article-title><source>Nature Methods</source><volume>6</volume><fpage>359</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1322</pub-id><pub-id pub-id-type="pmid">19377485</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Lyon</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>NAA10-related syndrome</article-title><source>Experimental &amp; Molecular Medicine</source><volume>50</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/s12276-018-0098-x</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname> <given-names>H</given-names></name><name><surname>Kim</surname> <given-names>HL</given-names></name><name><surname>Chun</surname> <given-names>YS</given-names></name><name><surname>Shin</surname> <given-names>DH</given-names></name><name><surname>Lee</surname> <given-names>KH</given-names></name><name><surname>Shin</surname> <given-names>CS</given-names></name><name><surname>Lee</surname> <given-names>DY</given-names></name><name><surname>Kim</surname> <given-names>HH</given-names></name><name><surname>Lee</surname> <given-names>ZH</given-names></name><name><surname>Ryoo</surname> <given-names>HM</given-names></name><name><surname>Lee</surname> <given-names>MN</given-names></name><name><surname>Oh</surname> <given-names>GT</given-names></name><name><surname>Park</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>NAA10 controls osteoblast differentiation and bone formation as a feedback regulator of Runx2</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>5176</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms6176</pub-id><pub-id pub-id-type="pmid">25376646</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeger</surname> <given-names>SL</given-names></name><name><surname>Liang</surname> <given-names>KY</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Longitudinal data analysis for discrete and continuous outcomes</article-title><source>Biometrics</source><volume>42</volume><fpage>121</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.2307/2531248</pub-id><pub-id pub-id-type="pmid">3719049</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>HM</given-names></name><name><surname>Conway</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Restricted <italic>Pax3</italic> deletion within the neural tube results in congenital hydrocephalus</article-title><source>Journal of Developmental Biology</source><volume>4</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.3390/jdb4010007</pub-id><pub-id pub-id-type="pmid">26949601</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65952.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Lin</surname><given-names>Hening</given-names></name><role>Reviewing Editor</role><aff><institution>Cornell University</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/10.1101/2020.12.19.422860">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.12.19.422860v1.full">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The manuscript describe the phenotype when Naa10 and Naa12 are inactivated and how Naa12 compensates Naa10 deficiency, reducing the phenotype observed when Naa10 is inactivated. The finding of a new N-acetyltransferase will be useful to the field of N-terminal acetylation.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Naa12 rescues embryonic lethality in Naa10-Deficient Mice in the amino-terminal acetylation pathway&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Philip Cole as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Summary:</p><p>Mutations in the X-linked gene Naa10, which encodes a major protein N-terminal acetyltransferase, are known to be causative in Ogden syndrome, a genetic disorder associated with infantile death. The manuscript reports that hemizygous knockout of Naa10 in male mice does not cause complete embryonic lethality despite the fact that it is responsible for the acetylation of about 50% of all the proteins. This leads the authors to discover a paralogous mouse gene Naa12 and demonstrate that Naa12 can compensate for Naa10 loss of function and that null mutations in both genes lead to complete embryonic lethality. This is an important finding. The authors also provided a thorough account of the variety of development abnormalities in the Naa10 hemizygous mice at all stages of development. Importantly, the authors identified several phenotypes in the mice that upon further analysis, we also noted in the some patients.</p><p>All reviewers are enthusiastic about the finding of a new N-terminal acetyltransferase and think that this is a major strength of the manuscript. In addition, the phenotypical characterization of Naa10 is also useful to the field.</p><p>Essential revisions:</p><p>Some of the revision recommendations requires additional experiments. The reviewers and the Reviewing Editor have discussed and agree that these additional experiments should only take a few weeks to complete.</p><p>1) Carry out an in vitro acetyltransferase assays with Naa12-Naa15 to validate the proposed mechanistic model.</p><p>2) Check whether Pax3 and HoxC8 proteins' abundance/stability are affected in NAA10 KO mouse tissue or MEF.</p><p>3) Obtain experimental evidence to support that N-terminal acetylation is lost in the double knockouts. If such evidence is not possible or will take too much experimental effort, please tone down the claim that the complete machinery for the process of amino-terminal acetylation of proteins in mouse development is identified.</p><p>4) Revise the text according to the comments by all three reviewers to make it easier for readers to understand.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1) It is important to show that N-terminal acetylation is lost in the double knockouts. Only with that, the authors can conclude that they have identified the &quot;the complete machinery for the process of amino-terminal acetylation of proteins in mouse development.&quot;</p><p>2) Naa12 is new, so if not done yet, the sequence needs to be deposited into Genbank.</p><p>3) The presentation needs to be polished.</p><p>i) The title &quot;Naa12 rescues embryonic lethality in Naa10-Deficient 1 Mice in the amino-terminal acetylation pathway&quot; is misleading. When I saw the title, I got the impression that Naa10-dficient 1 mice show embryonic lethality. I would suggest to change it to indicate that Naa10 and Naa12 have redundant roles in embryonic development. Also, &quot;Naa10-Deficient 1 Mice&quot; needs to be changed to &quot;Naa10-deficient mice.&quot;</p><p>ii) In the impact statement &quot;Mice doubly deficient for Naa10 and Naa12 display embryonic lethality…&quot;, the word &quot;doubly &quot; is unnecessary.</p><p>iii) Too many acronyms, which make the reading a bit difficult. The terms NTA and Nt-acetylation could be avoided.</p><p>iv) At the end of page 9, please cite the sequence alignment in Figure S6.</p><p>v) On page 12, &quot;Naa12 may rescue loss of Naa10 in mice&quot; could be more assertive.</p><p>vi) Overall, I feel that the authors could polish the manuscript so that the salient points could be conveyed more easily to readers.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Overall this is a very good paper, but some issues need further attention.</p><p>– Authors present data showing that mNAA12 can acetylate some peptides at their N-end, however these reactions are performed with just the monomer and NatA activity is catalysed in vivo by the heterodimer Naa10-Naa15, showing an N-terminal acetylation in vitro activity different to Naa10 and being more similar to the observed in cells. Therefore, it is important to characterize Naa12-Naa15 in vitro enzymatic activity assessing its specificity using diverse NatA described peptidic substrates and compare it with the regular NatA enzymatic complex that presents NAA10 as catalytic subunit.</p><p>– There is a clear phenotype when mNAA10 is inactivated however, there is not a dramatic defect in protein N-terminal acetylation as it has been observed in other organisms like yeast and Arabidopsis thailiana. It has been observed by several authors that some proteins stability is affected when they are not N-terminal acetylated influencing the biological activity of these proteins. Authors comment that Pax3 and HoxC8 proteins regulate some of the biological activities deregulated in mice when mNAA10 is inactivated. As both proteins are NatA substrates and their stability could be affected when mNAA10 is inactivated it would be interesting to assess their abundance in NAA10KO embryos, mice tissue and/or MEFs in comparison with the observed in wild-type samples. These results could bring some light to the molecular mechanisms that are governing the effects observed in these mice.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Line 55 of the abstract &quot;Male mice lacking Naa10 show no globally apparent in vivo NTA impairment and, surprisingly, do not exhibit embryonic lethality&quot;. This statement is misleading as written (and appears again in the discussion) as later in the paper, the authors describe that homozygous mice were underrepresented at birth, and describe embryonic phenotypes and embryos that underwent lysis by 10.5. Suggest rephrasing to.…do not exhibit complete embryonic lethality.</p><p>The fate of the Naa10 mice could be written more clearly. As it stands, there is a vagueness as to the number of mice that were not born, that die as early neonates and the number that survived to adulthood. Authors should consider adding a Kaplan Myer survival curve. Statements like &quot;Some of the Naa10 hemizygous mice survived to 4 months is..&quot; is not helpful.</p><p>Given the phenotypic effect of Naa12+/- Naa10 +/-, females, it may have been interesting to access any effects in acetylation?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65952.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Some of the revision recommendations requires additional experiments. The reviewers and the Reviewing Editor have discussed and agree that these additional experiments should only take a few weeks to complete.</p><p>1) Carry out an in vitro acetyltransferase assays with Naa12-Naa15 to validate the proposed mechanistic model.</p></disp-quote><p>We added these analyses in the manuscript, and this does add new evidence showing that the complex has activity.</p><disp-quote content-type="editor-comment"><p>2) Check whether Pax3 and HoxC8 proteins' abundance/stability are affected in NAA10 KO mouse tissue or MEF.</p></disp-quote><p>We have attempted to perform the experiments, but the results were not compelling, as described below.</p><disp-quote content-type="editor-comment"><p>3) Obtain experimental evidence to support that N-terminal acetylation is lost in the double knockouts. If such evidence is not possible or will take too much experimental effort, please tone down the claim that the complete machinery for the process of amino-terminal acetylation of proteins in mouse development is identified.</p></disp-quote><p>Double knockouts show early embryonic lethality (Table 4), so if we want to confirm the N-terminal acetylation level of double knockout, the embryos have to be isolated before E8.5 day. We have not yet been able to obtain sufficient material for these experiments. Therefore, we toned down the wording regarding complete machinery, as recommended.</p><disp-quote content-type="editor-comment"><p>4) Revise the text according to the comments by all three reviewers to make it easier for readers to understand.</p></disp-quote><p>We have made these changes.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1) It is important to show that N-terminal acetylation is lost in the double knockouts. Only with that, the authors can conclude that they have identified the &quot;the complete machinery for the process of amino-terminal acetylation of proteins in mouse development.&quot;</p></disp-quote><p>We have decided to remove this sentence, as the reviewer is correct that there might be even more unidentified N-terminal acetyltransferase enzymes in mice. For now, we simply present the data showing embryonic lethality for mice doubly deficient in Naa10 and Naa12. We did add a concluding sentence to the abstract, which is more toned down.</p><disp-quote content-type="editor-comment"><p>2) Naa12 is new, so if not done yet, the sequence needs to be deposited into Genbank.</p></disp-quote><p>When looking for homolog sequences, we did a blast-search using the sequence for Naa10. That led to the automatically annotated gene identifier on chromosome 18, which we named Naa12: Gm16286. This predicted gene translates to NM_001384178.1 (predicted gene mRNA) and NP_001371107.1 (N-α-acetyltransferase 11-like protein). This means that Naa12 is already in Genbank, however, with a different name and the status &quot;predicted&quot;. We cannot find a way for us to re-annotate existing sequences, so we assume it will be re-annotated by the curators of Genbank after our paper is published. We modified the following sentence to read: &quot; We found a predicted gene (Gm16286, UniProt: Q9CQX6) on chromosome 18, with high similarity to Naa10, which we name Naa12, and RiboSeq and mRNA traces of this region suggest possible transcription and translation of this gene.”</p><disp-quote content-type="editor-comment"><p>3) The presentation needs to be polished.</p></disp-quote><p>We have edited throughout with this in mind.</p><disp-quote content-type="editor-comment"><p>i) The title &quot;Naa12 rescues embryonic lethality in Naa10-Deficient 1 Mice in the amino-terminal acetylation pathway&quot; is misleading. When I saw the title, I got the impression that Naa10-dficient 1 mice show embryonic lethality. I would suggest to change it to indicate that Naa10 and Naa12 have redundant roles in embryonic development. Also, &quot;Naa10-Deficient 1 Mice&quot; needs to be changed to &quot;Naa10-deficient mice.&quot;</p></disp-quote><p>We have changed the title to: <italic>Naa12</italic> compensates for <italic>Naa10</italic> in mice in the amino-terminal acetylation pathway.</p><disp-quote content-type="editor-comment"><p>ii) In the impact statement &quot;Mice doubly deficient for Naa10 and Naa12 display embryonic lethality…&quot;, the word &quot;doubly &quot; is unnecessary.</p></disp-quote><p>Removed.</p><disp-quote content-type="editor-comment"><p>iii) Too many acronyms, which make the reading a bit difficult. The terms NTA and Nt-acetylation could be avoided.</p></disp-quote><p>We replaced NTA and Nt-acetylation with amino-terminal acetylation throughout the manuscript. We have also tried throughout to expand on acronyms.</p><disp-quote content-type="editor-comment"><p>iv) At the end of page 9, please cite the sequence alignment in Figure S6.</p></disp-quote><p>We inserted this.</p><disp-quote content-type="editor-comment"><p>v) On page 12, &quot;Naa12 may rescue loss of Naa10 in mice&quot; could be more assertive.</p></disp-quote><p>We changed this to &quot;<italic>Naa12</italic> rescues loss of <italic>Naa10</italic> in mice&quot;.</p><disp-quote content-type="editor-comment"><p>vi) Overall, I feel that the authors could polish the manuscript so that the salient points could be conveyed more easily to readers.</p></disp-quote><p>We have edited the manuscript throughout, attempting to clarify reading.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Overall this is a very good paper, but some issues need further attention.</p><p>– Authors present data showing that mNAA12 can acetylate some peptides at their N-end, however these reactions are performed with just the monomer and NatA activity is catalysed in vivo by the heterodimer Naa10-Naa15, showing an N-terminal acetylation in vitro activity different to Naa10 and being more similar to the observed in cells. Therefore, it is important to characterize Naa12-Naa15 in vitro enzymatic activity assessing its specificity using diverse NatA described peptidic substrates and compare it with the regular NatA enzymatic complex that presents NAA10 as catalytic subunit.</p></disp-quote><p>We have attempted to prepare recombinant Naa12/Naa15 complex from Sf9 insect cells for biochemical studies, but were unfortunately unable to prepare sufficient levels of complex for detailed enzymatic analysis. Nonetheless, we were able to prepare a sufficient amount of recombinant complex to analyze fractions from a final size exclusion chromatograph purification. This analysis demonstrated that the Naa12/Naa15 complex harbored detectable amino-terminal acetylation activity toward the SESSSKS- peptide (Figure 4C), thus demonstrating catalytic activity of a NatA complex with mouse Naa12.</p><disp-quote content-type="editor-comment"><p>– There is a clear phenotype when mNAA10 is inactivated however, there is not a dramatic defect in protein N-terminal acetylation as it has been observed in other organisms like yeast and Arabidopsis thailiana. It has been observed by several authors that some proteins stability is affected when they are not N-terminal acetylated influencing the biological activity of these proteins. Authors comment that Pax3 and HoxC8 proteins regulate some of the biological activities deregulated in mice when mNAA10 is inactivated. As both proteins are NatA substrates and their stability could be affected when mNAA10 is inactivated it would be interesting to assess their abundance in NAA10KO embryos, mice tissue and/or MEFs in comparison with the observed in wild-type samples. These results could bring some light to the molecular mechanisms that are governing the effects observed in these mice.</p></disp-quote><p>We included the references to Pax3 and Hoxc8 as possible future directions, and it would be an entire new paper to demonstrate this mechanism. Nonetheless, to attempt to address this for the reviewer, we have performed Western blotting for Pax3 and Hoxc8. It is not easy to detect Pax3 level with western blot, so B16F10 (mouse melanoma cell line) stably expressing pax3 was used as a control. We have detected a slight decline only in NAA10KO E10.5 embryos, but this is very small and likely not significant, and this is only semi-quantitative at best with Western blotting, and so we are not prepared to publish this result until we have confirmed it with further experiments, including mass spectrometry. For Hoxc8, signal detection was not successful using one antibody that we purchased, and we will have to try again for a future paper. Of course, this does not specifically address the N-terminal acetylation of either protein, but N-terminal peptides from Pax3 and Hoxc8 are not present in our mass spectrometry data (included here and also unpublished data). As such, we cannot determine if there are differences in their N-terminal acetylation levels, and we are beginning now various approaches to try to determine this.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Line 55 of the abstract &quot;Male mice lacking Naa10 show no globally apparent in vivo NTA impairment and, surprisingly, do not exhibit embryonic lethality&quot;. This statement is misleading as written (and appears again in the discussion) as later in the paper, the authors describe that homozygous mice were underrepresented at birth, and describe embryonic phenotypes and embryos that underwent lysis by 10.5. Suggest rephrasing to.…do not exhibit complete embryonic lethality.</p></disp-quote><p>We modified this to read: &quot;Male mice lacking <italic>Naa10</italic> show no globally apparent in vivo amino-terminal acetylation impairment and do not exhibit complete embryonic lethality.&quot;</p><disp-quote content-type="editor-comment"><p>The fate of the Naa10 mice could be written more clearly. As it stands, there is a vagueness as to the number of mice that were not born, that die as early neonates and the number that survived to adulthood. Authors should consider adding a Kaplan Myer survival curve.</p></disp-quote><p>We have added such a curve, and have referred to it in the Results.</p><disp-quote content-type="editor-comment"><p>Statements like &quot;Some of the Naa10 hemizygous mice survived to 4 months is..&quot; is not helpful.</p></disp-quote><p>We have quantified this in the Results, with statements such as: “Out of 32 Naa10-/Y that survived past the third day of life and which were then examined longitudinally, about 60% survived past 200 days of life (~7 months)”.</p><disp-quote content-type="editor-comment"><p>Given the phenotypic effect of Naa12+/- Naa10 +/-, females, it may have been interesting to access any effects in acetylation?</p></disp-quote><p>This is not an easy experiment to perform, as we have spent several years attempting to demonstrate decreased acetylation in KO males, with no success, leading us to the characterization of Naa12. The compound heterozygous Naa12+/- Naa10 +/- females are born in small numbers, and we have now quantified this in detail in a new section titled “Genotype distribution modeling of Naa10- and Naa12-deficient offspring”. It is outside the scope and timeframe for the current paper to attempt to quantify amino-terminal acetylation levels in the compound heterozygous females, and we are likely going to focus instead on dying (or just before dying) doubly deficient embryos, where the degree of acetylation difference will likely be greater.</p></body></sub-article></article>